Process simulation as a decision support tool for biopharmaceutical process development in a South African context by Collair, Wesley
Process simulation as a decision support tool 
for biopharmaceutical process development in 
a South African context 
Wesley Collair 
In fulfilment of the requirements for the degree of 
Master of Science 
Supervisor: Dr. Siew L. Tai 
Department of Chemical Engineering 
Faculty of Engineering and the Built Environment 











The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 












1. This dissertation has been submitted to the Turnitin module and I confirm that my supervisor
has seen my report and any concerns revealed by such have been resolved with my supervisor.
2. I know that plagiarism is wrong. Plagiarism is to use another’s work and to pretend that it is
one’s own.
3. I have used the Harvard (University of Cape Town variant) system for citation and referencing.
Each significant contribution to, and quotation in, this report from the work, or works, of other
people has been attributed, and has been cited and referenced.
4. This is my own unaided work, except for assistance received from the teaching staff.
5. I have not allowed, and will not allow, anyone to copy my work with the intention of passing it





Signed at Kenilworth 

Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair Abstract 
v 
Abstract 
In 2010 the incidence of neo-natal Group B Streptococcus (GBS) disease in South Africa was 3 per 
1000 live births, more than twice the global average of 1.21 per 1000 live births. A recent life cycle 
impact assessment showed that a new vaccine against GBS disease in South Africa could have a 
potential value of $ 2 million - $ 4 million /kg (R 25 million – R 50 million /kg), as an attractive investment 
opportunity if a novel process can be successfully synthesised and licensed commercially. 
In the current global market new biopharmaceutical products require innovative and expedited 
development pathways. To achieve this, low-cost analytical tools with short turnaround times are 
needed to assist with process development decision making. Process simulation is one such tool which 
has been shown to be useful for evaluating process development decisions without the typically 
expensive investment required for experimental development of a new process. 
Three technology platforms (stainless steel, single-use, and a hybrid of both) were identified for use in 
a novel process to manufacture a GBS serotype III polysaccharide-protein conjugate antigen, for 
formulation into a vaccine against GBS disease. The three technology choices were compared and 
evaluated for the novel process at two fermentation scales of 20 L and 200 L, with cost of goods (COG) 
used as a comparison of economic performance for the six different scenarios. It was hypothesised that 
single use technology would yield the lower COG at both scales compared to stainless steel. Based on 
a literature survey, single use technology should require lower capital costs for pilot scale processes 
and should also have lower operating costs due to single use equipment not requiring sterilisation in 
place (SIP) and cleaning in place (CIP). It was further hypothesised that hybrid technology would yield 
the lowest COG by combining the best properties of stainless steel and single use technologies. 
A 3 x 2 factorial experiment design was used to structure the simulation exercise with three technologies 
at each of the two scales. A GBS serotype III process model was synthesised from literature sources, 
with fermentation stoichiometry based on an empirical material balance and fermentation kinetics fitted 
to a two-parameter Monod kinetic model. Equipment, consumables, and raw materials specifications 
were made using literature and empirical models. A base case simulation model, built for 20 L scale 
using stainless steel technology, was developed into the five additional scenarios. The best performing 
scenario in terms COG was then selected for sensitivity analysis using three parameters: fermentation 
titer, solid-liquid separation efficiency, and electricity dependence on diesel generation. 
At 20 L scale there was little difference in COG between the three technology options, with COG range 
across the three platforms of $ 9.7 million – $ 9.8 million /kg.  At 200 L scale the best performing 
technology was stainless steel with a COG of $ 3.7 million /kg, which was $ 600 000 /kg less than the 
COG for single use of $ 4.3 million/kg. The difference was due to a higher cost of consumables for 
single use technology, and negligible differences in capital costs for single use over stainless steel. The 
effect of SIP and CIP costs on operating cost for stainless steel technology was found to be small 
compared to the greater consumables cost for single use. The 200 L stainless steel process was found 
to be sensitive to fermentation titer, with an increase in titer to 600 mg/L resulting in the lowest COG of 
$ 2.2 million /kg. The process was found to be least sensitive to electricity dependence on diesel, with 
only a $ 60 000 /kg increase in COG when 75% of electricity was derived by diesel generator. 
The hypothesis was disproved, with single use technology having the higher COG at both 20 L and 200 
L scales compared to stainless steel technology. Hybrid technology did not yield the lowest COG either, 
instead resulting in a COG somewhere between stainless steel and single use. Stainless steel 
technology outperformed single use and hybrid technologies in COG at both scales, contrary to both 
parts of the hypothesis. A process to make a GBS vaccine could be profitable at scales of 200 L and 
above using stainless steel technology. Process simulation modelling was effective for evaluating 
process technology options without performing costly physical experiments. The simulation exercise 
provided valuable information on the economic impact of process development decisions as well as 
context specific information for the South African context. This methodology is therefore recommended 
for commercial biopharmaceutical process development, particularly for evaluating techno-economic 
scenarios in different decision pathways during the development process.  
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Glossary of Terms 
Acetoin 3-hydroxybutanone 
Activation Addition of reactive functional groups to facilitate conjugation 
Adiabatic No energy crossing the system boundary (∆Q=0) 
Aerobic In the presence of biologically available oxygen 
Aliphatic Relating to a covalent bond with a carbon atom  
Anaerobic Without the presence of biologically available oxygen 
Antigen Compound which induces an immunologic response 
Aseptic Sterile, no viable microorganisms present 
Base case 
Simulation model scenario used as a starting point for developing further 
scenarios 
Batch process Process with a defined start time, finite running time, and defined end time 
Biomass Large quantity of biological cells, typically gram or kilogram scale 
Biopharmaceutical Pharmaceutical products produced using biological expression systems 
Bioreactor 
Vessel used for the culture of biological organisms (typically mammalian 
cells) 
Capsid Protective outer wall of a bacterium 
Capsular 
polysaccharide 
Polysaccharide attached to the outer wall bacterial capsid 
Carrier protein Detoxified bacterial toxin protein, “carries” covalently attached antigens 
Cascade control Fast responding inner control loop with slower responding outer loop 
Clean in place To clean a piece of equipment in the same location where it is installed 
Conjugate Polysaccharide covalently linked to a carrier protein 
Consumable Material that is used to facilitate a process and then discarded after use 
Continuous process Process without a finite running time, nor a defined end time 
Cross-contamination 
Contamination of material of high purity by another material used in the 
same equipment or area 
Cyanylation 
Chemical reaction where free hydroxyl groups are converted to cyanoester 
groups: R-OH → R-OCN 
Debottlenecking 
Identifying the part of a process which is limiting to productivity and 
suggesting ways to reduce or eliminate the limitation  
Decontaminate To kill microorganisms to less than 1 surviving from 1 million viable 
De-N-acetylate 
Removal of acetyl functional group from an N-acetyl functional group, the 
result is a primary amine group: R-NHCOCH3 → R-NH2 
Derivatized 
Chemical reaction which produces a derivative product which has a 
structure similar to the starting material 
Diafiltration 
Size exclusion separation by passing through a filter medium with 
continuous discharge of carrier and replacement with fresh carrier solution 
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  xiv 
Discount rate 
Rate of return on an investment. Discount rate accounts for cost of finance, 
real return, and risk return. 
Doubling time Time taken for total number of cells in a culture to double 
Doubling time Time taken for the number of organisms in a culture to double 
Extra-cellular Outside the cell wall 
Extractables 
Compounds that can move from material into a carrier fluid under normal 
conditions 
Extraction Release of a compound from a solid into a liquid extractant solution 
Fermentation Conversion of ADP to ATP by substrate level phosphorylation 
Fermentor Vessel used for the culture of microbial organisms 
Glycosidic linkages Covalent bond joining a carbohydrate to another carbohydrate or group 
Hetero-lactic 
Fermentation reaction products include at least one other type of organic 
acid in addition to lactic acid. For example, acetic acid and lactic acid. 
Hexavalent Vaccine formulation containing six antigens 
Homo-lactic Fermentation reaction products include only lactic acid 
Hurdle rate The discount rate at which NPV=0. 
Hybrid technology Combination of stainless-steel and single-use technologies 
Inactivation To kill all viable microorganisms at the end of fermentation culture 
Inoculum Small volume of live organisms added to a larger volume of growth medium 
Internal Rate of 
Return 
A discount rate which can be used to evaluate the present value of future 
cash flows (IRR > hurdle rate at NPV=0) 
Intra-cellular Within the cell wall 
Kinetic Time dependent property or properties of a chemical reaction 
Laminar flow Fluid flow pattern in which fluid “streams” do not overlap or cross paths 
Leachables 
Compounds that can move from a material into a carrier fluid under normal 
conditions 
Lymphocyte Type of immune cells (white blood cells) found in vertebrates  
Medium Solution containing more than one substrate, used for culturing 
Microbial Relating to bacterial microorganisms 
Monoclonal antibody Antibody with monovalent antigen binding affinity 
Monoseptic One unique species of microorganism 
Neo-natal Babies less than 6 months of age 
Neutral pH of 7.00 
Neutralize  pH adjustment of a solution until the solution pH is neutral  
Net Present Value Interest adjusted present value of future cash flows 
Organic Compounds based on covalently bonded carbon atoms 
Orthogonal carbon 
Three-dimensional woven carbon medium with strands in x and y co-
ordinates perpendicular to each other, and strands in z co-ordinate 
supporting x and y strands  
Pathogen Bacterium or virus that causes disease 
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xv 
Pellet Solid product from centrifugation separation process 
Permeate 
Solution containing compounds which pass through a tangential flow 
filtration membrane 
Phagocytosis Process by which a host organism’s immune cells destroy foreign particles  
Polycarbonate 
Durable plastic compounds derived from petroleum hydrocarbon starting 
materials 
Polysaccharide 
Carbohydrate compound of repeating monosaccharides joined by 
glycosidic linkages 
Precipitation  Phase change of a solute from liquid in solution to solid 
Process simulation Execution of computer model simulation of a process 
Recombinant Organism with an artificially modified genome 
Re-N-acetylate 
Re-addition of acetyl functional group to a primary amine group, the result 
is an N-acetyl functional group: R-NH2 → R-NHCOCH3   
Respiration Conversion of ADP to ATP by oxidative phosphorylation 
Retentate 
Solution containing compounds which are retained by a tangential flow 
filtration membrane 
Sensitivity Response of a simulation model outputs to changes in information inputs 
Simulation model 
Mathematical model of a real process, taking information as inputs and 
producing information outputs which simulate real material and energy 
inputs and outputs 
Single use 
technology 
Process technology (vessels, separation, fluid management) where 
equipment/consumables are disposed of as waste after one use 
Specific growth rate Unit time dependence factor of microbiological growth 
Stainless steel 
technology 
Process technology (vessels, separation, fluid management) based on re-
useable equipment/consumables 
Sterilize To kill microorganisms to less than 1 surviving from 1 million viable 
Sterilize in place Sterilize a piece of equipment in the same location where it is installed 
Substrate 
Starting material which is consumed in a biochemical reaction to produce 
products 
Supernatant Liquid product from centrifugation separation process 
Technology platform 
Classification of equipment and consumables which have common 
technological properties 
Technology tree Diagram describing possibilities for different technologies as branches from 
Titer Concentration of product in a culture at the end of the fermentation process 
Unit operation 
Simulated event or process which takes place in a simulated piece of 
equipment 
Unit procedure Series of unit operations taking place in one piece of equipment 
Validation 
Proving a process, material, or piece of equipment performs as designed 
and intended to 
Wild type Naturally occurring organism (no genome modification) 
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Acronyms and Abbreviations 
ADH Adipic acid Di-Hydrazide 
ADP Adenosine Diphosphate 
ATP Adenosine Triphosphate 
CAPEX Capital Expenses 
CDAP 1-Cyano-DimethylAminoPyridinium 
COG Cost of Goods 
CPS Capsular Polysaccharide 
CRM-197 Cross Reactive Material 197 
DCW Dry Cell Weight 
DES Discrete Event Simulation 
DFC Direct Fixed Capital 
DO Dissolved Oxygen 
DTP Diphtheria, Tetanus & Pertussis 
EDC 1-Ethyl-3-(3-Dimethylaminopropyl) Carbodiimide 
EPI Expanded Program on Immunisation 
EPI-SA Expanded Program on Immunisation in South Africa 
FORTRAN Formula Translation 
GAVI Global Alliance for Vaccines and Immunisation 
GBS Group B Streptococcus 
GE General Electric 
GSK GlaxoSmithKline 
HIV Human Immunodeficiency Virus 
HY Hybrid technology platform 
IAP Intrapartum Antibiotic Prophylaxis 
IP Intellectual Property 
IRR Internal Rate of Return 
LAF Laminar Air Flow 
LCA Life Cycle Assessment 
LCIA Life Cycle Impact Assessment 
MES 4-MorpholinoEthaneSulfonic acid 
NPV Net Present Value 
OD Optical Density 
OPEX Operating Expenses 
PBS Phosphate Buffered Saline 
PFD Process Flow Diagram 
Polio Poliomyelitis 
R&D Research & Development 
RMPRU Respiratory and Meningeal Pathogens Research Unit 
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SA South Africa 
SS Stainless Steel technology platform 
STR Stirred Tank Reactor 
SU Single Use technology platform 
SUT Single Use Technology 
TB Tuberculosis 
TEA Triethylamine 
TRIS Tris (Hydroxymethyl) Aminomethane 
TT Tetanus Toxoid 
UNICEF United Nations Children's Fund 
UPC Unit Production Cost, equivalent to COG 
US United States of America 
VBA Visual Basic for Applications 
VLP Virus Like Particles 
WFI Water for Injection 
WHO World Health Organisation 
 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Chemical Formulae 
  xviii 
Chemical Formulae 
(C35H52O31N2)n GBS serotype III Capsular polysaccharide 
C2H5OH Ethyl alcohol (Ethanol) 
C6H12O6 D-(+)-Glucose 
CaCl2 Calcium chloride 
CH3CHOHCOCH3 3-hydroxybutanone 
CH3CHOHCOOH Lactic acid 
CH3COOH Acetic acid 
CO2 Carbon dioxide 
HCl Hydrochloric acid 
HCOOH Formic acid 
KH2PO4 Potassium di-phosphate 
Na2CO3 Sodium carbonate 
Na2HPO4.2H2O Disodium phosphate (dihydrate) 
NaCl Sodium chloride 
NaH2PO4.H2O Monosodium phosphate (monohydrate) 
NaOH Sodium hydroxide 
TRIS Tris (hydroxymethyl) aminomethane 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Units 
  xix 
Units 
$ US Dollars (2017 exchange rates) 
% DO 
Percentage dissolved oxygen concentration relative to saturation 
concentration (100% DO) 
% vv Percentage by volume per volume 
°C Degrees Celsius  
µg Microgram (1 x 10-9 kg) 
µm Micrometer (1 x 10-6 m) 
atm Atmosphere (101325 Pa) 
bar 1000 kPa 
barg Bar pressure in addition to 1 atm 
Da Dalton 
g Gram (1 x 10-3 kg) 
gDCW Grams of dry cell weight 
h hour 
kDa Kilodalton (1 x 103 Da) 
kg kilogram 
kVA Kilovolt-Ampere (1 x 103 VA) 
L Liter (1 x 10-3 m3) 
M Moles per liter (mol/L) 
m meter 
mg Milligram (1 x 10-6 kg) 
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1 Introduction 
1.1 Manufacturing Human Vaccines 
Vaccines are one of the most effective modern healthcare interventions due to their low cost and 
efficacy in preventing the spread of infectious diseases. Vaccines protect vulnerable patients by 
conferring to the recipient long term immunity against disease (Kremer, 2002; Pagliusi, Leite, et al., 
2013; Rader & Langer, 2014). The eradication of many of the most deadly infectious diseases is a result 
of decades of scientific research and development, although in recent times post-modernist populism 
has given rise to science deniers who believe vaccines cause diseases rather than cure them (Kata, 
2012).  
Before vaccines, contracting a highly infectious disease like measles or smallpox meant death for the 
infected patient (Hotez, 2017). There have been many ground-breaking advances in medical science 
in the field of vaccines, as shown below in Figure 1. One of the first documented cases of use of a 
vaccine to provide immunity against an infectious disease was in 1796, when Edward Jenner used 
cowpox pus to immunise patients against the human disease smallpox. A major breakthrough in the 
field of vaccines and immunology was Jonas Salk’s 1955 discovery of an effective vaccine against 
Poliomyelitis (Josefsberg & Buckland, 2012). Polio is a virus that attacks the nerves and spinal cord, 
causing deformation and debilitation which is especially cruel when the victims are young children 
(WHO, 2017a). As shown in Figure 1, since the discovery of the Polio vaccine a number of technologies 
have been developed for vaccine manufacture including recombinant virus like particles (VLPs) and 
conjugated polysaccharide vaccines, the latter of which first appeared in 1987 (Josefsberg & Buckland, 
2012). The modern era of high-quality vaccines regulated by current Good Manufacturing Practice 







































The global demand for medicinal pharmaceutical products is dynamic, with new markets continuously 
emerging in developing countries, as well as growing demand in established markets such as Europe, 
Asia and the US  (Kremer, 2002; Papavasileiou et al., 2007; Pagliusi, Makhoana, et al., 2013; Ampofo, 
2016). To meet this demand manufacturers invest heavily in research and development of new 
products, with an estimated average investment of $ 2.8 billion (2013 USD) per approved compound 
(DiMasi, Grabowski & Hansen, 2016). With such large investments and limited patent protection for 
intellectual property it is essential that manufacturers minimize the time to market for new products, and 
recover their investments into research and development (Papavasileiou et al., 2007; Papavasileiou, 
Siletti & Petrides, 2008; Toumi et al., 2010).  
1.1.1 The South African Context for Manufacturing Human Vaccines 
In the 1980s and 90s South Africa’s state vaccine manufacturing programme produced human vaccines 
for tuberculosis (TB), polio, rabies, diphtheria tetanus & pertussis (DTP), typhoid, smallpox, and yellow 
fever. This programme was abandoned in the early 2000s due to an inability to keep up with the global 
renaissance in vaccine processing technology, and stricter regulations which required large capital 
investments in order to keep up with the rapidly transforming industry (Makhoana, 2011). In an attempt 
Figure 1: A brief history of vaccines, bioprocessing simulation, and single use technology 
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to restore domestic vaccine manufacturing capacity to South Africa, a public-private partnership (PPP) 
between the South African Government and the Biovac Consortium was launched in 2003 (Stanford, 
2003). The African market for vaccines has always been a lucrative prospect due to governments and 
non-governmental organisations like UNICEF each spending billions every year to procure vaccines 
from manufacturers in other countries and distribute them to African countries. 
While local vaccine manufacturing capacity was being lost, South Africa had implemented the WHO’s 
Expanded Programme on Immunisation (EPI) in 1995 (Baker, 2010). On the modern EPI-SA infants 
and children are vaccinated against a range of diseases as a basic public health service. The EPI-SA 
has been successful in reducing the mortality rate of children under 5 (Madhi, 2015) in a country where 
many types of disease burdens are higher than global averages. As a result many vaccines including 
those intended for children on the EPI are trialled in South Africa (Madhi et al., in press, 2000, 2010; 
Klugman et al., 2003; Day et al., 2013; Geldenhuys et al., 2015; Madhi, 2015); however, no human 
vaccines were manufactured in South Africa as of 2019. 
Streptococcus agalactiae, also identified as Group B Streptococcus (GBS) by Lancefield’s classification 
(Lancefield, 1932), is the most prevalent cause of severe early onset bacterial infection in infants. In 
some cases GBS infection leads to infant mortality or permanent disability, with a mortality rate of 
between 10% and 50% of invasive cases (WHO, 2017b). The bacteria are believed to be transmitted 
from mother to child during childbirth, with an estimated 20% of all women being carriers (Burns & 
Plumb, 2013). 
The disease burden of GBS around the world is relatively low compared to heart-disease, diabetes, 
auto-immune diseases, cancer, and HIV. Incidence of neo-natal and infant GBS disease in 2010 was 
as low as 0.3 cases per 1000 live births in the USA, up to ten times lower than South Africa with 3 cases 
per 1000 live births (Schrag & Verani, 2013; Kim et al., 2014).  The discrepancy between the market 
power of the South African region, and the high GBS disease burden in South Africa is a potential 
reason why no commercial vaccine exists, despite the morbidity of the victims being infants and 
children. 
The inertia of the market for a GBS vaccine has somewhat been overcome by the WHO and various 
research groups through awareness initiatives, and  based on the need to develop a GBS vaccine on 
humanitarian grounds rather than commercial viability (WHO, 2017b). The existing use of alternative 
therapies such as Intrapartum Antibiotic Prophylaxis (IAP) has slowed the progress of vaccine 
development research; however, IAP is ineffective in preventing late onset GBS infection and is 
logistically impractical in rural areas of developing countries like South Africa. Despite the availability of 
IAP and the relatively small market for a GBS vaccine, development is currently underway by multiple 
research groups and commercial vaccine manufacturers (Burns & Plumb, 2013; Kim et al., 2014; WHO, 
2017b). 
1.1.2 Process Simulation for Biopharmaceutical Processes 
The goal of pharmaceutical manufacturing processes is to maximise productivity, which is 
complimented by prioritising speed to market during process development (Sinclair & Monge, 2002; 
Buckland, 2005; Ransohoff, 2005; Sinclair & Monge, 2005). The role of process simulators in this 
approach is to assist with process development decision making within expedited time frames, without 
the cost of investing in physical experiments. Aspen Batch Plus and Intelligen SuperPro Designer are 
described as the best available commercial simulation products which offer an integrated process 
modelling package (Gosling, 2005; Farid, Washbrook & Titchener-Hooker, 2007; Toumi et al., 2010), 
with all the required features for an effective process simulator. 
Process simulators have been used in the chemical processing industry since the 1960s as a tool for 
evaluation of the performance of operations planning and techno-economic efficiency (Shanklin et al., 
2001; Papavasileiou et al., 2007; Toumi et al., 2010). Early process simulation tools were developed 
in-house by chemical companies for specific continuous processes using coding languages like 
FORTRAN (Lang, Biegler & Grossmann, 1988). These early models developed quickly into commercial 
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packages, successful in part due to the availability of fundamental first principles models such as 
thermodynamic equilibrium for the modelling of various unit operations (Shanklin et al., 2001).  
The application of process simulation to biopharmaceutical manufacturing is primarily at the pre-
feasibility design stage of large-scale process development. This type of exercise is performed by 
relevant trained engineering personnel either as consulting service, or in-house by commercial 
biopharmaceutical manufacturers. These tools are used to evaluate process development decisions 
before investing in new products or expanding existing capacity. 
1.1.3 Vaccine Manufacturing Technology 
There are many processes used around the world for making vaccines. A vaccine product may contain 
a variation of chemical structures of the same antigenic compound, which makes vaccines more easily 
defined by the process of manufacture than laboratory measurements of the product characteristics 
(Josefsberg & Buckland, 2012).  
Vaccine antigens can be produced either by culture of a naturally occurring organism (wild type) that 
expresses a specific antigen, or by engineering the genome of an organism (recombinant) to induce 
expression of the antigen. Antigens may be expressed either intra-cellularly or extra-cellularly, 
depending in the organism and the nature of the antigen itself. Biological cultures are grown in large 
quantities in fermentors or bioreactors, followed by purification to recover the antigen only, and then 
formulation into a vaccine product (Smith, Lipsitch & Almond, 2011; Cox, 2012; Josefsberg & Buckland, 
2012). After formulation, the vaccine is packaged in an aseptic environment and distributed through a 
supply chain network designed and operated to preserve the potency and efficacy of the vaccine 
product (Lydon & Raubenheimer, 2011).  
Due to the varying range of diseases that vaccines are used against, the process of making a vaccine 
is often unique, making the entire industry widely varied. A technology tree of different types of vaccines 
is shown in Figure 2 below, and based on a review of Vaccine technologies by Josefsberg & Buckland 
(2012). Each colour below represents a different process approach. 
 
The “gold-standard” for bioreactor technology in vaccine production is the stainless-steel stirred tank 
reactor (STR). The widespread use of STR technology in a range of modern bioprocessing industries 
from mining to pharmaceuticals is attributed primarily to their enhanced flexibility for a wide range of 
applications whilst achieving high mixing performance (Nienow, 2014). The nature of industrial 
bioprocessing is generally one which requires control of mass transfer, which translates into control of 
the growth characteristics of the culture inside the processing vessel. These physical phenomena have 
been the driving force for technological development of many industrial bioprocesses (Godoy-Silva, 
Berdugo & Chalmers, 2010; Nienow, 2014, 2015).  
Figure 2: Different vaccine products 
Based on (Josefsberg & Buckland, 2012) 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Introduction 
 
  4 
 
Stainless steel stirred tanks feature robust mechanical or magnetic agitation systems, allowing for either 
high or low power to volume ratio around the impeller zone, depending on the requirements of the 
process. This feature remains a critical one for microbial culture where fast cell growth and high cell 
density require equivalent mass transfer and heat dissipation (Löffelholz et al., 2013; Shukla & 
Gottschalk, 2013).  Stainless steel fermentors, a type of STR with a high vessel aspect ratio, have been 
successfully used to produce vaccines against pneumococcal disease, diphtheria, tetanus, and 
pertussis (whooping cough). The manufacturing preference for stainless steel has been largely 
unchallenged until the turn of the 21st century, when single use technology became a viable alternative 
for many applications, particularly for shear sensitive processes like monoclonal antibodies or 
microalgae production (Chisti, 2007; New Brunswick Scientific et al., 2009; Pörtner, 2015). 
The first successful demonstration of a single use bioreactor was Vijay Singh’s rocking bag reactor for 
small to medium scale (0-100L) cell culture (Singh, 1999, 2001). A more robust bioreactor design, 
shown in Figure 3 (below), was patented in 2009 by Xcellerex (now GE Healthcare) (Hodge, Galliher 
& Fisher, 2009). The design featured a plastic bag set inside an open tank body with temperature control 
jacket. The bag contained an agitator coupled magnetically to an external drive unit. In contemporary 
bioreactor engineering this type of STR design may be used for mammalian cell culture up to volumes 
of 2000 L, but has only limited application for microbial cultures (Shukla & Gottschalk, 2013). The same 
design concept has been applied to micro-scale reactors as small as 10 mL (Sartorius Stedim - Tap, 
2018), allowing for end to end use of a single reactor design from cell bank development to industrial 
manufacture. 
  
Figure 3: Single use bioreactor design 
Redrawn from Hodge, Galliher & Fisher, (2009) 
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1.2 Scope and constraints  
This investigation included the development and production of at least six simulation models of a 
process for the production of a polysaccharide-protein conjugate vaccine antigen against Group B 
Streptococcus (GBS) serotype III. The process was limited to antigen production and did not include 
formulation and filling of the final vaccine product.  The simulation models included various scenarios 
involving the use of three different technology platforms: stainless steel, single-use, and hybrid 
technologies. The project was extended to predicting the effect of scale up from 20 L to 200 L 
fermentation capacity. A sensitivity analysis was done to expand one of the six models into multiple 
scenarios to test the sensitivity of the selected model to input parameters. 
Real experimental data (unpublished raw data) was used to develop a structured kinetic model for batch 
fermentation of Streptococcus agalactiae (GBS).  Purification and conjugation models were based on 
literature only and were not based on experimental data. A simplified representation of the scope and 
limitations of this project as described above is shown in Figure 4 below. Content included in this 
investigation is shown in green, with content not included shown in red. 
Literature review 
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Figure 4: Process simulators project scope and limitations. 
1.3 Defining and Investigating the Problem 
Developing a new vaccine manufacturing process in South Africa is complex and requires multiple 
processing options to be considered for achieving required product quality, regulatory compliance, and 
lowest cost. Process engineering science may be most effective at evaluating the latter, with the 
assumption that a real process development approach would normally account for all other relevant 
considerations. Tools for performing this evaluation should in turn be evaluated for their effectiveness 
in assisting the most cost-effective choices between different processing options.  
Computerised process simulation is used extensively in process engineering, but its use for 
biopharmaceutical process development in South Africa is not extensively documented in literature. 
The South African context for manufacturing a GBS vaccine had to be defined for this project, as a 
justification for choosing this process as a case study to demonstrate the use of process simulation in 
the identified context. A process for making GBS vaccine antigen had to be defined, as well as 
investigation of some of the different technology platforms available for executing the process. To 
evaluate these technology choices, the capabilities of process simulation tool had to be defined as a 
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framework for the outputs for the simulation models to be demonstrated. These aspects, brought 
together, inform a hypothesis (or hypotheses) around the cost effectiveness of the GBS vaccine 
process. The results of testing this hypothesis were then used to evaluate the effectiveness of process 
simulation as a decision support tool for biopharmaceutical process development in South Africa. 
1.4 Structure of this dissertation 
1. Introduction 
 Summary of project context for vaccine manufacturing in South Africa, process simulation tools 
for biopharmaceutical process development, and vaccine manufacturing technology options. 
 Scope and constraints of the project. 
2. Literature survey 
 As per the approach defined in the introduction, a detailed survey of: 
o State of human vaccine manufacturing in South Africa as of 2017. 
o Selected examples of existing GBS vaccine process technology. 
o Selected examples of computerised process simulations for biopharmaceutical process 
development. 
o Introduction to commercial drivers for single use technology and the benefits and limitations 
thereof. 
 Definition of a problem statement as informed by the preceding literature survey 
 Hypothesis/hypotheses formulated in response to the problem statement 
3. Methodology and experimental approach 
 Statement of research methodology to be used 
 Description of the experimental structure and approach to be followed for execution. 
 Detailed documentation of the execution of the experimental approach: 
o Process definition by synthesis of multiple existing technologies for GBS vaccine. 
o Specification of a base case simulation model, including the use of specific data input 
relative to a South African context. 
o Description of the approach used for the evolution of new scenarios from base case model. 
o Structure and specifications for sensitivity analyses on the best performing case scenario, 
including specific input relative to a South African context. 
4. Results 
Reporting the findings from the execution of the experimental approach:  
 Fermentation kinetic model parameters found, which will then be used in the simulation models. 
 Reporting the simulation models produced as a result of the simulation exercise. 
 Compiled economic performance results of computer simulations, including graphic 
comparisons between the three different technology platforms. 
 Results of sensitivity analyses on best case scenario. 
5. Discussion 
 Describing relationships and trends observed in the economic performance results at the two 
different scales, and between the three different technology platforms. 
 Comment on the feasibility of the process, in terms of Internal Rate of Return (IRR) relative to 
a specified discount rate (the hurdle rate). 
 Discussion of the influence of the methods and experimental approach on results. 
 Discussion of the influence of the South African context on results. 
 Comment of the use of process simulators for biopharmaceutical process development. 
6. Conclusion & recommendations 
 Assessment of the hypothesis/hypotheses. 
 Conclusions on the following: 
o Best performing technology platform and scale for the process modelled 
o Feasibility of the process, in terms of IRR relative to the hurdle rate used.  
o The use of process simulation for process development in a South African context. 
 Recommendations on the use of simulation modelling as a decision support tool for 
biopharmaceutical process development in a South African context 
 Recommendation on potential future applications of this research. 
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2 Literature Review 
2.1 South African Human Vaccine Manufacturing 
South Africa in the Global Vaccine Market 
In 1998 Africa represented just 1% of the global market for 
pharmaceuticals (by monetary value) with government 
spending on healthcare in sub-Saharan Africa averaging 
just $ 18 per capita, compared to $ 4000 per capita in the 
USA (Kremer, 2002). In the 2017 biopharmaceutical world 
market shown in Figure 5, South African manufacturing 
made up less than 0.2% (BioPlan Associates, 2017). 
Despite not producing human vacccines, the humanitarian 
market for vaccines in the sub-Saharan Africa region is 
lucrative.  Over 60% of vaccines procured by UNICEF in 
2011 were used in this region (Ampofo, 2016), which was 
valued as a potential market over $ 560 million in 2013 
(Pagliusi, Makhoana, et al., 2013). This same market 
nearly doubled in value by 2014 to $ 900 million (Ampofo, 
2016).  At present, UNICEF procures vaccines for many 
Global Alliance for Vaccines and Immunization (GAVI) 
eligible African countries (shown in Figure 6). Sub-
Saharan Africa and North Africa  are the general 
exceptions to this trend, yet only five African countries 
have vaccine manufacturing facilities: Egypt, Senegal, 
Tunisia, South Africa, and Ethiopia (Makhoana, 2011; 
Ampofo, 2016). 
The scarcity of producers on the African continent is due 
to high barriers to market entry. Vaccines are a technically 
challenging product to design and produce, as illustrated 
by the broad range, and specificity of claims made in 
modern vaccine patents (Khandke et al., 2016). 
Regulatory requirements for licensing and possible royalty 
payments to third party developers can also be barriers. 
There are long time-scales involved in creating a vaccine 
manufacturing enterprise capable of patenting new 
technologies (Buckland, 2005; Smith, Lipsitch & Almond, 
2011). 
Immunisation in South Africa 
The South African Department of Health introduced the 
WHO Expanded Program on Immunisation (EPI) to South 
Africa in 1995 (Baker, 2010). The EPI-SA is a public health 
policy for infant and early childhood immunisation against 
diseases including polio, tuberculosis, pneumococcal 
disease, and rotavirus. The EPI-SA has been criticised by 
ex-officials in the program, with challenges described 
relating to human-resource constraints and cold-chain 
management (Bateman, 2016).  
Figure 5: World Biopharmaceutical Markets 
Drawn based on (BioPlan Associates, 2017). 
  
Figure 6: African vaccine market demand (top) and 
supply (bottom) capacity.  
Drawn based on (Ampofo, 2016) 
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Despite the supposed challenges, the EPI SA has also experienced a number of successes (Dlamini & 
Maja, 2016):  
 First in Africa to publicly roll-out both the Pneumococcal and Rotavirus vaccines - both in 2009. 
 Implementation of a patient friendly single liquid dose hexavalent (6-in-1) vaccine in 2015. 
The EPI-SA is credited by Madhi, (2015) for reducing child deaths under 5 in the period between 2000 
and 2013. This statistic increased from 75 753 deaths in 2000 to 89 418 in 2005, but the impact of the 
EPI saw the number decrease to 47 409 by 2013. Madhi’s research is (as of 2019) conducted at the 
Respiratory and Meningeal Pathogens Research Unit (RMPRU) at Chris Hani Baragwanath hospital in 
Johannesburg (RMPRU, 2019). This unit is responsible for a large body of research outputs which 
provide insight into disease burdens in Southern Africa and also into efforts to curb infectious diseases 
in South African children including pneumococcal disease, HIV, tuberculosis, and rotavirus (Madhi et 
al., in press, 2000, 2010; Klugman et al., 2003; Madhi, 2015).  
Madhi and the RMPRU have also been involved in research into a maternal vaccine against GBS 
disease (RMPRU, 2019), publishing investigations which describe the need for- and potential 
effectiveness of a maternal GBS vaccine in South Africa (Madhi et al., 2003; Cutland et al., 2009; Kim 
et al., 2014; Kobayashi et al., 2016). This body of work adds to the international publications on GBS 
disease and the need for a GBS vaccine (Burns & Plumb, 2013; Schrag & Verani, 2013; Heath, 2016). 
Group B Streptococcus (GBS) Disease 
Group B Streptococcus is the most prevalent cause of severe early onset bacterial infection in infants, 
and in some cases leads to infant mortality or permanent disability. The bacteria are believed to be 
transmitted from mother to child during childbirth or during late pregnancy (Edmond et al., 2012). It is 
estimated that between 20 and 25% of all women are carriers of GBS (Burns & Plumb, 2013). 
In 2010 the incidence of neo-natal GBS infection in South Africa was 3 per 1000 live births, while the 
same number for Africa was 1.21 per 1000 live births. In Africa the mortality rate for GBS disease was 
22% (Kim et al., 2014). In developed countries like the United States of America (USA) the infection 
rate in 2010 was only 0.26 per 1000 live births. In the USA and United Kingdom (UK), mothers are 
screened for GBS colonization and treated with intrapartum antibiotic prophylaxis (IAP) if required. In 
countries like South Africa without screening infrastructure, IAP is administered in SA based on an 
assessment of risk factors (Bomela, Ballott & Cooper, 2001). Although IAP is reported to have 80-90% 
efficacy in preventing early-onset GBS disease (0-7 days), it has no effect in preventing late-onset 
disease (7-90 days). A vaccine could increase prevention of GBS disease in South Africa by almost 
four times the efficacy of current best-practices (Schrag & Verani, 2013; Kim et al., 2014; Heath, 2016). 
When compared to existing available GBS treatments, a Life Cycle Impact Assessment (LCIA) by Kim 
et al., (2014) found that a GBS Vaccine would be cost-effective as a public healthcare intervention even 
at a selling price of $20 - $30 (US) per dose, equivalent to about R 250 – R 400. 
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2.2 Manufacturing Conjugate Polysaccharide Vaccines 
Figure 7 above shows a representation of how conjugate vaccines 
are synthesised by covalently bonding one or more antigens, such 
as a bacterial polysaccharide, to a carrier protein. Antigens may be 
produced by either classical fermentation (bacterial, mammalian) or 
by recombinant protein expression. Some pathogenic gram-negative 
bacteria produce a capsular polysaccharide which interferes with the 
immune response of the host organisms and allows the bacterium to 
evade phagocytosis (Bae et al., 2009; Paoletti, 2016). The same 
polysaccharide may be used as an antigen to produce an 
immunologic response in a patient receiving the antigen in a vaccine. 
Polysaccharide vaccines produce a satisfactory specific immune 
response, conferring relatively short-term protection. The linking of 
the polysaccharide to a carrier protein as shown in Figure 7 
previously, stimulates a stronger immune response than that elicited 
by the native polysaccharide alone (Jennings & Lugowski, 1982; 
Michon & Blake, 2001; Lees, Sen & Lopezacosta, 2006; Frasch, 
2009; Lee et al., 2009; Josefsberg & Buckland, 2012; Hamidi et al., 
2016). The recipient’s immune system generates the required 
immunologic response to the native polysaccharide with antigen 
specific B lymphocytes (B cells), but linking the polysaccharide to a 
carrier protein induces the response of T lymphocytes (T cells) which 
can program long term immunity (Frasch, 2009). A block diagram 
describing the process for conjugate vaccines is shown in Figure 8.  
Bacterial polysaccharides and proteins can both be produced by 
culturing bacteria. In the case of polysaccharide production, the 
extracellular polysaccharide is released into the culture liquid by 
chemical treatment which simultaneously decontaminates the 
product (killing the pathogen). The polysaccharide is then recovered 
by gravitational separation, size exclusion filtration, affinity filtration, 
and/or precipitation, depending on its chemical nature (Jennings & 
Lugowski, 1982; Michon & Blake, 2001; Frasch, 2009; Josefsberg & 
Buckland, 2012). The carrier protein is fermented separately, and 
purified by homogenization, gravitational separation, size exclusion 
filtration, and affinity filtration. 
Figure 7: Simplified process for a protein-polysaccharide conjugate vaccine. 
Redrawn from (Gambillara, 2012) 
Figure 8: Block flow of conjugate vaccine 
production process. 
Redrawn from (Josefsberg & Buckland, 
2012) 
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Processes to Manufacture a GBS Vaccine Antigen 
A number of patents have been awarded to various inventors for a method of producing and purifying 
capsular polysaccharides of Streptococcus agalactiae also known as Group B Streptococcus (GBS). 
GSK (formerly Novartis A.G.) has patented a fermentation, purification, and conjugation process for 
three different serotypes of GBS capsular polysaccharide (CPS) to a carrier protein. The GSK trivalent 
conjugate vaccine patent describes a state-of-the-art process to manufacture a GBS conjugate vaccine; 
however, there have been a number of other patents which describe the process of obtaining the CPS 
and conjugating it to a protein which are also worthy of consideration for a novel process. Fermentation 
of GBS at 20 L – 200 L scales is classified as Biosafety Level 2. 
2.2.1.1 GBS Fermentation Stoichiometry 
Mickelson (1972) studied the aerobic metabolism of Streptococcus agalactiae (GBS) by analysis of 
products after a monoseptic culture of GBS. The primary carbon source studied was glucose, with 
cultures grown in chemically defined medium with a composition as shown in Table 2-1 below: 
Table 2-1    Chemically defined culture medium used by Mickelson (1972) 
Component Concentration Units 
Glucose 7 mmol/L 
Casitone 0.5 % w/w 
Yeast extract 1.0 % w/w 
Phosphate 0.05 mol/L 
Thiamine 0.5 µg/mL 
Riboflavin 0.5 µg/mL 
Niacin 1.0 µg/mL 
Pantothenate 0.5 µg/mL 
Pyridoxal 1.0 µg/mL 
Biotin 0.0025 µg/mL 
Magnesium Sulfate heptahydrate 0.2 mg/mL 
Sodium Chloride 0.01 mg/mL 
Manganese Sulfate tetrahydrate 0.01 mg/mL 
Iron (II) Sulfate heptahydrate 0.01 mg/mL 
Six cultures were used to generate data for two experiments in triplicate. The cultures were grown in a 
30 mL working volume inside respirometer vessels with 160 mL total volume. Conditions were 
maintained at pH 6.8 and 37 °C, and agitation was at 90 oscillations per minute.  
Mickelson calculated that under anaerobic conditions the GBS cultures metabolised 75% of glucose to 
lactic acid, and the balance to acetic acid, formic acid, and ethanol. Mickelson reported that under 
anaerobic conditions the GBS cultures generated an average of 2 moles ATP per mole of glucose 
consumed from substrate level phosphorylation. Under aerobic conditions, Mickelson reported one 
mole of oxygen was utilised per mole of glucose consumed, and that about a third of glucose consumed 
was converted to lactic acid, with the remainder to acetic acid, formic acid, acetoin, and carbon dioxide. 
Under aerobic conditions 5 moles of ATP were generated per mole of glucose consumed. Mickelson 
estimated 50% of the ATP was generated from substrate level phosphorylation and 50% from oxidative 
phosphorylation.  
  
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Literature Review 
 
  11 
 
The following stoichiometric equations were reported by Mickelson (1972): 
Aerobic conditions 
𝐶 𝐻 𝑂 →  2𝐶𝐻 𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 → 2 𝐿𝑎𝑐𝑡𝑖𝑐 𝑎𝑐𝑖𝑑  
Equation 2-1 
𝐶 𝐻 𝑂 → 2𝐶𝐻 𝐶𝑂𝑂𝐻 + 𝐶𝑂 + 𝐻𝐶𝑂𝑂𝐻 + 𝐶𝐻 𝐶𝐻𝑂𝐻𝐶𝑂𝐶𝐻   
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 → 2 𝐴𝑐𝑒𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐶𝑎𝑟𝑏𝑜𝑛 𝑑𝑖𝑜𝑥𝑖𝑑𝑒 + 𝐹𝑜𝑟𝑚𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐴𝑐𝑒𝑡𝑜𝑖𝑛 
Equation 2-2 
𝑪𝟔𝑯𝟏𝟐𝑶𝟔 → 𝟎. 𝟕𝟖 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑶𝑯 + 𝟎. 𝟖𝟓 𝑪𝑯𝟑𝑪𝑶𝑶𝑯 + 𝟏. 𝟏𝟑 𝑪𝑶𝟐 + 𝟎. 𝟏𝟐 𝑯𝑪𝑶𝑶𝑯
+ 𝟎. 𝟎𝟗 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑪𝑯𝟑 
𝑮𝒍𝒖𝒄𝒐𝒔𝒆 → 𝟎. 𝟕𝟖 𝑳𝒂𝒄𝒕𝒊𝒄 𝒂𝒄𝒊𝒅 + 𝟎. 𝟖𝟓 𝑨𝒄𝒆𝒕𝒊𝒄 𝒂𝒄𝒊𝒅 + 𝟏. 𝟏𝟑 𝑪𝒂𝒓𝒃𝒐𝒏 𝒅𝒊𝒐𝒙𝒊𝒅𝒆
+ 𝟎. 𝟏𝟐 𝑭𝒐𝒓𝒎𝒊𝒄 𝒂𝒄𝒊𝒅 + 𝟎. 𝟎𝟗 𝑨𝒄𝒆𝒕𝒐𝒊𝒏 
Equation 2-3 
Anaerobic conditions 
𝐶 𝐻 𝑂 → 𝐶𝐻 𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 + 𝐶𝐻 𝐶𝑂𝑂𝐻 + 𝐶 𝐻 𝑂𝐻 + 𝐻𝐶𝑂𝑂𝐻 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 → 𝐿𝑎𝑐𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐴𝑐𝑒𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐸𝑡ℎ𝑦𝑙 𝑎𝑙𝑐𝑜ℎ𝑜𝑙 + 𝐹𝑜𝑟𝑚𝑖𝑐 𝑎𝑐𝑖𝑑  
Equation 2-4 
𝐶 𝐻 𝑂 → 1.48 𝐶𝐻 𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 + 0.26 𝐶𝐻 𝐶𝑂𝑂𝐻 + 0.15 𝐶 𝐻 𝑂𝐻 + 0.28 𝐻𝐶𝑂𝑂𝐻
+ 2𝐴𝑇𝑃 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 → 1.48 𝐿𝑎𝑐𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 + 0.26 𝐴𝑐𝑒𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 + 0.15 𝐸𝑡ℎ𝑦𝑙 𝑎𝑙𝑐𝑜ℎ𝑜𝑙
+ 0.28 𝐹𝑜𝑟𝑚𝑖𝑐 𝑎𝑐𝑖𝑑 + 2𝐴𝑇𝑃 
Equation 2-5 
While Mickelson’s analysis is thorough and includes the major metabolic systems of Streptococcus 
agalactiae, his findings and the analytical methods used were over 35 years old as of 2019. 
2.2.1.2 GBS Growth Media 
(Wessels et al., 1989, 1990) describe the successful culture of Group B Streptococcus serotype III strain 
M781 grown on purified Columbia Broth medium. A commercially available composition of Columbia 
Broth is shown in Table 2-2 below. In the experiment of Wessels et al. (1990) the medium is also 
supplemented with a glucose solution of 80 g/L. 
Table 2-2    Becton Dickinson Columbia Broth Composition 
Component Conc.[g/L] 
Pancreatic digest of Casein 10.0 
Yeast Extract 5.0 
Proteose Peptone No. 3 5.0 
Tryptic Digest of Beef Heart 3.0 
L-Cysteine HCl 0.1 
Dextrose 2.5 
Sodium Chloride 5.0 
Magnesium Sulfate (anhydrous) 0.1 
Ferrous Sulfate 0.02 
Sodium Carbonate 0.6 
Tris (Hydroxymethyl) Aminomethane 0.83 
Tris (Hydroxymethyl) Aminomethane.HCl 2.86 
Source: (Zimbro, 2009) 
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2.2.1.3 US 8 445 239 B2 - Fermentation processes for cultivating streptococci and 
purification processes for obtaining CPS therefrom (Costantino et al., 2013) 
A process for a GBS conjugate vaccine patented GSK (formerly Novartis A.G.) begins with an inoculum 
prepared in four 5 L Fernbach shake flasks, each with 1 L of complex growth medium with a composition 
shown in Table 2-3 below: 
Table 2-3    Complex seed medium for inoculum preparation 
Component Conc.[g/L] 
D-Glucose monohydrate 28.7 






Pyridoxine HCl 0.4 
Niacinamide 0.4 
Biotin 0.9 
The flasks are inoculated with 2.75 mL each of working cells. The flask contents are then cultured at 35 
°C, with agitation of 200 rpm until an OD590 of 0.6 – 1.2 (approximately 4 hours), after which the contents 
are harvested and pooled in a 5 L glass bottle, to serve as the inoculum for a 300 L fermentor. The 
fermentor is filled with 150 L of growth medium with a composition shown in Table 2-4 below: 
 Table 2-4    Growth medium for pilot scale fermentation 
Component Conc.[g/L] 
D-Glucose monohydrate 33.7 




After sterilizing the medium by 0.2 µm filtration into the vessel, the fermentor is inoculated with 4 L of 
inoculum with an average OD590 of 0.6 – 1.2. The batch phase of the fermentation is controlled at 36°C, 
0.2 barg head pressure, and pH 7.3. The initial agitation is set to 50 rpm and aeration at 20 NL/min. 
Dissolved oxygen level is maintained at 30% DO, and regulated by a PID control cascade with stirring 
speeds of 50 – 350 rpm, followed by aeration of 20 – 100 NL/min, and finally by oxygen partial pressure 
using an addition of 0 – 100 NL/min pure oxygen. At an OD590 of 2.5 - 3.0, an addition of 3.6 L of 150 
g/L yeast extract solution is made at 550 mL/min to maintain the culture doubling time at approximately 
5 h. At an OD590 of 4.5 - 5.0, a second addition of 13.4 L of 150 g/L yeast extract solution is made at 
550 mL/min to maintain the culture doubling time at approximately 50 min. At an OD590 of 10 - 12, a 
third feed of 17 L of 550 g/L D-Glucose monohydrate is made at a linear feed rate of 95 mL/min. The 
final productivity of capsular polysaccharide is between 0.35 g/L and 1.00 g/L. 
The vessel is harvested directly via transfer line into a continuous flow disc stack bowl centrifuge, where 
the biomass is separated from the spent medium at a rate of 100 L/h for 7 minutes. The biomass is then 
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washed with water at 100 L/h for 3 minutes. The pellet is collected in a 100 L disposable mixing system 
while the supernatant is discarded to waste treatment. The pellet is inactivated by the addition of 4 M 
NaOH to a final concentration of 0.8 M based on a pellet density of 1 kg/L. During this step, the capsular 
polysaccharide is released into solution. The inactivation & extraction proceeds for 36 h at 37 °C and 
180 rpm agitation. 
A buffer of 1 M TRIS base is added to the inactivated product to a final concentration of 0.1 M, based 
on the mass of inactivated material. The product is then neutralized in the disposable mixing bag by 
addition of 6 M HCl until the final pH is in the range 7.5 – 8.5. Proteins and nucleic acids are then 
precipitated by addition of solutions of 2 M CaCl2 and 96% ethanol, to final concentrations of 0.05 M, 
and 30%, respectively. 
The product of the previous step is then concentrated 10 times by 0.22 µm tangential flow filtration 
(TFF), followed by dialysis against 3 volumes of buffer solution with a composition shown in Table 2-5: 





Ethanol 25 wt% 
The permeate containing the waste biomass and precipitate is collected in a 200 L disposable bag via 
0.22 µm filtration and sent to waste disposal. The retentate (of about 10 kg) containing the 
polysaccharide is then diafiltered through a 30 kDa TFF membrane, against 20 volumes of 50 mM TRIS 
+ 0.5 M NaCl buffer at pH 8.8, followed by 10 volumes of 0.3 M Na2CO3 + 0.3 M NaCl buffer at pH 8.8. 
The retentate is collected through a 0.2 µm filter and stored at 2 – 8 °C for up to 15 days.  The retentate 
is then depth filtered through activated carbon supported on cellulose to remove all residual protein 
contaminants. The filtrate is collected through a 0.2 µm filter and stored at 2 – 8 °C for up to 15 days. 
The filtrate from the depth filtration step is diluted to 2 mg/mL polysaccharide using 0.3 M Na2CO3 + 0.3 
M NaCl buffer at pH 8.8. The diluted product is then re-N-acetylated using 8.3% (vv) acetic anhydride 
in water and approximately 8% Ethanol. The acetic anhydride solution is added to the polysaccharide 
solution ibn a ratio 0.5 L per litre and reacted at room temperature for 2 h. The re-N-acetylated product 
is then filtered through a 30 kDa TFF membrane against 13 volumes of 10 mM KH2PO4. The retentate 
is collected through a 0.2 µm filter and stored at – 20 °C until needed. 
The purified polysaccharide is then typically subjected to a conjugation process; however, the details 
of this are not included in the invention described by Costantino et al. (2013). 
A process flow diagram of this process is shown in Figures 9 and 10 on the proceeding pages. 
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Costantino et al. (2013), Polysaccharide production for GBS conjugate vaccine - Process Flow Diagram sheet 1 of 2 
 
Figure 9: Process for fermentation and purification of GBS polysaccharide - Page 1 of 2 
 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Literature Review 
 
  15 
 
Costantino et al. (2013), Polysaccharide production for GBS conjugate vaccine - Process Flow Diagram sheet 2 of 2 
 
Figure 10: Process for fermentation and purification of GBS polysaccharide - Page 2 of 2 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Literature Review 
 
  16 
 
2.2.1.4 Activation of carrier protein by ADH derivatization, and recovery of proteins by 
ammonium sulfate precipitation 
Rana et al., (2016) describe the preparation of polysaccharide – protein conjugate vaccines against 
Neisseria meningitides to an activated carrier protein. The invention is described for use with either 
Tetanus Toxoid (TT) or CRM-197 as a carrier protein, which is derivatized by reaction with Adipic acid 
Di-Hydrazide (ADH) in the presence of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). In the 
process described by Rana et al. (2016) the carrier protein is reacted with ADH hydrochloride in the 
presence of EDC in a buffer of 4-Morpholinoethanesulfonic acid (MES). The product is a protein with 
carboxyl functional groups substituted with aliphatic amino functional groups. The aliphatic amino 
groups are suitably reactive with available functional groups on an activated polysaccharide. 
This method of activation has also been described by Bartoloni et al. (1995) for activation of group B 
Neisseria meningitides capsular polysaccharide for conjugation to either Tetanus toxoid or CRM-197 
carrier proteins. In this case the method is used to derivatize the polysaccharide rather than the carrier 
protein as in the example of Rana et al., (2016). 
Recovery of large molecular weight products from solution is described by precipitation with saturated 
Ammonium Sulfate, in the case of Bartoloni et al. (1995) the method is used for recovery of a carrier 
protein CRM-197. 
2.2.1.5 Activation of polysaccharide by cyanylation 
The invention of Capiau et al. (2000) describes protein – polysaccharide conjugate vaccines of several 
bacterial species: Haemophilus Influenza b, Neisseria meningitidis, Streptococcus Pneumoniae, and 
Moraxella catarrhalis. The patent claims application of this method to Streptococcus agalactiae but this 
embodiment is not explicitly described. The invention utilises a specific conjugation chemistry of 
activation of the polysaccharide by cyanylation with 1-cyano-dimethylaminopyridinium (CDAP) 
tetrafluoroborate.  The reaction with CDAP forms reactive cyanoester (O-CN) groups on the 
polysaccharide. This is achieved by the swap of a cyano group from the CDAP with a proton from a 
hydroxyl group on the CPS. The cyanoester is very reactive and forms stable linkages with amino 
groups on the activated protein. 
This method has been described by (Frasch, 2009) as an alternative to a more established 
polysaccharide activation by periodate oxidation. 
2.2.1.6 Conjugation of polysaccharides to proteins by reductive amination  
Roy, Katzenellenbogen & Jennings (1984) describe the method of covalent bonding of polysaccharides 
to amino functional groups of a protein by reductive amination with sodium cyanoborohydride. This 
method of conjugating proteins to polysaccharides is a direct reaction mechanism in which the 
cyanoborohydride ion acts as a nucleophile to reduce free functional groups on the polysaccharide, 
generating a stable covalently bonded alkylamine. The reaction is reported to be extremely slow when 
conducted on native polysaccharide reactants but can be accelerated by the addition of more reactive 
functional groups such as aldehydes or carbonyl groups. The latter can be conveniently added by 
oxidation of the polysaccharide with sodium periodate, as described by Lees, Sen & Lopezacosta, 
(2006). Periodate attacks vicinal diols selectively, opening the ring of a cyclic polysaccharide and 
creating two terminal carbonyl groups. These carbonyl groups are the sites for conjugation to a carrier 
protein by reductive amination. Reductive amination appears to be a popular method for conjugating 
proteins to polysaccharides and has been used by multiple authors (Jennings & Lugowski, 1982; 
Wessels et al., 1990; Mistrette, Danve & Moreau, 2010; Buurman et al., 2019).  
However, it is important to note that periodate oxidation opens the polysaccharide ring structure, which 
could negatively affect the immunogenicity of the polysaccharide as a vaccine antigen (Roy, 
Katzenellenbogen & Jennings, 1984). 
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2.3 Process simulation for Biopharmaceuticals 
Commercial batch process simulation software 
The requirements of an effective batch process simulator are described by multiple authors (Petrides 
et al., 1989; Shanklin et al., 2001; Papavasileiou et al., 2007; Toumi et al., 2010): 
 Ability to generate a single visual representation of the entire process. 
 Solve material and energy balances for each process stream. 
 Estimate the size of process equipment. 
 Estimate equipment occupancies. 
 Estimate resource and utility usage and supply capacity.  
 Evaluate the economic feasibility of the process. 
 Calculate batch time and scheduling. 
There are many simulation tools available commercially, but Aspen Batch Plus, and Intelligen SuperPro 
Designer are the two most popular commercial software packages. There are also other discrete event 
simulation (DES) software products such as Rockwell Arena and Witness, or ImagineThat Extend which 
can be used for process simulation (Gosling, 2005; Papavasileiou, Siletti & Petrides, 2008). A more 
versatile tool is Microsoft Excel which can be used to model chemical- and bio-processes, but may 
require additional coding with Visual Basic for Applications (VBA) scripts (Papavasileiou, Siletti & 
Petrides, 2008; Toumi et al., 2010). VBA has also been useful for interfacing data between different 
software tools, for example using an Excel add-in such as Oracle Crystal Ball to perform a Monte Carlo 
simulation sensitivity analysis (Biwer, Griffith & Cooney, 2005; Papavasileiou et al., 2007; Toumi et al., 
2010; Chuan et al., 2014). 
Aspen Plus and Intelligen SuperPro were both introduced to the market around the same time in the 
1990s, although initially Aspen Plus was found to contain a number of software bugs compared to 
Intelligen SuperPro. Gosling, (2005) reported that Aspen Plus had an advantage for simulating dynamic 
processes with transient behaviour, or processes requiring more flexibility in some operations. 
SuperPro Designer appears to be a popular choice amongst researchers and commercial 
pharmaceutical manufacturers, possibly due to the less expensive software license fees and the 
availability of comprehensive models of a variety of commercial bio-processes (Papavasileiou et al., 
2007; Papavasileiou, Siletti & Petrides, 2008; Toumi et al., 2010; Chuan et al., 2014; Kulkarni, 2015). 
The capabilities of both packages are generally similar, and both also have limitations. Neither software 
is able to account for all of the dynamic aspects inherent in batch processes, such as flexible scheduling 
of resources and equipment, or modelling of auxiliary shared services like clean in place (CIP) and 
sterilize in place (SIP) operations (Shanklin et al., 2001; Gosling, 2005; Farid, 2007; Toumi et al., 2010).  
SuperPro Designer can fulfil the need for flexible scheduling when used together with SchedulePro 
scheduling and debottlenecking software (Toumi et al., 2010). 
Building a simulation model 
Building a batch process simulation model begins by compiling a comprehensive and reliable database 
of materials, labour, and processing equipment.  For more accurate results it may also be necessary to 
include data on process performance in the model database. Collecting reliable information on costs 
and usage parameters of materials and equipment increases model accuracy, but information is not 
always available for every aspect of every component. Missing data requires assumptions to be made 
either by consulting subject matter experts, or by using literature and making assumptions based on 
scientifically accepted empirical knowledge (Papavasileiou et al., 2007; Toumi et al., 2010; Hamidi et 
al., 2016). 
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The process model is developed from the Process Flow Diagram (PFD), by building up unit procedures 
sequentially. Each unit procedure is built from multiple unit operations, and the process model is built 
from unit procedures which model real process equipment operations, or steps in a process. The model 
is also tested after each added step to confirm that it produces sensible results before connecting 
material flows to the next processing step (Petrides et al., 1989; Toumi et al., 2010). When the 
sequential building up of unit procedures is complete, the resulting process model is a “base case” of 
the process. The base case is the starting 
point for all subsequent process 
development and optimization 
investigations (Petrides et al., 1989; Tan et 
al., 2006; Farid, Washbrook & Titchener-
Hooker, 2007; Papavasileiou, Siletti & 
Petrides, 2008; Hamidi et al., 2016).  
After establishing a base-case process 
model; process development decisions are 
made by making a specific change to the 
base case and comparing the resulting 
model to evaluate the change 
(Papavasileiou et al., 2007; Toumi et al., 
2010; Chuan et al., 2014). This “technology 
tree” approach to model development is 
shown in Figure 11 (right). After each 
progression, the various outcomes can be 
compared to the base case or to each other. 
Typically, process inputs are evaluated by sensitivity analysis. A method similar to that used by Toumi 
et al., (2010) was used by Chuan et al., (2014) for selecting the most economical processing route for 
a recombinant viral protein vaccine. Both authors utilised Monte Carlo sensitivity analysis to 
quantitatively evaluate the uncertainty in the result of a simulation. This type of analysis is characterized 
by testing the sensitivity of model outputs to randomized input data. The resulting outputs are typically 
plotted in a histogram that resembles a distribution curve. This provides a much larger data set which 
can be used to determine more accurate estimations for the mean and standard deviation of the mean. 
The data set can then be used to determine the probability that a given result, say, a base case or 
optimization model, is achievable. This type of sensitivity analysis is one of the only practical ways to 
quantitatively determine the uncertainty of a simulation result or series of results. 
It should be noted that publications such as Toumi et al. (2010) and Chuan et al. (2014) used Intelligen 
SuperPro Designer and followed a similar methodology for evaluating techno-economic process 
development decisions. Their method for sensitivity required VBA scripting software to process the 
amount of data needed to generate sensitivity distributions. An example of this type of software is Oracle 
Crystal ball (Oracle, 2008) plugin for Microsoft Excel. 
The methodology for creating a simulation model of a biopharmaceutical process using Intelligen 
SuperPro Designer  has been demonstrated for many different types of processes (Petrides et al., 1989; 
Petrides, Koulouris & Siletti, 2003; Papavasileiou et al., 2007; Toumi et al., 2010; Chuan et al., 2014), 
making SuperPro Designer a useful database of bio-pharmaceutical process equipment, labour, and 
materials. The steps for building a process model can thus be summarised as follows: 
1. Create database of materials and equipment performance data 
2. Build unit procedures from unit operations. 
3. Complete base-case model. 
4. Evaluate process decisions by comparing results after varying model inputs / structure. 
5. Complete one or more model scenarios, compare to base case and to other scenarios. 
6. Perform sensitivity analysis of the models to changes in information inputs. 
 
Figure 11: Technology tree approach used for process simulation 
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Benefits and Limitations of Process Simulation Exercises 
The basic outputs from a batch process simulation for biopharmaceutical processes are published for 
a variety of processes (Petrides et al., 1989; Papavasileiou et al., 2007; Papavasileiou, Siletti & 
Petrides, 2008; Toumi et al., 2010) which have been summarised in Table 2-6 on the proceeding page. 
It can be observed from the outputs listed below, that the required outputs of an effective simulation 
model follow directly from the requirements of an effective simulator tool discussed previously in 2.4.1: 
 A comprehensive visual process flow diagram 
 Mathematical solutions to all Material and energy balances 
 Equipment size estimates & occupancy Gantt charts 
 Utility usage and supply capability 
 Economic analysis of capital and operating costs 
 Throughput analysis 
 Sensitivity analysis
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Benefits of Process Simulation Exercises 
Economic analysis is one of the most reliable outputs of process simulation due to the availability and 
accessibility of relatively accurate input data (prices, labour cost, taxation, etc.). Simulation exercises 
can evaluate the advantages and disadvantages of two competing systems based on the outcomes of 
different process models. Some of the key findings from economic evaluations for five selected studies 
are summarised in Table 2-6 on the preceding page. Table 2-6 shows that techno-economic studies 
using process simulation are able to generate quantitative data for a number of different scenarios. Of 
key importance to the value of these studies is the low initial investment required. Simulations require 
very little in terms of man hours and materials as compared to setting up and executing the same 
number of experiments to physically generate data on different process options. 
The primary output of a simulation model is to provide information on the key areas of focus for process 
development including but not limited to: equipment types and sizes, types and quantities of raw 
materials, utilities, shared services, and operations scheduling (Papavasileiou et al., 2007; 
Papavasileiou, Siletti & Petrides, 2008; Toumi et al., 2010; Chuan et al., 2014). Toumi et al. (2010) 
identified valuable indirect benefits of a rigourous simulation exercise for the development of a large-
scale process to produce monoclonal antibodies. The simulation exercise provided a universal platform 
for communication between process development scientists, engineers, and their operations team. The 
facilitation of communication between teams with different specialisations on a large-scale project with 
complex interdependencies was emphasised as a key outcome of the simulation exercise, and one that 
was not part of the initial aims of the exercise. 
Simulation exercises are useful at the pre-feasibility stage of project development, for making decisions 
early on and focusing on key areas. As such, simulation models may also be applied in a cyclic process 
development and design spaces. Simulation modelling is a versatile tool, in that it may be used at any 
stage of a design process for generating information and evaluating decisions. 
Limitations of Process Simulation Exercises 
A popular phrase for simulation modelling is that a model is only as good as the data that goes into it. 
This is often represented by a difference between real process outputs and simulation model results. 
The output of a process model is also affected by the accuracy of the mathematical models and 
algorithms used within the unit procedures (Petrides et al., 1989). More rigorous models can improve 
prediction of real outputs; however, this is only possible  where such models exist (Shanklin et al., 
2001). This is the greatest limitation of simulation modelling, in that real processes are too complex to 
be modelled precisely by mathematical equations. It should; however, be noted that the required 
precision of simulation models is not to be exact but rather to direct process development, making them 
no less effective despite this limitation. 
The published literature on process simulation exercises is more aligned with the European and US 
markets for biopharmaceutical products, with many studies published on monoclonal antibody 
production processes, with fewer studies focusing on vaccine production processes (Petrides et al., 
1989; Farid, 2007; Papavasileiou, Siletti & Petrides, 2008; Toumi et al., 2010; Chuan et al., 2014). 
Application of simulation modelling as an analytical tool for other types of processes and in other 
contexts will require more rigorous database construction, as the existing databases in commercial 
software packages are generic for the US & European context.  
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2.4 Single use process technology 
The first successful demonstration of single use 
bioreactor was Vijay Singh’s rocking bag reactor for 
small to medium scale (0 - 100 L) cell culture (Singh, 
1999, 2001), shown in Figure 12. The technology 
for single use mixing vessels that could compete 
with industrial stainless-steel technology was 
developed over time though. Some of the first 
patents were different to the universally accepted 
STR type design. One such design by Hyclone 
Laboratories employed a hydraulic mixing block 
(Stewart, 1999) which was used in a patent for a 
single use bag mixer by Merck  (Ekambaram et al., 
2000). 
A magnetic drive mixer was patented in the 1980s for use in stainless steel tanks by Rains & Rathbun 
(1980), but this was not realised in single use mixers for another 20 years. The advent of single use 
mixers in the early 2000s required a novel solution to physically separate the agitator bearing and drive 
unit to enable the use of integral plastic film technology. Hyclone laboratories was one of the first to 
employ this design in a single use  STR in 2006 (Goodwin, Elgan & Larsen, 2006). A more sophisticated 
design (shown in Figure 3 on page 4) using a magnetic bearing similar to that of Rains & Rathbun 
(1980) with a turbine mixer set inside a plastic film bag was patented in 2009 by Xcellerex (Hodge, 
Galliher & Fisher, 2009). 
This type of design has been used by bioreactor manufacturers such as Sartorius Stedim, GE 
Healthcare (GE acquired Hyclone and Xcellerex), and Pall. The general design of modern 
developments of single use bioreactors uses a magnetically coupled impeller inside an integral plastic 
bag. Contemporary single use reactor systems feature steel or polycarbonate tanks with the product 
contact portion of the vessel made from plastic polymers. The benefit is that the inner plastic bag can 
be sterilized by gamma irradiation before use and disposed of immediately after use, eliminating the 
need for in-house validation of cleaning and sterilization processes.  
Commercial driving force for single use technology 
In two decades spanning 1999 to 2019, one of 
the most important decisions for new and 
existing bio-pharmaceutical manufacturing has 
been whether (and if so to what extent) to 
deploy Single Use Technology (SUT). Initially, 
SUT was initially introduced as a strategy for 
mitigating cross-contamination between 
different products in multi-product facilities 
(Shukla & Gottschalk, 2013), but has been 
demonstrated to also have the capability to 
enable additional economic, regulatory, and 
technological advantages (Ransohoff, 2005; 
Shukla & Gottschalk, 2013; Lopes, 2015). 
SUT can be attractive for high risk projects such 
as new drug development, due to the 
decreased capital cost, reduced operating 
costs, and increased speed to market 
(Gottschalk, 2008; Allison & Richards, 2014; 
Lopes, 2015). As much as 90% of 
investigational drug projects do not make it 
Figure 12: Rocking platform bioreactor. 
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Figure 13: Project risk for novel biologics.  
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through full clinical trials to commercialisation, and those that are successful can cost investors up to 
$2.8 billion in total investment and opportunity costs (DiMasi, Grabowski & Hansen, 2016). It can be 
seen in Figure 13 (previous page bottom right) that project risk is extremely high in the initial stages of 
a project, where the prospect of success is low, and the cost of capital is high. Introducing SUT can 
reduce financial risk for new projects by reducing the capital costs, particularly in pre-clinical and early 
clinical development stages of the project life cycle. 
 
Advantages and Disadvantages of Single Use technology 
Single use technology has both advantages and disadvantages. Each unit operation in a bioprocess 
needs to be evaluated on a case-by-case basis for the appropriateness of SUT (Gottschalk, 2008). 
Some of the commonly listed advantages and disadvantages in published literature are shown in Table 
2-7 on the proceeding page. 
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Table 2-7    Advantages and disadvantages of Single Use Technology 
Advantages Examples of advantages Disadvantages Examples of disadvantages 
Reduced capital 
cost 
Monoclonal antibody multi-product facility COG model 
capital cost savings of 40 €/g (Sinclair & Monge, 2005) 
Capital costs an order of magnitude lower than for single 
use facilities compared to stainless steel based facilities 
(Zheng, 2010) 
Viral vaccine process potential 50% reduction in capital 
costs by implementing single use technology (Lopes, 2015) 
High cost of 
consumable 
material 
Monoclonal antibody multi-product facility COG model 





Single use technology more cost-effective for multi-product 
facilities (Sinclair & Monge, 2005) 
Process performance is not compromised by SUT 
(Whitford, 2010) 
Single use technology for an aseptic filling operation 
reduced campaign fill time from  36 h to 12 h per 100 000 
vials (Merck Millipore, 2013). 
Loses 
competitiveness 
with stainless steel 
at large scales 
(above 2000 L) 
High consumables costs limit the scalability of single use 
processes (Eibl et al., 2010) 
Single use bag requirements increase with scale, a 
monoclonal antibody process at 2000 L scale using 60 x 
200 L reactor bags per batch would require 220 bags per 
batch when scaled up to 8000 L (Papavasileiou, Siletti & 
Petrides, 2008). 
Reduced risk of 
cross contamination 
Disposable product contact layer reduces risk of cross 
contamination (Eibl et al., 2010; Zheng, 2010; Flaherty & 




Extensive validation requirements for single use 
components (Lopes, 2015) 
Reduced utility 
costs for CIP & SIP 
Monoclonal antibody 2x2000 L fermentation, cost savings: 
28 800 kWh, $ 250 000 WFI generation, $ 7 300 CIP 
chemicals (Flaherty & Perrone, 2012) 
Monoclonal antibody 200 kg/y single use 65% less WFI 
and CIP chemicals, 50% less steam (Papavasileiou, Siletti 
& Petrides, 2008). 
Increased 
emissions footprint 
of single use 
materials 
(petroleum plastics) 
Monoclonal antibody, 1000 L scale: Total energy demand 
for manufacture stainless steel technology of 1000 MJ, 
while the equivalent plastic single use bags, total energy 
demand is 4000 MJ (Rawlings & Pora, 2009) 
Reduced Labour 
costs 
Monoclonal antibody multi-product facility COG model 
Labour savings of 30 €/g (Sinclair & Monge, 2005) 
Monoclonal antibody 2x2000 L fermentation, labour 
savings: $ 60 000 in direct labour costs for cleaning tanks 
(Flaherty & Perrone, 2012) 
Technology gap to 
stainless steel 
Lack of reliable single use sensors (Aranha, 2004; Eibl et 
al., 2010; Löffelholz et al., 2013) 
Maximum scale of equipment available for single use is 
2000 L, for stainless steel 20 000 L (Shukla & Gottschalk, 
2013; Pörtner, 2015) 
Reduced overall 
cost of goods 
Monoclonal antibody 200 kg/y, cost of goods for single use 
$ 317 /kg, vs. $ 415 /kg for stainless steel (Papavasileiou, 
Siletti & Petrides, 2008)  
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Leachables and Extractables 
Many types of single use equipment and consumables 
(e.g. bags, filter membranes, transfer and connection 
assemblies) are constructed with plastic product contact 
parts, These plastic parts carry a risk of transfer of organic 
compounds (polycarbonates) from the product contact 
surface into product solutions or solvents (organic acids, 
ethanol). An illustration of these effects is shown in Figure 
14. 
Some compounds (e.g. 2-Ethylhexanoic acid or Lauric 
acid (Martin & Ding, 2009)) found in the product contact 
layer of single use components (liquid filters, reactor 
bags) can leach into a typical pharmaceutical solvent (e.g. 
1 N sodium hydroxide or 30% ethanol) under normal 
conditions such as those found in a typical production 
environment. These types of compounds are called 
Leachables – compounds that can move from the 
material into a drug substance under normal conditions (Martin & Ding, 2009). 
A much larger range of different compounds (e.g. Palmitic acid) found in the product contact layer of 
single use materials can be extracted into a carrier solvent (e.g. 10 N acetic acid or 10 N sodium 
hydroxide) by continuous liquid extraction under extreme conditions (concentrated organic solvent or 
low pH). These types of compounds are called Extractables – compounds that can move from the 
material into a model solvent under extreme conditions. (Martin & Ding, 2009). 
The concentrations of these  two types of compounds (Leachables and Extractables) allowable in a 
drug substance are specified by regulatory authorieis such as the FDA, WHO, and SAHPRA, as 
potential contaminants. The costs associated with testing single use components for compatiblity with 
a process is a technologoical risk described by mupltiple literature sources on the implementation of 
single use technology (Sinclair & Monge, 2002; Aranha, 2004; Martin & Ding, 2009; Eibl et al., 2010; 
Martin, 2010; Zheng, 2010; Löffelholz et al., 2013; Shukla & Gottschalk, 2013). 
Manufacturers of SUT disclose their materials of construction, but the burden of process validation for 
regulatory product licensing purposes still lies with the manufacturer. Validation for stainless steel 
equiment  is well-known in the biopharmacuetical industry, and includes welding, passivation, pickling, 
and electropolishing certification, as well as valves, sensors and fittings with quality certification. 
Validation for SUT is less well-known compared to requirements for stainless-steel, but typically 
requires extractables and leachables testing with all process fluids (normal  conditions) as well as 
validation of the bag manufacturing process itself. 
  
Figure 14: Leachables and extractables 
Redrawn from (Merck Millipore, 2013) 
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2.5 Defining the Research Project 
Problem Statement 
GBS disease affects a small percentage of the global population; however, the incidence is large 
enough to warrant a humanitarian intervention to prevent further loss of life and suffering (Edmond et 
al., 2012; Kim et al., 2014; Kobayashi et al., 2016). Vaccines are scientifically proven beyond doubt to 
be one of the safest and most effective healthcare interventions, yet as of 2019 there is no vaccine for 
GBS disease. A Life Cycle Assessment (LCA) study by Kim et al., (2014) reported that a maternal 
vaccine against GBS disease could be sold for up to $30 per dose (R 400), giving the finished vaccine 
a potential value of between $2 million and $4 million/kg depending on the final dosage. 
Time to market for new vaccine products is critical since IP protection is limited and R&D investment 
needs to be recovered quickly (Ransohoff, 2005; DiMasi, Grabowski & Hansen, 2016). Patents offer 
international protection for countries (including South Africa) which are party to the World Intellectual 
Property Organisation (WIPO) IP protection treaties, but these protections typically cover specific claims 
and can be challenged in court. New vaccine development must follow an integrated approach which 
includes process and analytical method development within relatively short time frames, and without 
compromising quality (Chu & Robinson, 2001; Buckland, 2005; Chuan et al., 2014; Hamidi et al., 2016). 
Low-cost analytical tools are needed to assist with process development in the expedited project 
development pathway, particularly with decision making when multiple processing routes and 
technology choices are available. This type of decision support tool must identify the most critical areas 
of a process to be considered in further detail before proceeding with pilot scale operations (Shanklin 
et al., 2001; Gosling, 2005; Papavasileiou et al., 2007; Toumi et al., 2010). 
Developing and operating biopharmaceutical processes in South Africa is a unique scenario subject to 
limited industrial manufacturing capacity. The South African market for biopharmaceuticals is small 
compared to global competitors, making it challenging for manufacturers to procure starting materials 
and to find buyers for products at competitive prices. Projects are exposed to the financial risks of an 
economy based on volatile commodities markets, and investors face unique context specific risks in 
addition to an already high-risk investment environment associated with novel biopharmaceutical 
products. Identifying these and evaluating the quantitative impact on a prospective process under 
development could help to mitigate some of the risks involved. 
Simulation model objectives 
 Build a relevant database of materials, equipment, and process parameters from literature 
(Dean, 1999; Perry & Green, 2008; Haynes, 2014), and appropriate software tools (Aspen 
Technology Inc., 2017; Intelligen Inc., 2017). 
 Determine a simple kinetic model (Monod, 1949) for GBS serotype III cultivation at 20 L scale. 
 Build a process simulation model of a trial GBS vaccine process at 20 L and 200 L production 
scales using three different technology approaches (Stainless Steel, Single Use, and Hybrid) 
at each of the two scales. 
Analysis objectives 
 Quantitative: Economic evaluation of three technology choices - stainless steel, single use, and 
hybrid technology, at two scales – 20 L and 200 L, using a trial GBS vaccine as an example. 
 Qualitative: Evaluate the use of simulation model results for technology selection and scale-up 
performance forecasting.  
 Quantify the uncertainty associated with the models used to generate results by conducting a 
sensitivity analysis of the model outputs to the model inputs. 
 Evaluate the use of process simulation tools for a novel GBS vaccine process in a South African 
context. 
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Cost of goods influences a new vaccine’s commercial viability in an industry where lower product price 
is competitive with market power. A Techno-economic evaluation of three technology options for the 
production of a GBS trial vaccine antigen will provide information to reduce financial risk and support 
more commercially viable decisions during process development.  
In the case study of a trial vaccine; it is hypothesised that single use vessels will yield a lower cost of 
goods at 20 L and 200 L process scale, as compared to stainless steel vessels. This is hypothesised 
due to an expected reduction in operating costs for clean- and sterilize-in-place requirements for 
stainless steel technology. A hybrid of the two technology options would yield an even lower cost of 
goods by combining the best economic properties of both single use and stainless-steel technologies. 
Purpose & Function of this Research 
The purpose of this research is to test the application of an existing process design and analysis tool to 
a context which is not well understood. The method of computer simulation modelling for evaluating 
process development decisions is an established tool in commercial bioprocessing, yet its application 
to biopharmaceutical processes in a South African context is not well documented compared to the 
established biopharma markets of Europe, the US and Asia. The South African industry is in its infancy 
compared to the latter global market powerhouses, a comparison that lends credence to the idea that 
the same rules of thumb for process development may or may not apply in the South African context. 
The evaluation of single use vs. stainless steel technology is a well-known process development 
decision. Single use technology is often promoted as a time and money saving option, particularly for 
early process development. Part of the purpose of this research is to test this popular opinion in a South 
African context, where the deployment of new technology may be affected by economic and other 
forces. 
The function of this research is therefore to generate information on a novel vaccine process, and then 
to analyse the information to determine its relevance in terms of the problem statement. Firstly, the 
function is to determine the most cost-effective technology for a novel vaccine process, and secondly 
to determine the suitability of process simulation tools for biopharmaceutical process development in a 
South African context. The hypothesis being tested is deliberately formulated based on a literature 
survey which is overwhelmingly based in the more established biopharma markets. The result of the 
thesis should therefore give insight into the economic climate faced by South African biopharmaceutical 
processing industry as compared to traditional knowledge of this field in Europe and the US. 
This research is not intended to function as the sole consideration for the suitability of process 
simulation tools for biopharmaceuticals process development in South Africa but is intended to provide 
quantitative data on the subject from a process engineering perspective. In performing its function 
successfully, this research will make an evaluation of the feasibility of a novel GBS vaccine process, 
and also evaluate the suitability of process simulation tools for biopharmaceutical process development 
in a South African context. Subsequently this research may be used to support a decision to either use 
or not to use these tools for the development of future processes in this specific context. 
Key Research Questions 
 Which technology platform between single use and stainless-steel technology performs 
better in terms of cost of goods for production of a trial GBS vaccine antigen? 
 What kind of information can process simulation generate about scale-up implications of 
technology choices for the GBS vaccine antigen manufacturing process? 
 Which areas of the GBS vaccine antigen production process are most sensitive to input 
information and initial modelling assumptions? 
 What is the influence of a South African context on the development and operation of a 
process to make a GBS vaccine antigen? 
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3 Approach to Project and Methodology 
3.1 Research methodology  
A modified version of the scientific method described 
by Harrison (2017) (Figure 15) was used for this 
thesis. The modified approach was to define the 
problem after the literature survey rather than 
beforehand. This was done to create a better context 
specific understanding of the problem by literature 
survey before attempting to define it. Each step of the 
methodology was as follows: 
1. Characterise the problem by a literature 
survey (Refer to 2.1 – 2.4) 
2. Define a problem (Refer to 2.5) 
3. Define a hypothesis (Refer to 2.5)  
4. Design and execute experiments 
5. Analyse results 
6. Draw conclusions and make recommendations. 
3.2  Experimental approach  
The experimental design was factorial in that the different process options were compared based on 
simulation exercises with the experiment having a 2x3 factorial structure, shown in Table 3-1 below. 
The experiment was designed to evaluate the effect of scaling up three different approaches to process 
technology for the development of a process to manufacture a protein-polysaccharide conjugate 
vaccine against GBS disease. The process scale up was evaluated at 20 L and 200 L: 
Table 3-1    Experimental matrix for factorial experiment design 
 Stainless steel 
technology 
Single use technology Hybrid technology 
GBS III 
conjugate 20 L 
Stainless steel fermentor 
and media tanks, 
glassware 
Single use fermentor, 
disposable containers and 
mixing bags 
Stainless steel fermentor 
disposable containers and 
mixing bags 
GBS III 
conjugate 200 L 
Stainless steel fermentor 
and tanks, glassware 
Single use fermentor, 
disposable containers and 
mixing bags 
Stainless steel fermentor, 
disposable containers and 
mixing bags 
Three process models were built, starting with the industry standard practice of using stainless steel 
process equipment and glass laboratory equipment. The stainless-steel model forms the base case, 
from which scenarios were developed with either single use or hybrid technology platforms. The method 
for execution of the experimental programme was as follows: 
1. Fermentation experiments conducted in triplicate at 2 L scale. 
2. A reaction equation for aerobic stoichiometry of S.agalactiae on glucose was derived from literature 
(Mickelson, 1972). 
3. A simple fermentation kinetics model was derived using Microsoft Excel, using experimental data 
for cultivation of S.agalactiae serotype III on glucose (The Biovac Institute, 2018). 
4. A process model of a trial GBS vaccine process was built using Intelligen SuperPro Designer 9.5. 
The process was synthesised from literature on similar existing processes (Bartoloni et al., 1995; 
Swennen, 2012; Costantino et al., 2013; Rana et al., 2016). 
Figure 15: The Scientific method with iterative approach 
(Harrison, 2017) 
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5. The scenarios as shown in Table 3-1 were developed from the base case. 
6. A sensitivity analysis was performed on the scenario with the lowest cost of goods, using selected 
parameters and assumptions from the base case scenario. 
7. Different scenarios were compared to each other, with an evaluation of technology options based 
on the cost of goods. The analysis was extended to include project feasibility, based on an 
estimated product value in the current market. 
8. Conclusions were drawn on the best technology and scale for the chosen process, as well as on 
the potential feasibility of the process. Further conclusions were drawn on the relevance of process 
simulation tools for process development in the context of the developing South African vaccine 
manufacturing sector. 
3.3 Materials & methods 
The process models which form part of the research output of this thesis were built following a 
structured approach as described in the following section. The models were built in four steps: 
Step 1: Define a real process by written process description and process flow diagram 
Step 2: Build a base case simulation model of the real process defined in Step 1 
Step 3: Develop alternative scenarios from the base case, either by new technology platforms, or by 
scaling up the process 
Step 4: Develop alternative scenarios from the best performing model in the previous step, to test the 
model sensitivity to inputs and assumptions. 
Defining a Real Process to make a GBS polysaccharide-protein conjugate 
The starting point of the process was considered to be media preparation and inoculum preparation for 
fermentation. The base case at 20L scale was specified using stainless steel as a technology platform 
(Stainless steel fermentor and buffer tanks and pharmaceutical glassware for smaller volumes). The 
fermentation process was based on a patent of Novartis (acquired by GSK) (Swennen, 2012), with 
extraction of the Capsular Polysaccharide (CPS) from the cells by treatment with sodium hydroxide 
(Schifferle et al., 1985; Wessels et al., 1989; Michon & Blake, 2001). The purification process was based 
on another patent of GSK for adherent carbon filtration (Costantino et al., 2013), followed by a 
conjugation process adapted from multiple sources: Activation of the polysaccharide by cyanylation 
with CDAP (Capiau et al., 2000; Shafer et al., 2000) or by periodate oxidation (Roy, Katzenellenbogen 
& Jennings, 1984), while activation of the carrier protein would be done either by reaction with ADH and 
EDC (Bartoloni et al., 1995; Rana et al., 2016) or by reductive amination  (Jennings & Lugowski, 1982; 
Wessels et al., 1990; Mistrette, Danve & Moreau, 2010; Buurman et al., 2019). 
It was decided to proceed with cyanylation and ADH derivatization as a conjugation method as it is 
reported in literature (Roy, Katzenellenbogen & Jennings, 1984; Frasch, 2009) that periodate oxidation 
carries a risk of compromising immunogenicity of polysaccharides due to the opening of the cyclic ring. 
The major product of this process was a purified protein-polysaccharide conjugate. The product value 
was estimated as $ 4 million /kg as described in the Problem Statement on page 26. 
Fermentation process description 
The cell banks were aliquoted in 1mL of wild-type GBS serotype III bacteria suspended in glycerol and 
stored at -80°C. The raw material for fermentation was Columbia growth medium (Swennen, 2012; 
Costantino et al., 2013) and cell bank vials of GBS III bacteria. The medium composition has been 
defined by Zimbro (2009) but contains animal derived nutrients (beef heart) which were substituted for 
non-animal derived components, such as yeast extract or soytone (Vrang et al., 2002; Swennen, 2012). 
This is recommended for human vaccines as per current Good Manufacturing Practices 
(Pharmaceutical Inspection Co-operation Scheme, 2014).  
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The modified medium composition is shown in Table 3-2 below. 
Table 3-2    Fermentation medium Composition 
Component Conc.[g/L] 
D-(+)-Glucose 20.0 
Tryptic digest of casein (Soytone) 27.0 
Yeast Extract 5.0 
Sodium Chloride 5.0 
L-Cysteine HCl 0.1 
Sodium Carbonate 0.6 
Magnesium Sulfate (anhydrous) 0.14 
Ferrous Sulfate 0.02 
A 300 mL inoculum was prepared in the above medium by cultivation at 37°C and 150 rpm for 3h in 
baffled shake flasks inside a temperature-controlled incubator. Inoculum medium was supplemented 
with a buffer of 0.83 g/L Tris (Hydroxymethyl) Aminomethane (TRIS) and 2.86 g/L TRIS.HCl. The feed 
to the fermentation process was composed of 30 g/L Yeast Extract and 400 g/L Dextrose in WFI. 
The fermentation was carried out for 8 h at 37 °C with aeration of 0.5 vvm with production of Biomass 
and Capsular Polysaccharide (CPS). For modelling, SuperPro 9.5 academic software built in fed-batch 
mass/time model was used (Intelligen Inc., 2017). The fermentor was assumed to have a maximum 
stirred volume of 26 L for addition of the inactivation agent. Optical density at 590 nm (X), and glucose 
concentration (S) were recorded every hour for 8 hours. The resulting data was used to derive 
parameters for a Monod kinetic model of the fermentation. 
The process described below was not performed experimentally in this thesis but was used to 
define the structure of simulation models. 
The culture is inactivated with 5N NaOH to a final concentration of 0.8 N for 16 hours at 55 °C. This 
performs a dual operation by inactivation of the microorganism and releasing the CPS into solution 
(Schifferle et al., 1985; Wessels et al., 1989; Michon & Blake, 2001). Inactivation was followed by 
harvesting to a receiving tank with stirrer for neutralization with 6N HCl. Nucleic acids and proteins were 
precipitated in the same vessel by addition of 2 N CaCl2 and 96% ethanol (Costantino et al., 2013), to 
a final concentrations of 0.13 N and 30%, respectively. The precipitation reaction proceeded 
adiabatically for 1 h before harvesting to centrifugation.  
Purification process description 
A disk stack bowl centrifuge was used to recover the supernatant containing the CPS, which was 
concentrated 40 X by Tangential Flow Filtration (TFF) through a 30 kDa membrane, followed by 20 X 
diafiltration into 50mM TRIS + 8.5 mM NaCl buffer. The retentate is further 10 X diafiltered into 0.3N 
Na2CO3 (Costantino et al., 2013). The retentate was then filtered through an orthogonal carbon filter to 
remove residual proteins by adsorption. The filtrate was collected in a reaction vessel, to which 
saturated acetic anhydride was added to a concentration of 0.8N, to re-N-acetylate the CPS (Schifferle 
et al., 1985; Wessels et al., 1989; Michon & Blake, 2001). The reaction proceeds adiabatically for 1 h 
before filtration through a 0.22 µm filter into a sterile holding bag for storage at 2 – 8 °C. 
Conjugation process description 
The carrier protein was activated with 0.5N ADH in the presence of 0.1N EDC (Bartoloni et al., 1995; 
Rana et al., 2016). The reaction proceeded for 2 h at 4°C. The activated protein was then 20 X diafiltered 
into a buffer of 10mM MES and 0.2M NaCl. 
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The purified CPS was activated with 100 mg/mL CDAP in acetonitrile (Shafer et al., 2000; Frasch, 2009; 
Rana et al., 2016) to a final mass ratio of 3:4 CDAP:CPS. The reaction proceeds for 2 minutes and 30 
seconds at 4°C and pH 9.2, before addition of 0.2M Triethylamine (TEA) in 2:1 volumetric ratio with the 
CDAP solution. The activated protein was then added to the mixture and the reaction proceeds for 24 
h at 4°C with agitation of 50 rpm. 
After the conjugation reaction was completed, the conjugate was precipitated by addition of saturated 
ammonium sulfate (Bartoloni et al., 1995). The precipitation proceeded adiabatically for 12h with 
agitation of 50 rpm, before recovery of the precipitate by centrifugation in a tubular centrifuge. After 
centrifugation the pellet was re-suspended in MES/NaCl buffer before 20 X diafiltration through a 30 
kDa membrane into Phosphate Buffered Saline (PBS). The solution was filtered through a 0.22 µm 
membrane under LAF into a sterile holding bag. The final product was stored -20 °C until formulation 
(not included in this process). 
A Process Flow Diagram (PFD) of this process at 20L fermentation scale using stainless steel 
technology platform was drawn. The diagrams are shown in Figures 16 and 17 on the proceeding 
pages. 
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Process Flow Diagram of GBS 20L stainless steel technology platform 
Fermentation
8 h













2 x 400 mL
37 °C, 150 rpm
3h
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0.3N Na2CO3































Figure 16: Process Flow Diagram of GBS 3 20L stainless steel process page 1 of 2 
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~ 1.3 L 
5g/L CPS in
0.3N Na2CO3
From 2 - 8°C storage
CPS activation
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Figure 17: Process Flow Diagram of GBS 3 20L stainless steel process page 2 of 2 
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Building a Simulation model of 20L GBS III conjugate process (Base Case Model) 
The base case simulation model was built in SuperPro starting with unit procedures Inoculum 
preparation and fermentation media preparation. The next unit procedure was fermentation, followed 
by each successive procedure until final filtration of the purified conjugate drug substance. This method 
is more conveniently presented in Table 3-3 below. A detailed version of model construction is 
documented in Table A-4 in Appendix A. Screen capture images of the resulting models are shown in 
Appendix A. Equipment specifications and costs (Table A-5), consumables specifications and costs 
(Table A-8), and raw materials specifications and costs (Table A-11) are listed in detail in Appendix A. 
Table 3-3    Building a Simulation Model of a 20 L Process to make a GBS conjugate antigen  
Model 
Tag 
Real process step(s) SuperPro unit procedure(s) 
SS-01f 
Inoculum medium filtration 0.22 µm using 
peristaltic pump 
→ Filtration 




2 x Fernbach flasks each with 400 mL (800 mL 
total) Inoculum medium (Table A-15). Each flask 
inoculated with 1mL of wild type GBS type III in 
glycerol. 
Inoculum cultured for 3 hours at 37 °C, surface 
aerated. 
→ Inoculum preparation  




Media preparation 16L of batch media in a 50L, 
stainless steel media preparation tank 
→ Storage/Blending  
→ Bulk 
→ Batch 
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Real process step(s) SuperPro unit procedure(s) 
S-02f 
Inoculum medium filtration 0.22 µm using 
peristaltic pump 
→ Filtration 
→ Dead End Filtration 
 
S-03 
20 L fed-batch fermentation, 320 mL inoculum 
into 16 L batch medium (Table A-16), 5 L feed 
(Table A-17). Culture at 36 °C for 12h, pH 7.3, 
0.2 barg, 0.5 vvm sterile air 
Inactivation for 16 h at 55 °C in 0.8M NaOH 
→ Batch vessel procedure  
→ In a Seed Fermentor 
 
S-04 
Neutralisation to pH 7.0 with 6N HCl, followed by 
60min precipitation of nucleic acids for 60min in 
0.05N CaCl2 and 30% Ethanol. 
Assumptions: 100% precipitation of proteins and 
nucleic acids 
→ Storage/Blending  
→ Bulk 
→ Batch 
→ in a Blending Tank 
 
S-05 
Centrifuge in disk stack centrifuge with 88% 
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Real process step(s) SuperPro unit procedure(s) 
S-06 
Tangential flow filtration, concentrate to 
approximately 1 L, followed by 20X diafiltration 
against TRIS 50mM + NaCl 0.5M.  






Tangential flow filtration, 10X diafiltration against 
0.3N Na2CO3.  




S-08 Hold TFF product capture vessel 
→ Storage/Blending  
→ in a Disposable 
→ Generic container 
 
S-09 
Protein removal by adherent filtration though 
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Real process step(s) SuperPro unit procedure(s) 
S-10 
Re-N-acetylation of polysaccharide with Acetic 
anhydride (final conc. 8.3%vv). Reaction at room 
temperature for 2 h. 
→ Storage/Blending  
→ in a Disposable 
→ Generic container  
 
S-11 
Bioburden reduction filtration 0.22 µm using 
peristaltic pump 
→ Filtration 
→ Dead End Filtration 
 
S-12 Cold storage temporary hold for 16h at 2–8 °C 
→ Storage blending 
→ Bulk 
→ Batch 
→ in a Tote 
 
S-13 
Polysaccharide activation with CDAP (3:4 mass 





→ Batch vessel procedure 








SS-12 / Cold Room
2 - 8 °C hold
SS-13 / R-301
PS activation
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Real process step(s) SuperPro unit procedure(s) 
S-14 
Diafilter activated polysaccharide against 20x 







Carrier protein activation with Adipic Acid 
Dihydrazide (ADH) 
25°C for 1 h, 90% conversion of carrier protein 
→ Batch vessel procedure 




Diafilter activated TT protein against 20x 





Conjugation of derivatized TT protein to 
activated polysaccharide, 52% conversion of 
Modified Polysaccharide 
→ Batch vessel procedure 
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Real process step(s) SuperPro unit procedure(s) 
S-18 
Ammonium Sulfate precipitation of conjugate, 
5% product loss.  
→ Batch vessel procedure 




Centrifuge in tubular bowl centrifuge with 95% 
solid-liquid separation efficiency for solids 






Resuspension in 10 mM MES + 0.2N NaCl, 2% 
product loss 
→ Storage/Blending  
→ in a Disposable 
→ Generic container  
  
S-21 
Diafilter (polishing) Conjugate against 20x 
volumes of Phosphate buffered saline (PBS). 
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Real process step(s) SuperPro unit procedure(s) 
S-22 
Bioburden reduction final filtration before transfer 
to formulation. 1% product loss. 
→ Filtration 
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3.4 Base Case Model Specifications and Assumptions 
Process assumptions 
Several simplifications and assumptions were made to complete the base case process model. Areas 
which required most simplification were chemical reactions and solid-liquid separations. In doing so it 
was assumed that the function of the models was not to predict thermodynamic behaviour, but rather 
techno-economic behaviour.  
Where reliable thermodynamic models were not available, or where literature sources were limited or 
non-specific, model parameters were adjusted according to the assumptions listed in Table 3-4 below. 
A recurrent assumption for chemical reactions where no reaction data was found, was that products 
were simulated as water (with conservation of mass). This was made based on another assumption 
that the real products of these reactions were dilute (Concentration < 5% by mass) and could thus be 
simulated as water. In many cases, specific model inputs were chosen to achieve an assumed output 
yield. 
Table 3-4    Model Assumptions and Simplifications 
Model Tag(s) Real process Model assumptions and simplifications 
SS-01f, SS-02f, 
SS-11, SS-22 
0.22 µm filtration Assumed 100% Biomass removal (no other components 
removed in model) 
Assumed Flux rate 4000 L/m2h (EMD Millipore, 2013) 
SS-01, SS-03 Fermentation of GBS 
bacteria on Columbia 
growth medium 
Specified Nitrogen source as Soytone (8.7% Nitrogen) and 
Yeast extract (11% Nitrogen) (BD Biosciences, 2006). 
SS-02 Medium preparation Assumed 30 min mixing time for 95% homogeneity 
SS-03, SS-01 Fermentation Simulated fermentation stoichiometry as Equation 3-1 
Assumed 400 mg/L fermentation titer 
Assumed 8 h fermentation time 
Simulated inactivation as 
CH3COHCOOH → WFI 
Assumed 16 h inactivation reaction time 
SS-04 Neutralization of sodium 
hydroxide with hydrochloric 
acid 
NaOH (aq) + HCl (aq) → 
NaCl (aq) + H2O 
Assumed Extent of reaction 100% (wrt. NaOH) 
Assumed 60 min reaction time 
SS-04 Precipitation of nucleic 
acids with calcium chloride 
and ethanol.  
Assumed 5% product loss 
Reactions simplified to: 
CaCl2 → WFI 
Assumed extents of reaction 100% 
PS-III → WFI (X=5%) 
Assumed extents of reaction 5% 
 
Assumed 60 min reaction time 
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Model Tag(s) Real process Model assumptions and simplifications 
SS-05 Centrifugation Assumed 100% Biomass to solids 
Assumed 12% product (CPS) to waste 
Assumed 30% sedimentation efficiency 
Assumed 30 min centrifugation time 
SS-06 Diafiltration Assumed 90% < recovery of CPS to retentate 
Simplified to CPS rejection coefficient of 0.9975 (94% 
recovery) 
SS-07 Diafiltration Assumed 90% < recovery of CPS to retentate 
Simplified to CPS rejection coefficient of 0.9975 (92% 
recovery) 
SS-09 Protein removal Assumed 15% product loss 
Assumed filter flux rate 250 L/m2 
SS-10 Re-N-Acetylation 
R-NH2 + (CH3CO)2O → R-
NHCOCH3 
Reaction simplified to: 
(CH3CO)2O -> WFI 
Assumed Extents of reaction 100% 
Assumed no product loss 
Assumed 60 min reaction time 
SS-12 Cold storage for 16 h at 2-8 
C 
Simulated cold room equipment as a temperature-controlled 
tote with electrical cooling to simulate gas compressor 
running cost.  
Excluded refrigerant from utilities costing. 
SS-13 Polysaccharide activation 
by cyanylation with CDAP 
R-OH + R’-CN+ → R-OCN 
+ R’-N 
Simulated reactions as: 
PS-III → Mod-PS-III 
TEA → WFI 
Assumed extents of reaction 90% by mass for both reactions 
above  
Assumed 2 h reaction time 
SS-14 Diafiltration of activated 
CPS 
Assumed 90% < recovery of Mod-CPS to retentate 
Simplified to Mod-CPS rejection coefficient of 0.9975 (95% 
recovery) 
SS-15 Carrier protein activation 
by ADH / EDC 
Simulated reactions as: 
TT + ADH → TT-ADH 
Assumed extents of reaction 90% by mass of TT 
EDC → WFI (X=90%) 
Assumed extents of reaction 90% by mass 
Assumed 60 min reaction time 
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Model Tag(s) Real process Model assumptions and simplifications 
SS-16 Diafiltration of activated 
carrier protein 
Assumed 90% < recovery of TT-ADH to retentate 
Simplified to TT-ADH rejection coefficient of 0.9975 (95% 
recovery) 
SS-17 Conjugation 
R-OCN + R’-ADH → R-R’ 
Simulated reactions as 
Mod-PS-III + TT-ADH → TT-PS-III  
Assumed extents of reaction 100% relative to TT 
Assumed 24 h reaction time 
SS-17 Quenching of reaction by 
solid Glycine 
Simulated reactions as 
Glycine → WFI 
Assumed extents of reaction 100% 
Assumed 30 min reaction time 
SS-18 Conjugate precipitation by 
Salting out 
Assumed 95% recovery of conjugate 
Simulated reactions as: 
(NH4)2SO4 → WFI 
Assumed extents of reaction 95% 
TT-PS-III → WFI 
Assumed extents of reaction 5% 
Assumed 60 min reaction time 
SS-19 Centrifugation in tubular 
bowl centrifuge 
Assumed 95% recovery of conjugate to solids 
Assumed 30 min centrifugation time 
SS-20 Conjugate resuspension in 
MES buffer 
Assumed 2% product loss 
Simulated product loss as: 
TT-PS-III → WFI 
Assumed extents of reaction 2% 
Assumed 60 min reaction time 
SS-21 Diafiltration of conjugate 
into PBS 
Assumed 90% < recovery of conjugate to retentate 
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Fermentation Stoichiometry 
Fermentation stoichiometry was developed by combining three literature sources (Mickelson, 1967, 
1972; Swennen, 2012) and using material balances to simplify complex fermentation bio-reactions into 
a single stoichiometric equation. 
Mickelson (1972) conducted two experiments, each in triplicate, and quantified the reaction products 
through various chemical assays available at the time. Mickelson (1972) presented the following model 
for the aerobic degradation of glucose by Streptococcus agalactiae: 
Aerobic conditions 
𝐶 𝐻 𝑂 →  2𝐶𝐻 𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 → 2 𝐿𝑎𝑐𝑡𝑖𝑐 𝑎𝑐𝑖𝑑  
Equation 2-1 
𝐶 𝐻 𝑂 → 2𝐶𝐻 𝐶𝑂𝑂𝐻 + 𝐶𝑂 + 𝐻𝐶𝑂𝑂𝐻 + 𝐶𝐻 𝐶𝐻𝑂𝐻𝐶𝑂𝐶𝐻   
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 → 2 𝐴𝑐𝑒𝑡𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐶𝑎𝑟𝑏𝑜𝑛 𝑑𝑖𝑜𝑥𝑖𝑑𝑒 + 𝐹𝑜𝑟𝑚𝑖𝑐 𝑎𝑐𝑖𝑑 + 𝐴𝑐𝑒𝑡𝑜𝑖𝑛 
Equation 2-2 
𝑪𝟔𝑯𝟏𝟐𝑶𝟔 → 𝟎. 𝟕𝟖 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑶𝑯 + 𝟎. 𝟖𝟓 𝑪𝑯𝟑𝑪𝑶𝑶𝑯 + 𝟏. 𝟏𝟑 𝑪𝑶𝟐 + 𝟎. 𝟏𝟐 𝑯𝑪𝑶𝑶𝑯
+ 𝟎. 𝟎𝟗 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑪𝑯𝟑 
𝑮𝒍𝒖𝒄𝒐𝒔𝒆 → 𝟎. 𝟕𝟖 𝑳𝒂𝒄𝒕𝒊𝒄 𝒂𝒄𝒊𝒅 + 𝟎. 𝟖𝟓 𝑨𝒄𝒆𝒕𝒊𝒄 𝒂𝒄𝒊𝒅 + 𝟏. 𝟏𝟑 𝑪𝒂𝒓𝒃𝒐𝒏 𝒅𝒊𝒐𝒙𝒊𝒅𝒆
+ 𝟎. 𝟏𝟐 𝑭𝒐𝒓𝒎𝒊𝒄 𝒂𝒄𝒊𝒅 + 𝟎. 𝟎𝟗 𝑨𝒄𝒆𝒕𝒐𝒊𝒏 
Equation 2-3 
Mickelson (1972) excluded capsular 
polysaccharide (CPS) from his analysis, most likely 
due to the small quantities produced during 
fermentation relative to organic acids and carbon 
dioxide. Swennen (2012) reported the yield of CPS 
from a controlled fed-batch fermentation of GBS 
serotype III should be at least 30 mg/g dry cell 
weight (DCW) and preferably 60 mg/gDCW.  
Swennen (2012) showed that CPS yield was 
proportional to final biomass concentration. For 
GBS strain M781 – 3 (a strain of GBS serotype III) 
the typical fermentation titers achieved by 
Costantino et al. (2013) are shown in Figure 18. 
Equation 3-1 below was derived by adding to 
Mickelson's (1972) equation: By adding oxygen and biologically available nitrogen (NH3) to the 
reactants, and adding biomass (CH1.8O0.5N0.2), water, and CPS (C35H52O31N2)n to the products, and by 
using available degrees of freedom in the form of an empirical material balance for the coefficients (refer 
to Appendix A for material balance calculations).  
𝑪𝟔𝑯𝟏𝟐𝑶𝟔 + 𝒂 𝑶𝟐 + 𝒃 𝑵𝑯𝟑
→ 𝒄 𝑪𝑯𝟏.𝟖𝑶𝟎.𝟓𝑵𝟎.𝟐 + 𝒅 𝑪𝑶𝟐 + 𝒆 𝑯𝟐𝑶 + 𝒇 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑶𝑯




Figure 18: CPS productivity for GBS serotype 3 
Based on Costantino et al. (2013) 
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Fermentation Kinetics 
Three fermentations were carried out at 2 L scale, as described previously in 3.3.1. The optical density 
at a wavelength of 590 nm, and glucose concentration were recorded at specific intervals. The 




 Equation 3-2 
(Monod, 1949) 
𝜇 Specific growth rate [h-1] 𝑆 Limiting substrate concentration 




To determine the parameter 𝐾 , the differential equation for the growth of cells Equation 3-3 below 
had to be solved: 
𝒅𝑿
𝒅𝒕
= 𝝁𝑿 Equation 3-3 
Integration between the starting biomass concentration 𝑋 , at time 𝑡 , and any biomass 
concentration 𝑋 at time 𝑡: 
𝑑𝑋
𝑋
= 𝜇 𝑑𝑡 










One approach to determine the maximum specific growth rate 𝝁𝒎𝒂𝒙 was to plot optical density as a 
proxy for biomass (𝑿) over time, and then fit an exponential trend line to the data. The maximum specific 
growth rate 𝝁𝒎𝒂𝒙 could be estimated from the exponent of the trend-line (Equation 3-4 on the 
proceeding page), as shown in Figure 19 on the proceeding page. 






𝑑𝑋 = 𝜇 𝑑𝑡 
ln 𝑋 + 𝐵 = 𝜇𝑡 + 𝐴 
ln 𝑋 = 𝜇𝑡 + 𝐶 
𝑋 = 𝑒( ) = 𝑒 𝑒  
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By plotting log(X) vs. t including the exponential 
growth phase, the value of 𝝁𝒎𝒂𝒙 was estimated 
by the exponent of Equation 3-4 for the data in 
the exponential growth phase. This assumed that 
the maximum specific growth rate occurs during 
this phase of the culture.  
The half rate constant 𝑲𝒔 was estimated by 
plotting specific growth rate vs. substrate 
concentration and fitting a logarithmic trend line 
(Equation 3-6 below) to the data, as shown in 
Figure 20 (below right). This yielded an analytical 
expression (Equation 3-7 below) for 𝑲𝒔 (Refer to 




 Equation 3-5 
 




𝜶  Equation 3-7 
 
Method 2 linear trend line 
An alternative approach for finding 𝑲𝑺 and 𝝁𝒎𝒂𝒙 was by rearranging Equation 3-2 into terms 
𝑺
𝝁
 vs. 𝑺, 
































  Equation 3-8 
 






















Figure 20: Typical plot of specific growth rate vs. glucose 




























Figure 19: Typical plot of optical density over time with exponential 
trend line 
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The typical plot of Equation 3-8, with slope of , and a y-axis intercept of , is shown in Figure 
21 below. 
 
Figure 21: Typical plot of S/µ vs. S with straight trend line 








Both of the abovementioned Methods 1 and 2, were used to determine Monod kinetic parameters for 
use in the simulation models. The averages of parameters for each of the three fermentation 
experiments from each of the two methods were calculated (refer to Appendix A for derivations). The 
method for selecting the preferred method was by comparing literature values for the culture doubling 
time with the doubling times calculated by each of the two Method, using Equation 3-9. The criteria for 
selecting the preferred method was that the kinetic parameters that produced the closest doubling time 
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3.5 Model development into New Scenarios 
The approach to model development was similar to that shown in Figure 11 in section 2.3. Three 
progressions from the base case model generated 6 different models, shown in Figure 22 below. The 
base case model (Model 1 in Figure 22) was chosen as a 20L fermentation scale, with an established 
stainless-steel technology platform. The first progression produced two variations on the base case, a 
single use technology platform (Model 2.1 in Figure 22) and a hybrid of single use and stainless-steel 
technology (Model 2.2 in Figure 22). The third development was to scale-up the base case model to 
200 L fermentation scale (Model 3.1 in Figure 22), followed by development of the 200L scale model 
into two variations employing the alternative technology platforms of single use (Model 3.2 in Figure 
22), and hybrid (Model 3.3 in Figure 22). 
 
Figure 22: Model development approach 
The resulting models are submitted as electronic files with this thesis. Detailed model specifications and 
screen capture images appear in Appendix A. All electronic files submitted are listed in Chapter 4: 
Results.  
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It was assumed that the following properties and specifications of the models did not change with new 
scenarios: 
 Available equipment & consumables types 
 Reaction stoichiometry and extents of reactions 
 Process scheduling limited to one week per batch 
 Raw materials specifications* 
 Utilities specifications 
 Labour unit costs 
 Economic assumptions (hurdle rate etc.) 
 Fermentation stoichiometry and kinetic parameters* 
*For 200L fermentation the fermentation procedure time was reduced from 8 h to 7 h. This was required 
as the simulations would not converge to a solution when keeping the fermentation time at 8 h and the 
raw materials input to the fermentation constant. The error was found to be due to nutrient limitation 
and a specific minimum fermentation product concentration at the endpoint, which could be overcome 
either by increasing the nutrient input to the unit procedure, or by reducing the fermentation time. The 
latter was chosen (time reduction) as it did not have an effect on the recipe scheduling and maintained 
a consistent raw material input for all the 200 L scale scenarios. 
3.6 Sensitivity Analysis 
A sensitivity analysis was conducted for this thesis instead of a comprehensive type of Monte Carlo 
sensitivity analysis as described in the literature review of Chapter 2. The 200 L scale stainless steel 
technology simulation model was investigated for sensitivity of cost of goods (COG) and Internal Rate 
of Return (IRR) to four specific input or assumption parameters: fermentation titer, solid-liquid 
separation efficiency, TFF cartridge replacement frequency, and electricity dependency on diesel. 
Fermentation titer was defined as the concentration of CPS in stream exiting the final fermentation unit 
procedure SS200-04. Solid-liquid separation efficiency was defined as the percentage of protein-
polysaccharide conjugate recovered as solids in the final centrifugation unit procedure SS200-20. 
Fermentation titer was adjusted for the various scenarios by adjusting the volume of feed nutrients to 
the fermentation procedure, while solid-liquid separation efficiency was adjusted directly by 
specification of the material balances for the final centrifugation unit-operation. TFF cartridge 
replacement frequency was defined as the number of batches completed before replacing the filtration 
membranes used in TFF unit procedures (SS200-07, SS200-08, SS200-15, SS200-17, and SS200-22).  
 
The first two parameters, titer and separation efficiency, were chosen to give an indication of profitability 
gains which could be made during the optimization stage of process development. The third parameter, 
TFF cartridge replacement, was chosen to give an indication of the effect of operational decisions for 
the execution of the process. An extended use cycle for TFF cartridges would be subject to increased 
validation costs; however, a process developer may need to consider balancing this with a potential 
reduction in COG with less frequent replacement. 
These sensitivity scenarios are shown in Table 3-5 below: 










Very low 200 33% 3 
Low 300 50% 5 
Base case 400 67% 10 
High 500 75% 12 
Very high 600 90% 15 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair  Approach to Project and Methodology 
 
  50 
 
The fourth parameter, electricity dependency on diesel, was chosen to test for sensitivity to reflect an 
operational risk to manufacturing process industries in South Africa due to mismanagement at the South 
African state-owned power utility Eskom. This has resulted in extended periods of planned rolling black-
outs (Eskom Holdings SOC Limited, 2019). During these periods, manufacturing sites dependent on 
Eskom for their electricity are forced into unplanned downtime, where no manufacturing activity can 
take place as a result. 
Electricity costs were estimated by replacing a percentage of conventional electricity requirements by 
an increased cost to generate electricity on-site by diesel generator. The result was a composite cost 
of electricity per kWh (refer to Appendix A for sample calculation). The cost of electricity was adjusted 
in the SuperPro models for each of the sensitivity scenarios. The cost of additional equipment for 
electricity generation, shown below in Table 3-6, was adjusted in the models by increasing the factorial 
of unlisted equipment in the capital cost adjustment tab of the SuperPro models. 












0% 0.10 N/A 0.20 N/A 
10% 0.15 1 generator 0.21 $    50 000 
30% 0.20 1 generator + UPS 0.22 $  100 000 
50% 0.30 2 generators + UPS 0.23 $  150 000 
75% 0.35 4 generators + UPS 0.25 $  250 000 
 
Each of the scenarios in the different sensitivity scenarios were reported in terms of cost of goods 
(COG), and Internal Rate of Return (IRR), where possible (IRR was non-real for some scenarios). Both 
metrics were generated for each model by the Economic Evaluation Report from SuperPro software. 
IRR was included for the sensitivity analyses as a parameter which included the cost of capital as well 
as operating costs. The combined effects of these process characteristics determined which process 
embodiments would be feasible for a commercial project. 
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4 Results  
4.1 GBS III Fermentation Kinetic Model Parameters Results 
Method 1 Exponential trend line 
A plot in Figure 23 below shows the average optical density at 590 nm over time intervals of 1 hour, for 
three fermentations. The range includes the exponential growth phase, with an exponential trend line 
that appears linear with a logarithmic y-axis. The exponent of the trend line is 1.092 corresponding to 
the maximum specific growth rate per hour. 




Figure 23: Optical Density vs. time for Fermentation experiment 1 
𝑿 = 𝟏. 𝟎𝟖𝟒𝒆𝟏.𝟎𝟗𝟏𝟏𝒕 
To find the half rate constant, the substrate concentration was plotted against specific growth rate, 




 Equation 3-5 
𝝁 = 𝜶 𝐥𝐧 𝑺 + 𝜷 Equation 3-6 
The value of 𝑲𝒔 was determined by solving 
Equation 3-6 for the value of 𝑆 for  = 0.5, 
where 𝜇 = 1.092 ℎ  as per Figure 24. 
Doubling time was determined where 𝑡 = . 
(Refer to Appendix A for derivations). 
 
𝝁𝒎𝒂𝒙 = 𝟏. 𝟎𝟗𝟏 𝒉
𝟏  𝑲𝒔 = 𝟎. 𝟐𝟒𝟑 𝒈/𝑳  𝒕𝒅 = 𝟎. 𝟔𝟑𝟓 𝒉 










































Figure 24: Specific growth rate vs. Glucose concentration for 
Fermentation experiment 1 
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The same approach was followed for two additional fermentation experiments, yielding the plots for 
Method 1 for experiments 2 and 3, respectively: 
 
The kinetic parameters found by Method 1 for the three experiments are shown in Table 4-1 below. 
Table 4-1    Fermentation kinetic parameters summary – Method 1 
Method 1 Experiment 1 Experiment 2 Experiment 3 AVERAGE STDEV 
µ max [h-1] 1.091 1.220 1.017 1.109 0.084 
Ks [g/L] 0.243 0.000 0.000 0.081 0.115 
td [h] 0.635 0.568 0.681 0.628 0.046 
 
Method 2 Linear trend line 

























































































Figure 28: Optical Density vs. time for Fermentation experiment 3 

































Figure 26: Specific growth rate vs. Glucose concentration for 
Fermentation experiment 2 































Figure 25: Specific growth rate vs. Glucose concentration for 
Fermentation experiment 3 
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This is shown in Figure 29 below: 
 
Figure 29: Composite plot of rearranged Monod equation – Fermentation experiment 1 
𝑆
𝜇
= 1.0106𝑆 + 0.3880 
The plot above yielded the value of the two parameters required for the Monod kinetic model. The 
doubling time was also found using the formula 𝑡 = . 
𝝁𝒎𝒂𝒙 = 𝟎. 𝟗𝟗𝟎 𝒉
𝟏  𝑲𝑺 = 𝟎. 𝟑𝟖𝟒 𝒈/𝑳  𝒕𝒅 = 𝟎. 𝟕𝟎𝟎 𝒉 
Fermentation experiment 1: Parameters derived by Method 2 
 
The same approach was followed for two additional fermentation experiments, yielding the plots for 







































Figure 31: Composite plot of rearranged Monod equation – 
Fermentation experiment 2 
















Figure 30: Composite plot of rearranged Monod equation – 
Fermentation experiment 3 
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The kinetic parameters found by Method 2 for the three experiments are shown in Table 4-2 below. 
Table 4-2    Fermentation kinetic parameters summary – Method 2 
Method 2 Experiment 1 Experiment 2 Experiment 3 AVERAGE STDEV 
µ max [h-1] 0.990 1.166 0.870 1.008 0.121 
Ks [g/L] 0.384 0.093 0.016 0.164 0.158 
td [h] 0.700 0.595 0.797 0.697 0.083 
 
Methods 1 and 2 produced similar results for the Monod kinetic model parameters 𝝁𝒎𝒂𝒙 and 𝑲𝑺 shown 
in Tables 4-1 and 4-2. The Average maximum specific growth rate (𝝁𝒎𝒂𝒙) was found to be 1.109 ± 
0.084 h-1 for Method 1, and 1.008 ± 0.121 h-1 for Method 2. 
The doubling times (td) were also similar, with Method 1 average doubling time of 0.628 ± 0.046 h, and 
Method 2 average doubling time of 0.697 ± 0.083 h. Reported doubling times for GBS serotypes Ia, III, 
and V by Costantino et al. (2013) and Swennen (2012) were between 0.56 h and 1.11 h for GBS 
serotype III (strain M-781). This confirms that both methods produced parameters within the range of 
those published in literature. 
It was noted that the average value for the substrate half-rate constant, 𝑲𝑺, was very low when using 
Method 1, and that the average value was lower than the standard deviation. This was found to be due 
to the use of the logarithmic plot, with very low R2 values of between 0.208 and 0.398 for all three 
experiments. 
Due to the greater uncertainty associated with Method 1 it was decided to use the parameters 
derived by Method 2. 
 
 
𝝁𝒎𝒂𝒙 = 𝟏. 𝟎𝟎𝟖 ± 𝟎. 𝟏𝟐𝟏 𝒉
𝟏  𝑲𝑺 = 𝟎. 𝟏𝟔𝟒 ±  𝟎. 𝟏𝟓𝟖 𝒈/𝑳  𝒕𝒅 = 𝟎. 𝟔𝟗𝟕 ± 𝟎. 𝟎𝟖𝟑 𝒉 
 
Parameters derived by Method 2 
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4.2 Simulation models Results 
Simulation Models Economic Results 
The simulation methods described in Chapter 3 produced six models. A summary of the computer files 
submitted as part of the Results of this thesis is shown in Tables 4-3 and 4-4 below. These files can 
also be found online using the DOI: 10.25375/uct.9920081. 
 
Table 4-3    Simulation models produced 










Stainless steel (SS) 01_GBS3-20L-SS-kinetic2.spf 
2 Single Use (SU) 02_GBS3-20L-SU-kinetic2.spf 




5 SU 05_GBS3-200L-SU-kinetic2.spf 
6 HY 06_GBS3-200L-HY-kinetic2.spf 
 
Table 4-4    Reports Generated by SuperPro Designer 
Model Materials & Streams Report Economic Evaluation Report 
1 01_GBS3-20L-SS-kinetic2_SR.xls 01_GBS3-20L-SS-kinetic2_EER.xls 
2 02_GBS3-20L-SU-kinetic2_SR.xls 02_GBS3-20L-SU-kinetic2_EER.xls 
3 03_GBS3-20L-HY-kinetic2_SR.xls 03_GBS3-20L-HY-kinetic2_EER.xls 
4 04_GBS3-200L-SS-kinetic2_SR.xls 04_GBS3-200L-SS-kinetic2_EER.xls 
5 05_GBS3-200L-SU-kinetic2_SR.xls 05_GBS3-200L-SU-kinetic2_EER.xls 
6 06_GBS3-200L-HY-kinetic2_SR.xls 06_GBS3-200L-HY-kinetic2_EER.xls 
Table 4-5 below summarises the economic performance results of each simulation model in terms of 
Capital expense (CAPEX) per kg over 10 years, annual operating expense (OPEX), and the cost of 
goods per kg (COG). An additional column reports the break-even price for a 5 µg dose of the product, 
GBS serotype III conjugate antigen. The suggested selling price for the product is $ 30 /dose. 
Table 4-5    Economic Performance Summary 
Model Scale Technology Total Capital 
cost 











SS  $   5 851 000   $ 1 677 000   $ 9 661 000  $ 48.31  
2 SU  $   4 384 000   $ 1 693 000   $ 9 756 000   $ 48.78  
3 HY  $   5 248 000   $ 1 701 000   $ 9 799 000   $ 49.00  
4 
200 L 
SS  $ 1 206 000   $ 6 086 000   $   3 747 000   $ 18.74  
5 SU  $ 1 325 000   $ 6 964 000   $   4 289 000   $ 21.45 
6 HY  $ 1 234 000   $ 6 225 000   $   3 833 000   $ 19.17  
Table 4-5 shows that increasing the process scale ten-fold (20 L to 200 L) has an effect of approximately 
doubling (x2) capital costs, tripling (x3) operating costs, and halving cost of goods (x½). 
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Figure 32 (top right) presents the costs summary 
at 20 L scale, as described in Table 4-3. Single 
use technology offers the lowest total capital 
expense (CAPEX) at $ 4.4 million / kg product 
(over 10-year project life), while CAPEXs for 
stainless steel technology and hybrid technology 
were more expensive at $ 5.9 million /kg, and $ 
5.2 million /kg, respectively. The operating 
expenses (OPEXs) for the different technology 
platforms were relatively similar at about $ 1.7 
million each, while the Cost of Goods (COGs) for 
each were also relatively similar at about $ 9.8 
million/kg. As shown in Figure 32, CAPEX for 
stainless steel technology was $ 1.5 million /kg 
greater than for single use technology. 
Figure 33 (middle right) presents the costs 
summary at 200 L scale as described in Table 4-
3. Stainless-steel was the cheapest technology 
with a CAPEX of $ 1.2 million /kg, while single use 
and CAPEX was $ 1.3 million /kg. At the larger 200 
L scale, OPEX for stainless steel was $ 6.1 
million/y, with Single Use technology at $7.0 
million/y, and Hybrid technology at and $ 6.2 
million/y. Stainless steel also had the lowest COG 
of $ 3.7 million/kg, while hybrid was slightly greater 
at $ 3.8 million/kg. Single use was most expensive 
at $ 4.3 million/kg.  
Figure 33 also shows that OPEX for single use 
technology was $ 1.0 million greater than that of 
stainless steel, while OPEX for hybrid technology 
was only $ 0.2 million greater than stainless steel. 
Table 4-6 below summarises the economic performance of the six simulation models in terms of 
relevant variable costs. The costs in 2017 US dollars per annum per kg of product for raw materials, 
consumables, and waste disposal are shown, while utility consumption for WFI and steam are shown 
as tons per kg product per year (t/kg.y), and million tons per kg product per year (MT/kg.y), respectively. 


















SS  $    1 600 000   $    1 518 000  281.8 84.1  $ 88 235  
2 SU  $    1 559 000   $    3 094 000  167.1 81.2  $ 94 118  
3 HY  $    1 576 000   $    2 288 000  197.1 82.4  $ 94 118  
4 
200 L 
SS  $    1 771 000   $       630 000  70.7 11.2  $ 86 420  
5 SU  $    1 821 000   $    1 037 000  47.9 9.1  $ 91 358  
6 HY  $    1 764 000   $       698 000  56.4 10.1  $ 87 037  
Table 4-6 illustrates that increasing the process ten-fold (20 L to 200 L) resulted in an approximate ten-
fold (x10) increase in raw material costs, while consumables costs increased by about three-fold (x3).  
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Figure 34 (top right) presents materials costs at 
20 L scale, as described in Table 4-6.  Raw 
materials costs across the technology platforms 
were similar at about $ 1.6 million /kg.y, while 
consumables costs were more varied. Stainless 
steel technology yielded the lowest consumables 
cost of $ 1.5 million /kg.y, while single use 
technology yielded the highest of $ 3.1 million 
/kg.y about double that of stainless steel. Hybrid 
technology was in-between at $ 2.3 million /kg.y. 
The trend in consumables costs may be 
attributed to the additional single use mixing 
bags, reactor bags, and shake flasks required to 
operate a process with single use fluid handling 
capability.  
 
Figure 35 (middle right) presents materials costs 
at 200 L scale, as described in Table 4-6. At 200 
L scale raw materials cost for the different 
technology platforms were similar at about $ 1.8 
million /kg.y. Consumables cost was highest for 
single use technology at $ 1.0 million /kg.y, with 
stainless steel lowest at $ 0.6 million /kg.y, and 
consumables for hybrid technology costing $ 0.7 
million /kg.y. In Figure 35, the observed trend in 
consumables costs at 200 L scale is similar to the 
trend at 20 L scale shown in Figure 34. This 
suggests that consumables costs trends may be 
characteristic of each specific technology-
platform. It was also noted that the economy of 
scale at 200 L resulted in a reduction in both raw 
material and consumable costs per kg product. 
 
The break-down of resource utilisation and waste disposal costs per kg of product, at 20 L scale, is 
shown below in Figure 36, as described in Table 4-6:  
 
Figure 34: Annual Materials Costs at 20L Scale 
Figure 35: Annual materials costs at 200 L scale 



























































































































Figure 36c: Annual Waste 
Disposal Cost 20 L Scale
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Results 
  58 
 
As shown in Figure 36, WFI and steam consumption at 20 L scale were greatest for stainless steel 
technology at 281.8 t/kg.y WFI and 84.1 MT/kg.y steam, while single use technology required only 167.1 
t/kg.y of WFI and 81.2 MT/kg.y steam. Hybrid technology featured intermediate consumption with WFI 
usage of 197.1 t/kg.y and steam usage of 82.4 MT/kg.y. The difference in WFI and steam usage 
between stainless steel (281.8 t/kg.y WFI, 84.1 MT/kg.y steam) and single use (167.1 t/kg.y WFI, 81.2 
MT/kg.y steam) technology is attributed to the CIP and SIP requirements of stainless-steel technology. 
Waste disposal costs were similar for all three technology platforms at $ 88 000 /kg.y for stainless steel 
and $ 94 000 /kg.y for each of single use and hybrid technology. This is some indication that despite a 
perceived increase in solid waste from implementing single use technology, at the 20 L scale there is 
only a $ 6 000 /kg.y cost increase.  
The break-down of resource utilisation and waste disposal costs at 200 L process scale is shown in 
Figure 37 below, as described in Table 4-6. At 200 L scale utility consumption for stainless steel was 
70.7 t/kg.y of WFI and 11.2 MT/kg.y of steam. Single use technology featured the lowest utility usage 
of 47.9 t/kg.y of WFI and 9.1 MT/kg.y of steam. Hybrid technology was found to have a WFI usage of 
56.4 t/kg.y and a steam usage of 10.1 MT/kg.y at 200 L scale. 
Figure 37 shows that at 200 L scale, there is a clear difference in WFI and steam usage between 
stainless steel (70.7 t/kg.y WFI, 11.2 MT/kg.y steam) and single use (47.9 t/kg.y WFI, 9.1 MT/kg.y 
steam) technology platforms. The relative increases in these gaps (30% per kg increase for WFI, 18% 
per kg for steam) from the 20 L scale showed that scale-up of the process based on stainless steel 
technology was water resource intensive. 
As shown in Figure 37, the waste disposal costs for stainless steel and hybrid technology were similar 
at $ 86 000 /kg.y and $ 87 000 /kg.y respectively. Single use technology incurred a higher waste 
disposal cost of $ 91 000 /kg.y. The difference in waste disposal costs from stainless steel to single use 
technology was reduced to $ 5000 /kg.y at 200 L scale from $ 6000 /kg.y at 20 L scale. 
  











































































Figure 37c: Annual Waste 
Disposal Cost 200L Scale
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Capital costs at 20 L scale 
The breakdown of Direct Fixed Capital (DFC, 
excludes working capital and start-up cost) was 
relatively similar across the three technology 
platforms at 20 L scale. Figure 38 (above right) 
shows the breakdown of DFC costs for stainless 
steel technology at 20 L scale. Equipment 
comprised 21% of the total DFC cost of $ 9.4 
million. Facility construction (23%), Engineering 
(13%), Installation (9%) and Process Piping 
(9%) were the next greatest costs. The category 
“Other” included buildings, electrical 
components, and yard improvement, taking up 
a combined 5% of DFC. 
Figure 39 (below right) shows a slightly different 
breakdown of DFC for single use at 20 L scale. 
Construction costs comprised 23% of the total 
DFC of $ 7.1 million while equipment was only 
19%. Engineering (13%) and Installation (11%) 
costs were next greatest. The difference in DFC 
distribution compared to stainless-steel was due 
to installation cost factors being specified for 
each piece of equipment rather than a single 
factorial for all installation costs. This resulted in 
minor differences observed in the break-down 
of DFC for the different technology platforms. 
The breakdown of DFC for hybrid technology 
(total $ 8.5 million) shown in Figure 40 (below 
left) was identical to that of stainless-steel 
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Capital costs at 200 L scale 
At 200 L scale, the breakdowns of DFC across the 
three technology platforms were relatively similar, 
as was the case for the 20 L scale process. 
DFC for the 200 L scale with stainless steel 
technology is shown in Figure 41 above right. 
Construction costs were 23% of the total DFC of $ 
18.3 million, with Equipment costs second highest 
at 21%. Next greatest, in descending order, were 
Engineering (13%), Process piping (9%), and 
Installation (9%) costs. An identical distribution of 
DFC was seen for the 200 L scale hybrid 
technology process (total DFC $ 18.8 million), 
shown in Figure 42 below left. 
The breakdown of DFC for the 200 L scale process 
with single use technology is shown in Figure 43 
(below right). Construction and Equipment costs 
were 23% and 18%, respectively, of the total DFC 
of $ 20.1 million. Installation costs were 13% while 
Engineering costs were 13%. 
The same trends in DFC distribution were observed 
at the 200 L scale in Figures 41, 42, and 43, and 
at the 20 L scale in Figures 38, 39, and 40. 
Stainless steel and hybrid technology featured 
similar DFC breakdowns to each other at the same 
scale, whereas single use technology featured an 
increase in the proportions of construction and 
installation costs, with a reduction in the proportions 













































Figure 43: DFC for 200L scale hybrid technology 
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Operating costs at 20 L scale 
Figure 44 (top right) shows the breakdown of 
operating costs (OPEX) for the 20 L stainless steel 
technology platform. Raw materials and 
Consumables portions of OPEX were each 16%, 
while Labour Dependent costs were 13% of the 
total OPEX of $ 1.7 million /y. More than half (54%) 
of the OPEX was attributed to Facility-Dependent 
costs, which included equipment maintenance and 
depreciation. 
OPEX for single use technology at the 20 L scale 
is shown in Figure 45 (middle right). Consumables 
made up 31% of the total OPEX of $ 1.7 million /y. 
Facility Dependent costs were second largest at 
40%, while Raw materials and Labour-dependent 
costs were 16% and 12%, respectively. 
Figure 46 (bottom right) shows the OPEX 
breakdown for hybrid technology at 20 L scale. 
Facility dependent costs were 48% of the total 
OPEX of $ 1.7 million /y, while consumables costs 
were 23%. Raw materials and Labour-dependent 
costs were 16% and 12%, respectively.  
The trend that is observed across the three 
technology platforms is that stainless steel 
features a larger proportion of facility dependent 
costs, due to the larger capital cost of stainless-
steel fermentation vessels as compared to single 
use. This was due to the estimation of facility 
dependent costs as a direct proportion (factorial) 
of equipment purchase cost, and stainless-steel 
equipment was more expensive at the 20 L scale. 
Single use technology featured a much larger 
proportion attributed to consumables due to the 
cost of replacing single use consumables (bags, 
bottles etc.) for every batch. 
This relationship between facility dependent and 
consumable costs can be elucidated by comparing 
Figures 44, 45, and 46. 
Although the OPEX of the different technology 
platforms are relatively similar at 20 L scale, it is 
noted that the stainless steel was marginally less 
expensive than single use and hybrid 
technologies. Hybrid technology was marginally 
more expensive, suggesting that the aspects of 
each technology that were combined to create the 
hybrid platform did not provide any cost savings 
benefit at this scale. 
 
  
Figure 44: OPEX for 20 L Stainless Steel technology platform 
Figure 45: OPEX for 20 L Single Use technology platform 
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Operating costs at 200 L scale 
The breakdown of OPEX for the 200 L scale 
process using stainless-steel technology is shown 
in Figure 47 (top right). Raw materials comprised 
47% of the total OPEX of $ 6.1 million /y, while 
Facility dependent costs and Consumables were 
29% and 17%, respectively. Labour-dependent 
costs and Waste disposal costs were 5% and 2%, 
respectively. 
OPEX for single use technology at the 200 L scale 
is shown in Figure 48 (middle right). 
Consumables were nearly a quarter (24%) of the 
total OPEX of $ 7.0 million /y. Raw materials were 
just under half (42%) of OPEX, and Facility-
dependent costs were 28%. 
In Figure 49 (bottom right) the breakdown of 
OPEX for the Hybrid technology at 200 L scale is 
shown. Raw materials were 46% of the total 
OPEX of $ 6.2 million /y, with Facility dependent 
costs and consumables at 29% and 18%, 
respectively. 
At the 200 L scale, the trend across the different 
technology platforms saw a proportional 
escalation of the variable costs for raw materials 
and consumables with increasing scale. Despite 
greater capital costs ($ 18 million - $ 20 million) 
compared to 20 L scale ($ 7 million - $ 10 million), 
the proportion of facility dependent costs at 200 L 
scale decreased compared to other variable costs 
for raw materials and consumables. The single 
use process at 200 L scale featured the highest 
operating expense at just under $ 7 million /y. This 
was primarily due to the increased cost of 
consumables.  
Labour-dependent costs generally shrunk in 
proportion from 12% at the 20 L scale to about 5% 
at the 200 L scale. Labour requirements were 
assumed (refer to Appendix A for assumptions) to 
stay constant with scale. In addition, labour costs 
did not include Management, Validation, 
Regulatory, or Quality Control costs. The small 
proportion of Labour costs in the 200 L scale 
OPEXs suggests a possibility that some of the 
assumptions made were an oversimplification for 
this process.  
 
 
Figure 47: OPEX for 200 L Stainless Steel technology platform 
Figure 48: OPEX for 200 L Single Use technology platform 
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4.3 Model Sensitivity – 200 L stainless steel technology 
The 200 L scale process using stainless steel technology was chosen to proceed with as the sensitivity 
base case, as described in 3.6 Sensitivity Analysis. The sensitivity base case featured a COG of $ 
3.7 million /kg, and an Internal Rate of Return (IRR) of 14.9%. The hurdle rate used was 25%. The 
sensitivity base case parameters were 400 mg/L fermentation titer from procedure SS200-04, 67% 
solid-liquid separation efficiency in procedure SS200-20, TFF cartridge replacement every 10 cycles, 
and 0% electricity from diesel generator. The result of the sensitivity analyses produced an additional 
16 model scenarios. A summary of the additional computer files submitted is shown in Table 4-7 below. 
These files can also be found at DOI: 10. 25375/uct.9920081. 

















200 mg/L 08_200LSS_t200.spf 08_200LSS_t200_EER.xls 
9 300 mg/L 09_200LSS_t300.spf 09_200LSS_t300_EER.xls 
10 500 mg/L 10_200LSS_t500.spf 10_200LSS_t500_EER.xls 





33% 12_200LSS_c33.spf 12_200LSS_c33_EER.xls 
13 50% 13_200LSS_c50.spf 13_200LSS_c50_EER.xls 
14 75% 14_200LSS_c75.spf 14_200LSS_c75_EER.xls 





10% 16_200LSS_e10.spf 16_200LSS_e10_EER.xls 
17 30% 17_200LSS_e30.spf 17_200LSS_e30_EER.xls 
18 50% 18_200LSS_e50.spf 18_200LSS_e50_EER.xls 





3 20_200LSS_tff3.spf 20_200LSS_tff3_EER.xls 
21 5 21_200LSS_tff5.spf 21_200LSS_tff5_EER.xls 
22 12 22_200LSS_tff12.spf 22_200LSS_tff12_EER.xls 
23 15 23_200LSS_tff15.spf 23_200LSS_tff15_EER.xls 
 
Economic performance results of each of the sensitivity scenarios described above is summarised in 
Table 4-8, in terms of COG and IRR.  
Table 4-8    Sensitivity Analysis Summary 






COG [$/kg] IRR 
8 




200 mg/L  $   8 006 000  N/A 
9 300 mg/L  $   5 400 000  N/A 
10 500 mg/L  $   2 894 000  27.1% 
11 600 mg/L  $   2 179 000  41.0% 
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Table 4-8   Sensitivity Analysis Summary (continued) 






COG [$/kg] IRR 
12 





33%  $   7 606 000  N/A 
13 50%  $   5 021 000  0.7 % 
14 75%  $   3 348 000  20.1 % 





10%  $   3 759 000  14.6 % 
17 30%  $   3 771 000  14.3 % 
18 50%  $   3 784 000  14.1 % 





3  $   4 868 000  5.7 % 
21 5  $   4 228 000  11.2 % 
22 12  $   3 667 000  15.6 % 
23 15  $   3 587 000  16.2 % 
 
Sensitivity to Fermentation Titer 
 
Figure 50 (top left) shows the sensitivity of Cost of Goods (COG) to fermentation titer. It can be seen 
that a quadratic trend-line can be fitted to the data with an R2 value of 1. The form of the trend-line 
shows that the incremental increase in COG becomes smaller with incremental increases in 
fermentation titer, as well as exponential increases in COG as fermentation titer decreases. The lowest 
COG of $ 2.2 million /kg was achieved at a titer of 600 mg/L. Figure 51 (above right) shows that IRR 
increases linearly with increasing fermentation titer within the range tested. The slope of this relationship 
shows a 13% increase in IRR for every 100 mg/L increase in titer. Fermentation titers above 480 mg/L 
produced scenarios where IRR was greater than the hurdle rate of 25% (dashed line in Figure 51), 
corresponding to a commercially feasible process. This showed that small improvements in titer could 
make the project a substantially more attractive investment. A titer of 600 mg/L resulted in the highest 
IRR of 41.0%, which again illustrates the process’ sensitivity to increased product yields. 
Figure 50: Sensitivity of COG to fermentation titer Figure 51: Sensitivity of IRR to fermentation titer 
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Sensitivity to Solid-Liquid Separation Efficiency 
 
Figure 52 (above left) shows the sensitivity of COG to the solid-liquid separation efficiency of unit 
procedure SS200-20 in centrifuge C-301. For an increase in separation efficiency from 67% in the 
sensitivity base case to 75% in one of the scenarios modelled; a reduction in COG from $ 3.7 million 
/kg to $ 2.8 million /kg was observed. The trend-line fitted to the relationship between COG and 
separation efficiency was found to be quadratic (the same form as for fermentation titer) with an R2 of 
1. As shown in Figure 52, the quadratic relationship suggests an optimum separation efficiency, above 
which COG begins to increase again. Solving for the turning point (𝑥 = − ) of the trend line with form 
𝑦 = 𝑎𝑥 + 𝑏𝑥 + 𝑐, this point was found to be a separation efficiency of 91.5%. 
In Figure 53 (above right) the sensitivity of IRR to solid-liquid separation efficiency in SS200-20 is 
shown. The trend-line fitted to the data begins to fit a quadratic trend with an R2 of 1, as opposed to the 
linear trend observed between IRR and fermentation titer. The highest IRR of 28.5% for this parameter 
was achieved at a separation efficiency of 90%. This IRR was lower than the maximum IRR achieved 
by increasing fermentation titer (41.0%). The threshold for IRR greater than the hurdle rate of 25% 
(shown by the dashed line in Figure 53) was found at a separation efficiency greater than 83%. 
  
Figure 52: Sensitivity of COG to separation efficiency Figure 53: Sensitivity of IRR to separation efficiency 
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Sensitivity to TFF Cartridge Replacement Frequency 
  
Figure 54 (above left) shows sensitivity of COG to TFF cartridge replacement frequency. The trend line 
fitted follows an exponential trend, with an R2 of 0.98. The lowest COG of $ 3.6 million /kg was found 
when replacing TFF cartridges every 15 batches.  This reduction in COG from the base case of $ 3.7 
million /kg was relatively small as compared to the increase in COG for replacing TFF cartridges every 
3 batches with a COG of $ 4.9 million /kg. These two results showed that COG was more sensitive to 
TFF cartridge replacement frequency at low replacement frequency (every 10 - 15 batches), while 
sensitivity decreased at high replacement frequency (every 3 - 5 batches).  
The sensitivity of IRR to TFF cartridge replacement frequency is shown in Figure 55 (above right). The 
trend line fitted did not follow a linear or polynomial trend but was closest to a logarithmic trend, with an 
R2 of 0.96. This type of trend fitted the observed relationship between IRR and replacement frequency, 
similar to that between COG and replacement frequency. IRR was more sensitive at low replacement 
frequency and less sensitive at high replacement frequency. 
Sensitivity to Percentage Electricity Generation From Diesel 
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The sensitivity of COG to percentage electricity from diesel generator is shown in Figure 56 (previous 
page bottom left). The linear trend-line fitted to the data in Figure 56 shows that COG was not very 
sensitive to electricity dependence on diesel, with the slope of the trend line (𝑚 = 7.8𝑥10 ) being 100 
times smaller than the intercept (𝑐 = 3.8𝑥10 ). It was noted that increasing electricity dependence on 
diesel from 0% to 75% resulted in less than a $ 0.1 million /kg increase in COG, from $ 3.7 million /kg 
(0% electricity from diesel) to $ 3.8 million /kg (75% electricity from diesel). The latter scenario featured 
a $ 250 000 increase in purchased equipment cost, with an increase in electricity cost from $ 0.10 /kWh 
to $ 0.35 /kWh. 
Figure 57 (previous page bottom right) shows sensitivity of IRR to electricity dependence on diesel. 
IRR was not very sensitive to this parameter as compared to the other sensitivity parameters tested 
previously. An inverse linear trend was observed between IRR and electricity dependence on diesel. 
For each 10% increase in electricity requirements from diesel resulting in a 0.2% decrease in IRR. 
Sensitivity trends 
The process model at 200 L scale using stainless steel technology was not particularly sensitive to 
electricity dependence on diesel, with sensitivity of COG and IRR to this parameter being approximately 
100 times smaller than the range of COG and IRR values respectively. An increase from 0% to 75% 
electricity dependence on diesel resulted in just a 2% increase in COG, from $ 3.7 million / kg to $ 3.8 
million /kg. The same was found for IRR in this scenario, with a decrease of only 1.4% IRR. 
Sensitivities of the 200 L stainless steel technology process model to fermentation titer and separation 
efficiency were more notable. Sensitivity to fermentation titer illustrated the greatest gains in both COG 
and IRR, suggesting that this is an area of the process to focus on for optimization. The scenario of 600 
mg/L titer yielded a 40% reduction in COG from the base case $ 3.7 million /kg down to $ 2.2 million 
/kg. Similarly, the improvements from increasing separation efficiency were attractive as an optimization 
parameter. An increase from 67% to 90% separation efficiency for product recovery resulted in a 25% 
reduction in COG, from $ 3.7 million /kg to $ 2.8 million /kg. The relative improvements in COG between 
fermentation titer, separation efficiency, and TFF cartridge replacement frequency, are shown below in 
Figure 58. 
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In Figure 58 (previous page) all three trends in COG are overlaid using the sensitivity base case 
scenario 200 L stainless steel process as a reference point (COG $ 3.7 million/kg). The comparison 
shows that COG sensitivity to fermentation titer was greater than the sensitivity of COG to separation 
efficiency or TFF cartridge replacement frequency. This can be observed by the trend-lines of the latter 
two parameters being more horizontal about the reference point of the sensitivity base case scenario, 
as compared to the solid line representing the trend in fermentation titer.  
A similar comparison was generated for the sensitivity of IRR to the parameters of fermentation titer, 
separation efficiency, and TFF cartridge replacement frequency and is shown below in Figure 59.  
 
The comparitive sensitivies to IRR are illustrated in Figure 53 by the relative slopes of each of the three 
trend lines about the base case scenario point, which was an IRR of 14.9 % for the 200 L stainless steel 
process model. IRR was most sensitive to fermentation titer, as can be seen by the slope of the solid 
line in Figure 59. IRR was also least sensitive to TFF cartridge replacement at the base case scenario 
reference point; however, it is noted that the trend in sensitivity to TFF cartridge replacement was non-
linear, and sensitivity to this parameter was much greater at high replacement frequency (every 3 
batches).  
When comparing the sensitivity of the three parmaters to the hurdle rate (dotted line in Figure 59) it is 
visible that small increases in fermentation titer were sufficient to make the project viable (IRR > hurdle 
rate). This was found by increasing titer from 400 mg/L to 480 mg/L, a 20% relative increase. In 
comparison a greater improvement in separation efficiency was required, from 67 % in the sensitivity 
base case to 83%, a relative increase of 25%. 
In terms of the trend lines fitted and relative sensitivities of the parameters, fermentation titer fitted a 
linear trend, separation efficiency a quadratic trend, and TFF cartridge replacement fitted a logarithmic 
trend. It was observed that the more linear the trend, the more sensitive the model IRR was to that 
parameter. Amongst the three paramters shown in Figures 58 and 59, the model was most sensitive 
to fermentation titer, followed by separation efficiency, and least sensitive to TFF cartridge replacement 
frequency. An exception was found at high TFF cartridge replacement frequency where COG and IRR 
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5 Discussion 
Capital Expenses at 20 L and 200 L Scales 
At 20 L scale, CAPEX for single use technology was lower than both stainless steel and hybrid 
technology, but at 200 L scale it was the opposite case, with stainless steel CAPEX being the lowest. 
The major differences in CAPEXs at the 20 L scale may be attributed to differences in equipment cost 
between a stainless steel fermentor ($ 403 000) and a single use fermentor ($ 118 000) at the 20 L - 
50 L size range. The difference was seen again between stainless steel mixing vessels ($ 165 000) and 
single use mixing vessels ($ 74 000 - $ 100 000) in the 50 L - 70 L size range, which was required for 
the 20 L fermentor scale. 
At 200 L scale CAPEX for single use technology was $ 2 million greater than for stainless steel, while 
hybrid technology was only $ 0.5 million greater. At this scale the major difference in CAPEX was due 
to the much greater cost of a 200 L single use fermentor ($ 800 000) with 200 L – 650 L single use 
mixing vessels ($ 150 000 - $ 300 000) compared to a 200 L stainless-steel fermentor ($ 620 000) and 
200 L – 600 L stainless-steel mixing vessels ($ 171 000 - $ 199 000). The specific CAPEXs per kg of 
product for all three technology platforms at 200 L scale were on average 5 times less than the CAPEXs 
per kg of product at 20 L scale. The latter indicates a 5x economy of scale in terms of CAPEX when 
increasing from 20 to 200 L scale. 
As process scale was increased to 200 L, single use technology lost the advantage it had at 20 L scale 
in terms of lower capital costs. The observed result agrees with Table 2-6 in Section 2.3, which reported 
a decreasing technological competitiveness of single use technology at large scales. The increased 
cost of single use equipment at scale was described in Section 2.3 as due to inherent technological 
limitations which require more expensive components to achieve equivalent performance. Although 
technological development of single use technology could feature improvements to mitigate this, the 
result in this study confirms the scalability limitation of single use technology. 
Operating Expenses and Cost of Goods at 20 L Scale 
At 20 L scale OPEX was relatively similar across all three technology platforms, which indicated that 
the cost of replacing single use consumables had little effect on OPEX at this scale. It should be noted 
that the qualitative benefits of single use technology such as speed to market and reduced risk of cross 
contamination are not reflected in the economic analysis results reported in Chapter 4. These benefits 
would make single use technology the most desirable for a process at the pre-clinical and phase I trial 
stage of development, given the relatively similar operating costs of single use and stainless steel at 
this scale. It was also noted that waste disposal costs were similar for all platforms at 20 L scale, which 
is a reported drawback of single use technology in Table 2-6 in Section 2.3. The concern that large 
amounts of plastic waste would require disposal at a cost were not applicable to this process at the 20 
L scale, as the cost of disposing of the additional plastic waste was not enough to impact OPEX. 
At 20 L scale there was little difference in COG between the three technology options. This was a 
feature of the 20 L scale process, despite having 40 – 54% of OPEX attributed to facility dependent 
costs across the three technology platforms.  Facility dependent cost contribution to OPEX was a factor 
of the equipment purchase costs, which were different across technology platforms at both scales. This 
result suggests that CAPEX had little effect on OPEX for the 20 L scale process. Equipment costs were 
only 19 - 21 % of Direct Fixed Capital (DFC) as shown previously in Figures 32, 33 and 34. This result 
may be better understood when considering one of the assumptions made in this simulation exercise 
was to use a depreciation period of 10 years. This assumption reduced the effect of CAPEX on OPEX 
by reducing the absolute value of facility dependent costs, and subsequently enhanced the effect of 
other variable costs on OPEX. The outcome was that this simulation exercise was generally more 
focused on variable costs than fixed costs. 
Operating Expenses and Cost of Goods at 200 L Scale 
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At 200 L scale OPEX for single use technology was $ 1 million greater than both hybrid and stainless-
steel technologies, an effect of increased consumables costs for single use technology at the 200 L 
scale. The trend observed in OPEXs scaling up from 20 L to 200 L when is an effect of using fixed 
consumables costs at both scales. A result of this decision was that the operating cost of the 
consumable-intensive single use technology increased proportionally as the process scale increased. 
Despite this result, it should be noted that a manufacturer purchasing consumables in large shipments 
in South Africa may be able to negotiate discounts with suppliers, which could result in a reduction in 
these costs. An increased uptake of single use technology in other African countries and emerging 
markets in the future could further reduce the price of these consumables.  
Another consideration for large orders of material is increased storage and transportation costs. A 
simpler solution would be to select a technology platform with inherently lower capital- and consumable 
costs, thereby eliminating the need to buy large orders of material. The goal for a commercial process 
would be to minimize OPEX, which effectively excludes the choice of single use technology at the 200 
L scale. The hybrid technology platform featured a relatively lower OPEX of $ 6.2 million /y compared 
to single use at $ 7.0 million /y, and only marginally higher than stainless steel at $ 6.0 million /y. The 
advantage of this technology at the 200 L scale would be the retention of some of the qualitative benefits 
of single use technology as mentioned previously (speed to market, validation cost), whilst also being 
competitive in terms of the overall COG. 
At 200 L scale the best performing technology in terms of COG was stainless steel, with COG $ 650 000 
/kg lower than that for single use technology. This was attributed to the greater cost of consumables for 
single use technology at 200 L scale, taking up a quarter of OPEX as shown previously in Figure 42. 
The observed trend in OPEX between the three technology platforms (SU>HY>SS) at the 200 L scale 
was similar to the trend in COG (SU>HY>SS), which suggests a direct influence of OPEX on COG 
when scaling up a process to 200 L. Increasing the process scale ten-fold from 20 L to 200 L had 
approximate effects across all the technology platforms of doubling capital costs, tripling operating 
costs, but halving COG. The latter effect on COG demonstrates the difference in economies of scale 
between 20 L and 200 L fermentation capacity. 
Labour costs proportion of OPEX was reduced to about 5% for all three platforms at 200 L scale, 
compared to about 12 % at 20 L scale. The assumption that operational labour costs would be the same 
for the 200 L scale process as for the 20 L scale process was the primary reason for labour taking up 
such a small portion of costs as the process scale increased. In addition, the exclusion of administrative, 
quality (QA, QC), and regulatory labour costs also reduced the proportion of labour costs of OPEXs at 
200 L scale. Including these additional labour costs could have produced a more accurate 
representation of the overall cost breakdown. As a result of these assumptions made for labour costs, 
the results in this thesis are focused more on material and consumables costs. 
Further investigation into the real labour costs, as well as the costs of equipment and consumables at 
large process scale could identify a more accurate relationship between costs and processing scale for 
this particular process. Such an investigation could improve the usefulness of the simulation models 
produced in this thesis to accurately predict real process performance. It would also be useful to 
investigate the effect of reducing the depreciation period to 5 years, to determine whether CAPEX may 
begin to influence COG. 
Internal Rate of Return and feasibility 
IRR was found to be less than the hurdle rate of 25% for all six of the initial scenarios modelled, 
indicating that the base case process performance would not be feasible. At 20 L scale, IRR was non 
real, indicating an outright loss-making project at that scale. This was illustrated previously in Table 4-
3, where break even prices at the 20 L scale were close to $ 50 /dose, almost double the recommended 
selling price of $ 20 – $ 30 /dose. At 200 L scale, the break-even prices were about $ 20 /dose which 
was within the recommended selling price range, suggesting a marketable product. 
At 200 L scale IRR was highest for stainless steel technology, at 14.9 %, which formed the base case 
for further sensitivity analyses. The sensitivity analyses showed that optimization of some process 
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performance areas could make the process feasible, and a potential IRR value as high 41 % could be 
achieved with 600 mg/L fermentation titer. It should be noted that this performance increase may not 
be realistic but informs a process development decision to focus on this parameter as an area for 
optimization.  
Increasing process scale from 20 L to 200 L made the process profitable for all three technology 
platforms (IRR > 0). It is postulated that increasing the process scale above 200 L would make the 
process inherently feasible (IRR > hurdle rate) for one or more of the technology platforms even before 
optimization of performance. Although sensitivity was not performed on process scale as a parameter, 
this should be included in any further application of this research. 
Sensitivity of COG and IRR 
The sensitivity of COG to fermentation titer and separation efficiency showed that increasing the 
profitability of the 200 L stainless steel process was possible through process optimization. Although 
optimization is not included in this thesis, the sensitivity of COG and IRR shown in Figures 52 and 53 
indicated that small improvements in specific areas of the process could yield valuable improvements 
to profitability. It should be noted that such improvements would require investment of both time and 
money.  
The sensitivity analyses of fermentation titer and separation efficiency highlight two of the process 
parameters that could be improved to achieve reductions in COG and increases in IRR. For any 
prospective development of such a process, these parameters could be investigated for optimization. 
The sensitivity base case 200 L stainless steel technology process was not feasible, with an IRR of only 
14.9 % which was below the hurdle rate of 25.0 %. The feasibility of the process at 200 L scale is 
therefore dependent on increasing at least one of the sensitivity parameters of fermentation titer or 
separation efficiency. As shown in Figure 53, the scenarios where IRR was greater than the hurdle rate 
were only achieved after increasing fermentation titer or separation efficiency above the threshold 
values where IRR = hurdle rate.  
The results of the sensitivity analyses could be used to direct the process development decision making, 
in focusing attention on the most sensitive areas of the process. It was certainly true for the 200 L 
stainless steel process model’s sensitivity to electricity dependence on diesel generation. While this is 
a real risk for manufacturers, the process model was found to not be very sensitive to this parameter. 
The result showed that if the relevant contingency was in place (generators, diesel storage), then this 
was not an area to focus on for ongoing process development. In contrast, fermentation titer and 
separation efficiency would need to be prioritised.  
The sensitivity of COG and IRR to TFF cartridge replacement frequency also showed how operational 
decisions can affect profitability. Increasing the frequency of replacement from every 10 batches in the 
sensitivity base case, to every 3 batches resulted in a substantial increase in COG and decrease in 
IRR. The initial operational decisions regarding consumables would have an impact on the process 
feasibility, even if not as strongly as fermentation titer or separation efficiency. The magnitude of COG 
reduction was not the same when increasing TFF cartridge replacement from every 10 to every 15 
batches. The result is valuable to consider when increasing the re-usable lifespan of consumables, as 
this would incur additional validation costs to show cleaning efficacy. 
Environmental Impact and Sustainability 
It was noted that the annual cost of waste disposal per kg of product for single use technology at 200 L 
scale was $ 5 000 /kg.y  greater than that of stainless steel, while hybrid was only $ 600 /kg.y. This 
showed that the increase in consumables cost was the largest contributor to increased waste disposal 
costs for single use technology. In terms of mass the additional waste accounted for an additional 2.4 
tons of plastic waste per year which suggests that despite the relatively small impact on costs, the 
physical environmental impact may be greater. Considering that the 200 L scale stainless-steel process 
utilised an additional 23 t/kg.y of water and 2 MT/kg.y of steam for sterilization and CIP services, it is 
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understood that the environmental sustainability of both processes would need to be evaluated by LCIA 
before a definitive answer could be given on which was more sustainable. 
The effect of scaling up the process ten-fold, from 20 L to 200 L, resulted in an increase in waste 
disposal costs of over 800%, attributed primarily to the large increase in aqueous waste for disposal. 
Single use technology at 200 L scale also incurred a 6% increase in waste disposal costs compared to 
stainless-steel. This may be attributed to the cost of disposing of large single use reactor bags and 
other single use consumable items. 
At industrial manufacturing scales, the large amount of plastic waste generated by single use process 
technology may be a serious challenge in terms of environmental impact and sustainability. Single use 
plastics are non-biodegradable and in many cases are not recyclable as they are classified as 
biohazardous waste. The result is that a process that is reliant on single use technology will produce 
large quantities of plastic waste that will need to be incinerated. In addition to generating this plastic 
waste, the industrial scale demand for single use plastics would create an economy for the extraction 
of fossil fuels and refining of petroleum products used to make these plastics. 
In contrast stainless steel technology was water intensive, which may be more important when 
considered within the South African context. South Africa is a water scarce country, where the 
sustainability of any commercial process would be intrinsically linked to the efficient and frugal use of 
water. It is possible that in a South African context, a water intensive process technology like stainless 
steel may be less sustainable than a technology which generates large quantities of petroleum based 
plastic waste, such as single use technology. 
South African Context 
Some of the capital costs used in the simulations were estimated using built in software cost models 
supplied by Intelligen Inc., a software developer based in the US. For equipment costs specified using 
purchase costs from The Biovac Institute in South Africa, it was observed that the real cost for 
purchasing biopharmaceutical equipment in the South African market is more expensive than in Europe, 
Asia, and the US. This is due to the small relative size of the South African biopharmaceutical market, 
and global economic forces such as exchange rates and trade agreements. The cost of this type of 
equipment increases the economic appeal of single use technology at the 20 L scale, and similarly 
makes stainless-steel technology at the 200 L scale more appealing. The regulator of South African 
pharmaceutical products is also less experienced than their American counterpart with validation of 
single use systems, creating a further source of uncertainty over the potential speed-to-market benefit 
of single use technology in a South African context.  
 
This simulation exercise indicated there was very little benefit, in terms of COG and IRR, in using single 
use technology in the South African context. This result is contrary to similar exercises by others for 
contexts in developed economies (Sinclair & Monge, 2002, 2005; Papavasileiou, Siletti & Petrides, 
2008; Zheng, 2010; Flaherty & Perrone, 2012). The results of this thesis seem to indicate a reduced 
benefit when implementing single use technology in a developing economy away from main distribution 
and manufacturing centres, like that of South Africa. The effects on COG (identified in Chapter 4) from 
an increased cost of consumables were that single use technology featured up to 31% (at 20 L scale) 
of OPEX for the single use technology platform. This increased cost phenomenon is due to the African 
context for biopharmaceutical processing, where this region has a low market power compared to the 
US, Asian and European contexts in which other studies are based. Another finding was the CAPEX 
for single use equipment at 200 L scale being $ 2 million higher than for stainless steel. To a lesser 
extent this is also due to context and market power, although it may also be attributed to the decreased 
competitiveness of single use technology at the 200 L scale. 
An example of typical costs for a 50 kg/y process to make a viral vaccine using stainless steel 
technology in Australia featured a consumables cost of between $ 4 200 /kg and $ 12 000 /kg (Chuan 
et al., 2014). The 1.6 kg/y conjugate vaccine process (200 L, stainless steel) in this exercise in a South 
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African context featured a consumables cost of $ 631 000 /kg, while the single use technology platform 
featured a consumables cost of $ 1 million /kg. Although not included in this study, these costs may be 
expected to decrease at larger industrial scales. A 1000 L monoclonal antibody process based on single 
use technology in Europe would have a typical consumable cost of about $ 60 000 /kg (Sinclair & 
Monge, 2005). Another example for a 2000 L mAb process featured a consumables cost of $ 39 500 
/kg (Papavasileiou, Siletti & Petrides, 2008). 
It should be noted that these comparisons are made between vastly different processes and 
technologies. Comparing monoclonal antibodies to viral vaccines to conjugate vaccines all at different 
process scales is not precise enough to draw meaningful conclusions; however, the example does 
illustrate that consumables costs are process and context specific. The increased cost of consumables 
observed for the GBS vaccine process in a South African context would make the same process less 
profitable than if it were developed in a European context. 
An area where cost savings are possible due to a characteristic of the South African context is a lower 
average cost of labour. The simulation results showed a very small proportion of labour costs in OPEX, 
which was primarily due to some of the assumptions made which were discussed previously in 
Operating Expenses and Cost of Goods at 200 L Scale. It is also interesting to compare these costs to 
processes in the international contexts described above. A viral vaccine process in Australia (Chuan et 
al., 2014) featured a labour cost of $ 3.8 million /y, compared to the conjugate vaccine process in this 
study with a labour cost of $ 287 000 /y. Again, the differences between the processes are important to 
understanding the difference in labour costs, but context is also worth consideration. 
Labour in South Africa, as for other emerging economies such as India or China, is generally cheaper 
than in Europe, Asia, or the US. In terms of operational labour, the salary data retrieved from the website 
PayScale showed that the annual cost of a process operator in South Africa was $ 10 000 /y, while the 
same operator in the USA would cost $ 50 000 /y (PayScale, 2019a). Similarly, a production supervisor 
in South Africa would cost $ 15 000 /y, and in the USA, $ 60 000 /y (PayScale, 2019b). The trend 
indicates that labour costs in South Africa are about five times lower than the US. This suggests setting 
up in a process in South Africa could provide real costs savings, especially if increased costs in other 
areas could be mitigated. 
Process Simulation as a Decision Support Tool 
The simulation exercise showed that economic performance of the different process technologies could 
be simulated without purchasing any equipment or consumables, nor the hiring of any personnel. The 
accuracy of these economic projections is; however, dependent on the availability of accurate data on 
the pricing of equipment, consumables, materials, and labour costs for the process being modelled. 
The model is only as good as the information that goes into it. 
Crucial to the application of simulation modelling tools for biopharmaceutical process development is 
that the financial risk to a potential process developer would be considerably less than setting up a pilot 
scale plant. Novel biopharmaceutical processes are high risk with high project failure rates, and typically 
also require large upfront investment in order to develop a new product. Added to this is the opportunity 
cost of facility utilisation for a period of 5 - 10 years to take a new product from preclinical development 
to approval. A simulation exercise would provide valuable information at the pre-feasibility stage, 
particularly in terms of directing the technological development and direct fixed capital investment for 
the project, as well as providing information on how to expedite the development pathway. 
The direct fixed capital cost of installation and starting up a 20 L scale pilot process in this study would 
be approximately $ 9.5 million, whereas the cost of a simulation exercise (a software license and one 
engineer’s salary) to test multiple technology options would be less than $ 100 000. The cost saving in 
this regard is enhanced due to the reduced labour cost of conducting this exercise in South Africa.  
For any biopharmaceutical process under development the choice of which technology to use in a pilot 
scale process is a critical feasibility parameter. If a more expensive technology platform is chosen to 
build a pilot plant and also carried through for commercialization, the project would end up costing more 
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to the investor and could even be outright infeasible. In this project a 200 L scale process using the 
single use technology platform would start with an IRR of only 9% making it more challenging, even 
with optimization, to meet the required IRR of 25% to become feasible. Although not included here, it 
may not even be possible to achieve this target with the single use technology platform. This type of 
decision would be a fatal error during process development if realized at the stage of having built and 
installed a 200 L scale plant at a cost of $ 20 million. 
The simulation exercise in this study provided information on which platform to start for development. 
The tool was able to generate information on the choice of technology, as well as the areas of the 
process which could achieve the greatest gains in productivity and efficiency. The one area which the 
simulation exercise was not able to provide information on, was the qualitative benefits of each 
technology platform, such as the validation benefits of single-use technology. Single use technology 
may be beneficial for pre-clinical development due to reduced installation, start-up time, and validation 
requirements. This benefit was not modelled, nor was there any indication of it in the simulation results. 
Basing a decision solely on the results of a simulation exercise could therefore overlook some of these 
considerations and should be understood when using simulation results for making process 
development decisions.  
The information produced in a simulation exercise such as this one would definitely be of use to a 
process developer and could also be applied to future projects once a simulation database has been 
generated. The unique information related to the South African context would also be useful for 
mitigating some of the unique challenges faced by operating a biopharmaceutical process in this 
economic context. The results of this type of exercise would be able to inform the successful 
development of a potential process by directing technological choices, context specific decisions on 
areas of the process requiring optimization, and also which areas of the process in which to invest for 
the highest possible returns. 
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6 Conclusion and Recommendations 
Hypothesis 
Cost of goods influences a new vaccine’s commercial viability in an industry where lower 
product price is competitive with market power. A Techno-economic evaluation of three 
technology options for the production of a GBS trial vaccine antigen will provide information to 
reduce financial risk and support more commercially viable decisions during process 
development.  
In the case study of a trial vaccine; it is hypothesised that single use vessels will yield a lower 
cost of goods at 20 L and 200 L process scale, as compared to stainless steel vessels. This is 
hypothesised due to an expected reduction in operating costs for clean- and sterilize-in-place 
requirements for stainless steel technology. A hybrid of the two technology options would yield 
an even lower cost of goods by combining the best economic properties of both single use and 
stainless-steel technologies.  
Conclusions 
The Hypothesis is disproved. In contradiction with the hypothesis, at 20 L scale stainless steel and 
single use technology platforms yielded similar COGs of $ 9.7 million /kg and $ 9.8 million /kg, 
respectively. At 200 L scale stainless-steel technology had an advantage with a COG of $ 3.7 million 
/kg, compared to single use technology’s COG of $ 4.3 million /kg. Hybrid technology was not the best 
performing at either scale, with a COG of $ 9.8 million /kg at 20 L scale and an intermediate COG of $ 
3.8 million /kg at 200 L scale. The second part of the hypothesis is therefore also disproved, in that 
hybrid technology does combine the characteristics of single use and stainless-steel technology but 
does not result in the lowest COG. 
The process is infeasible and loss-making at 20 L scale regardless of technology platform, while at 200 
L scale the process was still infeasible but was at least profitable. Scaling the process up to 200 L and 
improving process performance are therefore basic requirements for commercial feasibility. 
The process in this study was modelled within a South African context, which influenced the economic 
performance of the process technologies tested. Single use equipment and consumables were 
relatively expensive to purchase in South Africa, making the single use technology platform less 
competitive at both scales. Reduced labour costs in the South African context also increased the 
influence of other variable costs such as raw materials and consumables. 
The environmental impacts of single use versus stainless steel technology were not investigated in this 
thesis; however, they are important to consider in the current global context of climate change and 
sustainable industries. The information required to assess and evaluate these impacts such as the 
quantity of plastic waste and the consumption of water and electricity was available as a product of the 
simulation exercise and this information must be used to quantify environmental impacts any 
subsequent evolutions of this type of research. The sustainability of a stainless steel or single use 
process technology may also be influenced by the South African context, given it is a water scarce 
country with a strong economic dependence on extractive industries and without particularly strong 
policies on reducing environmental deposition of plastic waste and its derivatives. 
Process simulation modelling is applicable to biopharmaceutical process development decision making 
at the pre-feasibility design stage of a project and may also be extended further into feasibility 
assessment. This process analytical tool is able to provide information on the economic impact of 
process development decisions by testing multiple processing options and comparing their relative 
economic performance. Single use technology was associated with an increase in plastic waste, while 
stainless steel technology was water intensive. The environmental sustainability of different process 
technologies may be evaluated using simulation modelling; however, more detailed analysis is required 
to evaluate environmental impacts. 
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Recommendations 
Stainless steel vessel technology is recommended for further development of a process to manufacture 
a novel GBS vaccine at 200 L scale or greater. Such a process could be feasible at commercial scales 
of 200 L with a fermentation titer of 480 mg/L or greater. Profitability could be further improved by one 
or more of: increasing the process scale beyond 200 L (assuming expansion into the global market), 
improving product recovery efficiency beyond 67%, and reducing the replacement frequency of 
expensive consumables such as TFF cartridges to more than 10 batches.  
At 20 L scale single use technology is recommended for development of the GBS vaccine process due 
to inherent qualitative benefits for start-up and pre-clinical development. For increasing the process 
scale above 20 L it is recommended to change to stainless steel technology. This technology 
changeover is recommended to be integrated into the process development plan to achieve the 
maximum benefit from both technology platforms. 
The application of process simulation modelling to biopharmaceutical process development in a South 
African context is strongly recommended. The unique effects of market forces and the South African 
economic climate require context-specific information on the performance of different process 
decisions. This is especially applicable to the areas of the process influenced by economic context, 
such as capital- and material costs. An effective simulation exercise at the pre-feasibility and feasibility 
stages of a novel biopharmaceutical product development project in a developing economy could save 
an investor from making costly decisions that would otherwise have been based on the performance of 
similar processes in established markets of Europe, Asia, and the US. 
Future applications of this research 
A future application of this research would be to expand the simulation exercise to include more detailed 
and updated costs for equipment, raw materials, consumables, and labour costs. Further investigation 
into equipment and consumables costs at 2019 prices, and adjusted pricing for large order quantities 
for 200 L processing scale (and above) could identify a more accurate relationship between costs and 
process scale. It would also be useful to investigate the effect of reducing the depreciation period to 5 
years, to determine a more accurate relationship between capital expenses and cost of goods.  
The scope of labour costs may also be expanded to include administration, quality assurance, quality 
control, and regulatory labour costs. An improvement to the sensitivity analyses would be to include 
process scale as a sensitivity parameter and to use Monte Carlo sensitivity analysis to provide 
quantitative measure of the uncertainty associated with the simulation results. 
An additional analysis that could be performed in future would be to assess the environmental impact 
of the different technology platforms, particularly in terms of plastic waste and water footprint. These 
investigations could improve the potential for these simulation models to accurately predict real process 
performance, and to provide further information on the development of biopharmaceutical processes in 
a South African context. 
On the use of process simulation as a decision support tool for biopharmaceutical 
process development in a South African context: 
Process simulation is a versatile tool for process development. The tool was deployed to evaluate a 
novel biopharmaceutical process for which there was little existing information and produced a 
quantitative analysis of the commercial potential of three technological decisions. Process simulation 
as a decision support tool can also be used in a specific context such as the unique South African 
biopharmaceutical process development and manufacturing landscape, and subsequently be able to 
produce information that informs practical context specific process development decisions. 
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Appendix A Methods 
A.1 Fermentation Stoichiometry: Material Balances 
Aerobic glycolysis by Streptococcus agalactiae: 
𝑪𝟔𝑯𝟏𝟐𝑶𝟔 + 𝒂 𝑶𝟐 + 𝒃 𝑵𝑯𝟑
→ 𝒄 𝑪𝑯𝟏.𝟖𝑶𝟎.𝟓𝑵𝟎.𝟐 + 𝒅 𝑪𝑶𝟐 + 𝒆 𝑯𝟐𝑶 + 𝒇 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑶𝑯
+ 𝒈 𝑪𝑯𝟑𝑪𝑶𝑶𝑯 +  𝒉 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑪𝑯𝟑 + 𝒊 𝑯𝑪𝑶𝑶𝑯 + 𝒋 𝑪𝑷𝑺 
Equation 3-1 
 





Glucose 𝟏 C6H12O6 180 
Oxygen 𝒂 O2 32 
Ammonia 𝒃 NH3 17 
Biomass 𝒄 CH1.8O0.5N0.2 24.6 
Carbon dioxide 𝒅 CO2 44 
Water 𝒆 H2O 18 
Lactic acid 𝒇 C3H6O3 90 
Acetic acid 𝒈 C2H4O2 60 
Acetoin 𝒉 C4H8O2 88 
Formic acid 𝒊 HCOOH 46 
GBS capsular polysaccharide (CPS) 𝒋 (C35H52O31N2)n 996 
 
Carbon balance 
𝐶6𝐻12𝑂6 = 𝑐 𝐶𝐻1.8𝑂0.5𝑁0.2 + 𝑓 𝐶𝐻3𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 + 𝑔  𝐶𝐻3𝐶𝑂𝑂𝐻 +  ℎ 𝐶𝐻3𝐶𝐻𝑂𝐻𝐶𝑂𝐶𝐻3 + 𝑖 𝐻𝐶𝑂𝑂𝐻
+ 𝑗 (𝐶35𝐻52𝑂31𝑁2)𝑛 
𝟔 = 𝒄 + 𝒅 + 𝟑𝒇 + 𝟐𝒈 + 𝟒𝒉 + 𝒊 + 𝟑𝟓𝒋 Equation A-1 
Oxygen balance 
𝐶6𝐻12𝑂6 + 𝑎 𝑂2 → 𝑐 𝐶𝐻1.8𝑂0.5𝑁0.2 + 𝑑 𝐶𝑂2 + 𝑒 𝐻2𝑂 + 𝑓 𝐶𝐻3𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 + 𝑔  𝐶𝐻3𝐶𝑂𝑂𝐻
+  ℎ 𝐶𝐻3𝐶𝐻𝑂𝐻𝐶𝑂𝐶𝐻3 + 𝑖 𝐻𝐶𝑂𝑂𝐻 + 𝑗 (𝐶35𝐻52𝑂31𝑁2)𝑛 
𝟔 + 𝟐𝒂 = 𝟎. 𝟓𝒄 + 𝟐𝒅 + 𝒆 + 𝟑𝒇 + 𝟐𝒈 + 𝟐𝒉 + 𝟐𝒊 + 𝟑𝟏𝒋 Equation A-2 
Nitrogen balance 
𝑏𝑁𝐻 → 𝑐 𝐶𝐻 . 𝑂 . 𝑁 . + 𝑗 (𝐶 𝐻 𝑂 𝑁 )𝑛 
𝟑𝒃 = 𝟎. 𝟐𝒄 + 𝟐𝒋 Equation A-3 
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Hydrogen balance 
𝐶6𝐻12𝑂6 + 𝑏 𝑁𝐻3
→ 𝑐 𝐶𝐻1.8𝑂0.5𝑁0.2 + 𝑒 𝐻2𝑂 + 𝑓 𝐶𝐻3𝐶𝐻𝑂𝐻𝐶𝑂𝑂𝐻 + 𝑔  𝐶𝐻3𝐶𝑂𝑂𝐻 +  ℎ 𝐶𝐻3𝐶𝐻𝑂𝐻𝐶𝑂𝐶𝐻3
+ 𝑖 𝐻𝐶𝑂𝑂𝐻 + 𝑗 (𝐶35𝐻52𝑂31𝑁2)𝑛 
𝟏𝟐 + 𝟑𝒃 = 𝟏. 𝟖𝒄 + 𝟐𝒆 + 𝟔𝒇 + 𝟒𝒈 + 𝟖𝒉 + 𝟐𝒊 + 𝟓𝟐𝒋 Equation A-4 
CPS yield 
𝐶𝑃𝑆 𝑦𝑖𝑒𝑙𝑑 =  60 𝑚𝑔 / 𝑐𝑒𝑙𝑙 𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 (Swennen, 2012) 
60 𝑚𝑔 𝐶𝑃𝑆 =
0.06 𝑔
996 𝑔/𝑚𝑜𝑙 
 = 6.02 𝑥10  𝑚𝑜𝑙 
1 𝑔 𝑑𝑟𝑦 𝑐𝑒𝑙𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 =  
1 𝑔
24.6 𝑔/𝑚𝑜𝑙
= 0.041 𝑚𝑜𝑙 
𝑀𝑜𝑙𝑎𝑟 𝑦𝑖𝑒𝑙𝑑 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝐶𝑃𝑆 𝑝𝑒𝑟 𝑑𝑟𝑦 𝑐𝑒𝑙𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 =
6.02 𝑥 10  𝑚𝑜𝑙
0.041 𝑚𝑜𝑙
= 𝟏. 𝟒𝟕 𝒙𝟏𝟎 𝟑 
𝒋 = 𝟏. 𝟒𝟕 𝒙 𝟏𝟎 𝟑 × 𝒄  
𝒋 = (𝟏. 𝟒𝟕 𝒙𝟏𝟎 𝟑)𝒄 Equation A-5 
Material balance Equations: 
𝑪𝟔𝑯𝟏𝟐𝑶𝟔 + 𝒂 𝑶𝟐 + 𝒃 𝑵𝑯𝟑
→ 𝒄 𝑪𝑯𝟏.𝟖𝑶𝟎.𝟓𝑵𝟎.𝟐 + 𝒅 𝑪𝑶𝟐 + 𝒆 𝑯𝟐𝑶 + 𝒇 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑶𝑯
+ 𝒈 𝑪𝑯𝟑𝑪𝑶𝑶𝑯 +  𝒉 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑪𝑯𝟑 + 𝒊 𝑯𝑪𝑶𝑶𝑯 + 𝒋 𝑪𝑷𝑺 
Equation 3-1 
𝟔 = 𝒄 + 𝒅 + 𝟑𝒇 + 𝟐𝒈 + 𝟒𝒉 + 𝒊 + 𝟑𝟓𝒋 Equation A-1 
𝟔 + 𝟐𝒂 = 𝟎. 𝟓𝒄 + 𝟐𝒅 + 𝒆 + 𝟑𝒇 + 𝟐𝒈 + 𝟐𝒉 + 𝟐𝒊 + 𝟑𝟏𝒋 Equation A-2 
𝟑𝒃 = 𝟎. 𝟐𝒄 + 𝟐𝒋 Equation A-3 
𝟏𝟐 + 𝟑𝒃 = 𝟏. 𝟖𝒄 + 𝟐𝒆 + 𝟔𝒇 + 𝟒𝒈 + 𝟖𝒉 + 𝟐𝒊 + 𝟓𝟐𝒋 Equation A-4 
𝒋 = (𝟏. 𝟒𝟕 𝒙𝟏𝟎 𝟑)𝒄 Equation A-5 
 
The following coefficients were used from Mickelson, (1972): 
𝒇 = 𝟎. 𝟕𝟖𝟒𝟓 
𝒈 = 𝟎. 𝟖𝟒𝟔𝟗 
𝒉 = 𝟎. 𝟎𝟖𝟗𝟔 
𝒊 = 𝟎. 𝟏𝟐𝟒𝟎 
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The material balance for Equation 3-1 and Equations A-1… A-4 were then solved for 𝒂, 𝒃, 𝒅, 𝒆 
using Microsoft Excel 2013 GRG non-linear Solver add-in by adjusting the value for 𝒄. 
Equation A-5 was solved for 𝒋 using the solution for 𝒄. 
Solver: adjust the numerical value of variable 𝒄, initial guess 𝒄 = 𝟎. 𝟓, Target column 𝑹𝒆𝒔𝒖𝒍𝒕 =  𝟎 
Table A-2    Material Balance Results 
Balance Equation Mass in Mass out Result 
Mass Eq. 3-1 192.51 192.51 0.00 
C Eq. A-1 6.00 6.00 0.00 
O Eq. A-2 6.55 6.55 0.00 
N Eq. A-3 0.22 0.22 0.00 
H Eq. A-4 12.66 12.66 0.00 
The coefficients 𝒂 … 𝒋 of Equation 3-1 determined in this way: 
𝑪𝟔𝑯𝟏𝟐𝑶𝟔 + 𝟎. 𝟐𝟕 𝑶𝟐 + 𝟎. 𝟐𝟐 𝑵𝑯𝟑
→ 𝟏. 𝟎𝟗 𝑪𝑯𝟏.𝟖𝑶𝟎.𝟓𝑵𝟎.𝟐 + 𝟎. 𝟑𝟓 𝑪𝑶𝟐 + 𝟎. 𝟖𝟎 𝑯𝟐𝑶
+ 𝟎. 𝟕𝟗 𝑪𝑯𝟑𝑪𝑯𝑶𝑯𝑪𝑶𝑶𝑯 + 𝟎. 𝟖𝟓 𝑪𝑯𝟑𝑪𝑶𝑶𝑯




𝒂 = 𝟎. 𝟐𝟕 
 
𝒈 = 𝟎. 𝟖𝟓 
 
𝒃 = 𝟎. 𝟐𝟐 
 
𝒉 = 𝟎. 𝟎𝟗 
 
𝒄 = 𝟏. 𝟎𝟗 
 
𝒊 = 𝟎. 𝟏𝟐 
 
𝒅 = 𝟎. 𝟑𝟓 
 
𝒋 = 𝟎. 𝟎𝟎𝟎𝟖 
 
𝒆 = 𝟎. 𝟖𝟎 
 
 





Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Appendix A: Methods 
 
  88 
 
A.2 Fermentation Kinetics: Model parameters 
𝒅𝑿
𝒅𝒕



































= 1.1854 ℎ  
Similarly, for t(1)… t(8): 
Table A-3    Fermentation data experiment 1 of 3 
t [h] X [OD590] S [g/L] µ [h-1] S/µ 
[h.g/L] 
T-1 0.081 5.688 N/A N/A 
0 0.101 5.310 N/A N/A 
1.00 0.264 5.760 1.1815 4.875 
2.00 1.440 7.020 1.439 4.878 
3.00 3.080 5.904 1.213 4.868 
4.00 6.920 3.348 1.112 3.011 
5.00 11.120 3.978 0.984 4.041 
5.50 12.140 4.032 0.911 4.427 
6.00 13.920 3.114 0.858 3.630 
6.50 15.360 2.394 0.807 2.967 
7.00 16.200 0.252 0.757 0.333 
7.50 17.430 2.196 0.716 3.066 
8.00 17.670 2.736 0.673 4.064 
(The Biovac Institute, 2018) 
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Kinetic parameters sample calculations: 
Method 1 exponential trend line 
𝒅𝑿
𝒅𝒕
= 𝝁𝑿 Equation 3-3 
1
𝑋
𝑑𝑋 = 𝜇 𝑑𝑡 
ln 𝑋 + 𝐵 = 𝜇𝑡 + 𝐴 
ln 𝑋 = 𝜇𝑡 + 𝐶 
𝑋 = 𝑒( ) = 𝑒 𝑒  
𝑿 = 𝑲𝒆𝝁𝒕   Equation 3-4 



































 Equation 3-8 
 
Method 1 Exponential trend line: 
𝑿 = 𝑲𝒆𝝁𝒕 Equation 3-4 
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 Equation 3-5 
𝜇 = 0.5 × 𝜇 = 0.5(1.091) = 0.546 ℎ  
However, this point is not represented in the experimental data. An approximation is made by 
interpolating the value of µ vs. S: 
  
Figure 61: Growth rate for S= 0 – 7 g/L 
 
𝝁 = 𝜶 𝐥𝐧 𝑺 + 𝜷 Equation 3-6 
𝝁 = 𝟎. 𝟏𝟔𝟗𝟔 𝐥𝐧 𝑺 + 𝟎. 𝟕𝟖𝟓𝟏 
𝑲𝒔 = 𝒆
𝟎.𝟓𝝁𝒎𝒂𝒙−𝜷






𝑲𝒔 = 𝟎. 𝟐𝟒𝟑 𝒈/𝑳 
𝝁
𝒎𝒂𝒙
= 𝟏. 𝟎𝟗𝟏 𝒉−𝟏 
𝒕𝒅 = 𝟎. 𝟔𝟑𝟓 𝒉 

































Specific growth rate vs. glucose
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  Equation 3-8 
 



























= 𝟎. 𝟕𝟎𝟎𝟓 𝒉 
 
𝑲𝑺 = 𝟎. 𝟑𝟖𝟑𝟗 𝒈/𝑳 
𝝁
𝒎𝒂𝒙
= 𝟎. 𝟗𝟗𝟎 𝒉−𝟏 
𝒕𝒅 = 𝟎. 𝟕𝟎𝟏 𝒉 
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Table A-4    Fermentation data experiment 2 of 3 
t [h] X [OD590] S [g/L] µ [h-1] S/µ [h.g/L] 
0.12 0.283 15.774 0 - 
0.12 0.287 17.305 0.120 144.373 
0.53 0.422 23.644 0.753 31.419 
0.74 0.560 25.428 0.923 27.556 
0.80 0.611 25.428 0.963 26.408 
0.80 0.63 27.242 1.000 27.233 
1.37 1.404 30.461 1.169 26.058 
1.47 1.611 30.461 1.183 25.746 
1.48 1.654 30.028 1.193 25.173 
1.83 2.775 26.374 1.247 21.143 
2.15 3.636 22.097 1.187 18.608 
2.15 3.692 19.879 1.195 16.639 
2.51 5.428 14.913 1.177 12.672 
2.83 8.179 7.705 1.189 6.482 
3.18 11.233 0.492 1.158 0.425 
3.24 11.472 0.492 1.143 0.431 
3.24 11.550 3.193 1.145 2.789 
3.86 12.731 2.251 0.986 2.283 
3.91 13.036 2.251 0.980 2.298 
3.90 13.167 0.633 0.980 0.646 
(The Biovac Institute, 2018) 
𝑲𝒔 = 𝟎. 𝟎𝟎𝟎 𝒈/𝑳* 
𝝁
𝒎𝒂𝒙
= 𝟏. 𝟐𝟎𝟑 𝒉−𝟏 
𝒕𝒅 = 𝟎. 𝟓𝟕𝟔 𝒉 
Fermentation experiment 2: Method 1 Exponential trend line 
* In this experiment, the calculation of 𝑲𝒔 using this method yielded a value of 2.3 x 10-6. 
𝑲𝒔 = 𝟎. 𝟎𝟗𝟕 𝒈/𝑳 
𝝁
𝒎𝒂𝒙
= 𝟏. 𝟐𝟐𝟎 𝒉−𝟏 
𝒕𝒅 = 𝟎. 𝟓𝟔𝟖 𝒉 
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Table A-5    Fermentation data experiment 3 of 3 
t [h] X [OD590] S [g/L] µ [h-1] S/µ 
[h.g/L] 
0.72 0.711 27.594 0 - 
1.04 1.087 28.748 0.408 70.530 
1.40 1.780 28.809 0.655 43.956 
1.45 1.927 28.809 0.687 41.913 
1.45 1.976 28.935 0.705 41.046 
2.07 4.168 21.434 0.854 25.091 
2.13 4.379 21.434 0.853 25.115 
2.13 4.442 18.789 0.860 21.845 
2.75 9.405 6.073 0.939 6.467 
2.80 9.964 6.073 0.943 6.441 
3.84 19.592 5.826 0.864 6.746 
3.89 20.091 1.225 0.859 1.426 
4.16 21.481 3.778 0.819 4.611 
4.51 21.301 0.915 0.754 1.214 
4.57 21.296 2.305 0.744 3.098 
(The Biovac Institute, 2018) 
𝑲𝒔 = 𝟎. 𝟎𝟎𝟎. 𝒈/𝑳 ∗ 
𝝁
𝒎𝒂𝒙
= 𝟏. 𝟎𝟏𝟕 𝒉−𝟏 
𝒕𝒅 = 𝟎. 𝟔𝟖𝟏 𝒉 
Fermentation experiment 3: Method 1 Exponential trend line 
* In this experiment, the calculation of 𝑲𝒔 using this method yielded a value of 1.2 x 10-5. 
𝑲𝒔 = 𝟎. 𝟎𝟐𝟎 𝒈/𝑳 
𝝁
𝒎𝒂𝒙
= 𝟏. 𝟏𝟎𝟐𝒉−𝟏 
𝒕𝒅 = 𝟎. 𝟔𝟐𝟗 𝒉 
Fermentation experiment 3: Method 2 Linear trend line 
 
Average values for kinetic parameters, calculated using Microsoft Excel formulae “AVERAGE” and 
“STDEV”: 
Table A-6    Fermentation kinetic parameters summary – Method 1 
Method 1 Experiment 1 Experiment 2 Experiment 3 AVERAGE STDEV 
µ max [h-1] 1.091 1.203 1.017 1.104 0.076 
Ks [g/L] 0.243 0.000 0.000 0.081 0.115 
td [h] 0.635 0.576 0.681 0.631 0.043 
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Table A-6    Fermentation kinetic parameters summary – Method 2 
Method 2 Experiment 1 Experiment 2 Experiment 3 AVERAGE STDEV 
µ max [h-1] 0.990 1.220 1.102 1.104 0.094 
Ks [g/L] 0.384 0.097 0.020 0.167 0.156 
td [h] 0.700 0.568 0.629 0.633 0.054 
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A.3 SuperPro Simulation Model Construction: GBS III 20L Stainless Steel Technology 







SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-01f 
→ Filtration 













 100% biomass 
removal 
 1% product loss 
 4000 L/m2.h 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-01 
→ Inoculum preparation  












 Transfer in total 800 










 Heating with electricity 
at 1°C/min 






 37°C for 3h, 0.5 vvm 




 Kinetic model (Monod, 
1949) 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-02 
→ Storage/Blending  
→ Bulk 
→ Batch 
→ in a Blending Tank 
 





 CIP with 13L 0.1N 
NaOH 
 Rinse with 67L WFI 
 
In-Place-Steaming 
Steam sterilize with saturated 
steam at 3 barg, 100 (kg/h)/m3 for 
30 minutes 
Charge 
Charge raw materials for 16 L of 
Fermentation medium (Table A-
16) at 100 kg/h 
Agitation Agitate at 50 W/m3 for 30min 
Transfer Out 
Transfer out 16L to SS-02/f 
100 kg/h 
In-Place-Cleaning 
 CIP with 13L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-02f 
→ Filtration 








area 0.014 m2 
 
Dead-End Filtration 
 100% biomass 
removal 
 1% product loss 
 4000 L/m2.h 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-03 
→ Batch vessel procedure  
→ In a Seed Fermentor 
 












 CIP with 16L 0.1N 
NaOH 
 Rinse with 81L WFI 
 
In-Place-Steaming 
Steam sterilize with saturated 
steam at 3 barg, 100 (kg/h)/m3 for 
30 minutes 
Transfer In Transfer in 16L from SS-02/f 
Batch Heating 
 Heating with saturated 
steam 3 barg, at 
1°C/min 
 Final temperature 
37°C 




 37°C for 8h, 0.5 vvm 
aeration with air, 2 
kW/m3 agitation. 
 Fed batch 5L feed 
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Charge 
Charge 5N NaOH to a final 
concentration of 0.8M 
Batch Heating 
 Heating with saturated 
steam 3 barg, at 
1°C/min 




CH3COHCOOH → WFI 
(X=100%) 
Inactivation for 16 h at 55 °C in 
0.8M NaOH 
Transfer Out Transfer out 26L to SS-04 
In-Place-Steaming 
Steam decontamination with 
saturated steam at 3 barg, 100 
(kg/h)/m3 for 30 minutes 
In-Place-Cleaning 
 CIP with 16L 0.1N 
NaOH 
 Rinse with 81L WFI 
 
  
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Appendix A: Methods 
 








SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-04 
→ Storage/Blending  
→ Bulk 
→ Batch 
→ in a Blending Tank 
 
Equipment: 50L, jacketed, 
stirred, Stainless steel tank, 
T-102 
In-Place-Cleaning 
 CIP with 13L 0.1N 
NaOH 




Steam sterilize with saturated 
steam at 3 barg, 100 (kg/h)/m3 for 
30 minutes 
Transfer In Transfer in 26 L from SS-03 
Charge Charge 6N HCl, 3417 mL 
Batch Stoichiometric 
Reaction 
NaOH + HCl → NaCl + H2O 
(XNaOH=100%) 
 Adiabatic reaction for 
60 min, 50 W/m3 
agitation 
Charge Charge 2N CaCl2, 2 L 
Charge Charge 96% Ethanol, 17 L 
Batch Stoichiometric 
Reaction 
CaCl2 → WFI (X=100%) 
PS-III → WFI (X=5%) 
 Adiabatic reaction for 
60 min, 50 W/m3 
agitation 
Transfer Out Transfer out 48.4 L to SS-05 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-05 
→ Centrifugation 
→ Disk stack 
 
Equipment: Disk stack 
centrifuge C-201 
In-Place-Cleaning 
 CIP with 15L 0.1N 
NaOH 
 Rinse with 75L WFI 
 
In-Place-Steaming 
Steam sterilize with saturated 
steam at 3 barg, 300 (kg/h)/m3 for 
30 minutes 
Centrifugation 
 100% biomass to 
waste 
 12% product to waste 
 150 g/L solids in waste 
 30 min (Σ=8200 m2) 
In-Place-Cleaning 
 CIP with 15L 0.1N 
NaOH 
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30 kDa TFF 
membrane 
In-Place-Cleaning CIP with 6L 0.1N NaOH 
 
Flush Flush with 12L WFI, 30 min 
Batch Concentration 
 Concentrate 40 X 
 20 L/m2.h 
 PS-III rejection 
coefficient 0.9975 
Diafiltration 
 Diafilter 20 X into 
8. 50 mM TRIS + 8.5 mM 
NaCl  
 20 L/m2.h 
 PS-III rejection 
coefficient 0.9975 
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30 kDa TFF 
membrane 
Diafiltration 
 Diafilter 10 X into 
9. 0.3N Na2CO3  
 20 L/m2.h 




 CIP with 5L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-08 
→ Storage/Blending  
→ in a Disposable 






5L glass bottle 
Transfer In 
Transfer in from SS-07 at 100 
kg/h 
 
Agitation Agitate at 50 W/m3 for 15 min 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-09 
→ Filtration 
→ Dead End Filtration 
 
 Equipment: Filter 
housing F-201, 
 Peristaltic pump 
P-201 
 Consumables: 
Carbon filter pod 
 
Dead end filtration 
 100% TT removal 
 15% product loss 
 250 L/m2.h 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-10 
→ Storage/Blending  
→ in a Disposable 






5L glass bottle 
Transfer In 
Transfer in from SS-09 at 100 
kg/h 
 
Charge Charge 150 mL of Ac2O 
Batch Stoichiometric 
Reaction 
(CH3CO)2O -> WFI (X=100%) 
 Adiabatic reaction for 
60 min, 50 W/m3 
agitation 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-11 
→ Filtration 








area 0.014 m2 
Dead-End Filtration 
 100% biomass 
removal 
 1% product loss 
 4000 L/m2.h 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-12 
→ Storage blending 
→ Bulk 
→ Batch 
→ in a Tote 
 
Consumable: 3L single 
use bag 
Transfer In 




Cooling with electricity at 
1°C/min 
Performance coefficient 4.5 
Final temperature 4°C 
Holding Hold for 16 hours (overnight) 
Batch Heating 
Heating at 1°C/min (no utility) 
Final temperature 20°C 
Transfer Out 




SS-12 / Cold Room
2 - 8 °C hold
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-13 
→ Batch vessel procedure 
→ in a Seed Bioreactor 
 
Equipment: 2L jacketed 
Glass reactor R-301 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
 Rinse with 25L WFI 
 
Transfer In 
Transfer in from SS-12 at 100 
kg/h 
Charge 
Charge 42 mL of CDAP 100 g/L 
in Acetonitrile 
Charge 




PS-III → Mod-PS-III (X=90%) 
TEA → WFI (X=90%) 
 React at 4 °C for 2 h, 
50 W/m3 agitation 
 Glycerol cooling agent 
Transfer Out Transfer out to SS-14 at 100 kg/h 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
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Equipment: TFF skid TF-
201 
Consumables: 
Consumables: 30 kDa TFF 
membrane 
In-Place-Cleaning CIP with 6L 0.1N NaOH 
 
Flush Flush with 12L WFI, 30 min 
Diafiltration 
 Diafilter 20 X into 
10. 10 mM MES + 0.2N NaCl 
 20 L/m2.h 
 Mod-PS-III rejection 
coefficient 0.9975 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-15 
→ Batch vessel procedure 
→ in a Seed Bioreactor 
 
Equipment: Glass reactor 
R-302 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
 Rinse with 25L WFI 
 
Charge 
Charge 60 mL of 50 mg/mL 
Carrier protein in PBS 
Charge Charge 26 g of ADH 
Charge Charge 2.6 g EDC 
Batch Stoichiometric 
Reaction 
TT + ADH → TT-ADH (XTT=90%) 
EDC → WFI (X=90%) 
 React adiabatically for 
60 min, 50 W/m3 
agitation.  
Transfer Out Transfer out to SS-16 at 100 kg/h 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
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Equipment: TFF skid TF-
301 
Consumables: 
Consumables: 30 kDa TFF 
membrane 
In-Place-Cleaning CIP with 6L 0.1N NaOH 
 
Flush Flush with 12L WFI, 30 min 
Diafiltration 
 Diafilter 20 X into 
11. 10 mM MES + 0.2N NaCl 
 20 L/m2.h 
 TT rejection coefficient 
0.9975 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-17 
→ Batch vessel procedure 
→ in a Seed Bioreactor 
 
Equipment: Glass reactor 
R-303 
In-Place-Cleaning 
 CIP with 4L 0.1N 
NaOH 
 Rinse with 22L WFI 
 
Transfer In 
Transfer in from SS-14 at 100 
kg/h 
Transfer In 




Mod-PS-III + TT-ADH → TT-PS-
III (XTT=100%) 
 React at 4 °C for 24 h, 
50 W/m3 agitation 
Charge Charge 1.14 g Glycine 
Batch Stoichiometric 
Reaction 
Glycine → WFI (X=100%) 
 React adiabatically for 
30 min, 50 W/m3 
agitation 
Transfer Out Transfer out to SS-18 at 100 kg/h 
In-Place-Cleaning 
 CIP with 4L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-18 
→ Batch vessel procedure 
→ in a Seed Bioreactor 
 
Equipment: Glass reactor 
R-304 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
 Rinse with 25L WFI 
 
Transfer In 
Transfer in from SS-17 at 100 
kg/h 
Charge 
Charge 5.88L of saturates 
(43wt% at 20°C) (NH4)2SO4 
Batch Stoichiometric 
Reaction 
(NH4)2SO4 → WFI (X=95%) 
TT-PS-III → WFI (X=5%) 
 React at 4 °C for 24 h 
with 50 W/m3 
Transfer Out Transfer out to SS-19 at 100 kg/h 
In-Place-Cleaning 
 CIP with 5L 0.1N 
NaOH 
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Equipment: Tubular bowl 
centrifuge C-301 
In-Place-Cleaning 
 CIP with 15L 0.1N 
NaOH 
 Rinse with 75L WFI 
 
In-Place-Steaming 
Steam sterilize with saturated 
steam at 3 barg, 300 (kg/h)/m3 for 
30 minutes 
Centrifugation 
 95% TT-PS-III 
recovery to pellet 
 90% liquid to middle 
fraction 
 10% liquid to top 
fraction 
 30 min (Σ=440 m2) 
In-Place-Cleaning 
 CIP with 15L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-20 
→ Storage/Blending  
→ in a Disposable 






5L glass bottle 
Transfer In 




Charge 4L of 10 mM MES + 0.2N 
NaCl buffer at 100 kg/h 
Batch Stoichiometric 
Reaction 
TT-PS-III → WFI (X=2%) 
 React adiabatically for 
60 min, 50 W/m3 
agitation 
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Equipment: TFF skid TF-
302 
Consumables: 
Consumables: 30 kDa TFF 
membrane 
In-Place-Cleaning CIP with 10L 0.1N NaOH 
 
Flush Flush with 20L WFI, 30 min 
Diafiltration 
 Diafilter 20 X into 
12. PBS 
 20 L/m2.h 
 TT-PS-III rejection 
coefficient 0.9975 
In-Place-Cleaning 
 CIP with 10L 0.1N 
NaOH 
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SuperPro parameters Screen captures of SuperPro operations dialogue 
SS-22 
→ Filtration 








area 0.014 m2 
Dead-End Filtration 
 100% biomass 
removal 
 1% product loss 
 4000 L/m2.h 
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A.4 Equipment specifications 







Figure 63: Stirred tank dimensions 
Assumptions for geometry of a mechanically agitated stirred tank reactor (STR): 
𝑉𝑒𝑠𝑠𝑒𝑙 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 =  𝑇 
𝑆𝑡𝑎𝑡𝑖𝑐 𝑙𝑖𝑞𝑢𝑖𝑑 𝑙𝑒𝑣𝑒𝑙 =  𝑍 =  𝑇 
𝐼𝑚𝑝𝑒𝑙𝑙𝑒𝑟 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 =  𝐷 =  𝑇/3 
𝐼𝑚𝑝𝑒𝑙𝑙𝑒𝑟 ℎ𝑒𝑖𝑔ℎ𝑡 𝑓𝑟𝑜𝑚 𝑏𝑜𝑡𝑡𝑜𝑚 =  𝐵 =  𝐷 =  𝑇/3 
𝑨𝒔𝒔𝒖𝒎𝒆 𝒂 𝒕𝒐𝒕𝒂𝒍 𝒘𝒐𝒓𝒌𝒊𝒏𝒈 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟐𝟔 𝑳 
𝑉 = 0.026 𝑚  
𝑽𝒄𝒚𝒍𝒊𝒏𝒅𝒆𝒓 = 𝝅𝒓
𝟐𝑳 Equation A-6 
𝑉𝑐𝑦𝑙𝑖𝑛𝑑𝑒𝑟 = 𝜋𝑟















𝑻 = 𝟎. 𝟑𝟐𝟏 𝒎 




= 𝟎. 𝟏𝟎𝟕 𝒎 
𝑩 = 𝑫 =
𝑻
𝟑
= 𝟎. 𝟏𝟎𝟕𝒎 
𝑨𝒔𝒔𝒖𝒎𝒆 𝒂 𝒕𝒐𝒕𝒂𝒍 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝟑𝟐 𝑳 
𝑉𝑒𝑠𝑠𝑒𝑙 ℎ𝑒𝑖𝑔ℎ𝑡 = 𝐻 
𝑉 = 0.032 𝑚  
𝑉𝑐𝑦𝑙𝑖𝑛𝑑𝑒𝑟 = 𝜋𝑟
















𝑯 = 𝟎. 𝟑𝟗𝟓𝒎 
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A.4.2 Fermentor stirring power input calculation 
𝐴𝑠𝑠𝑢𝑚𝑒 𝑡ℎ𝑒 𝑓𝑙𝑢𝑖𝑑 𝑖𝑠 𝑤𝑎𝑡𝑒𝑟 𝑎𝑡 37℃ 
𝑇 = 37 + 273.15 = 310.15 𝐾 
𝝆 = 𝟗𝟗𝟑. 𝟑𝟑 𝒌𝒈. 𝒎 𝟑 (NIST Chemistry WebBook, 2019) 
𝝈 = 𝟔. 𝟗𝟏𝟓𝟐 × 𝟏𝟎 𝟒 𝑷𝒂. 𝒔 (NIST Chemistry WebBook, 2019) 
𝐼𝑚𝑝𝑒𝑙𝑙𝑒𝑟 𝑟𝑜𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑠𝑝𝑒𝑒𝑑 𝒏 = 𝟔𝟎𝟎 𝒓𝒑𝒎 = 𝟏𝟎𝒔 𝟏 









10𝑠−1 × (0.107𝑚)2 × 993.33 𝑘𝑔. 𝑚−3
6.9152 × 10−4 𝑘𝑔. 𝑚−1. 𝑠−2. 𝑠
 
𝑵𝑹𝒆 = 𝟏. 𝟔𝟒𝟔 × 𝟏𝟎
𝟓 




 Equation A-8 
 
Figure 64: Impeller Reynolds’ number to Power Number correlation. 
𝐹𝑟𝑜𝑚 𝑭𝒊𝒈𝒖𝒓𝒆 𝟔𝟎, 𝑵𝑷 ≈ 𝟕  𝑵𝑷 =
𝑷
𝝆𝒏𝟑𝑫𝟓
 Equation A-8 














𝑸 = 𝟐. 𝟏𝟔𝟕 × 𝟏𝟎 𝟒𝒎. 𝒔 𝟏 
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Gassed Power: 
















(2.167 × 10−4𝑚. 𝑠−1)0.56
0.45
= 𝟓𝟎. 𝟒𝟒𝟎 𝑾 













= 𝟏𝟗𝟑𝟗. 𝟗𝟖𝟐 𝑾. 𝒎𝟑 ≈ 𝟐𝒌𝑾. 𝒎 𝟑 
Similarly, it was calculated that for a fermentor with a total volume of 320 L, and a maximum stirred volume 
of 260 L, the specific gassed power requirement would be approximately 10 kW/m3. 
 
A.4.3 Equipment Purchase costs 
Equipment Purchase cost escalation Sample calculation: 
𝟐𝟔 𝑳 𝑺𝒕𝒂𝒊𝒏𝒍𝒆𝒔𝒔 𝒔𝒕𝒆𝒆𝒍 𝑭𝒆𝒓𝒎𝒆𝒏𝒕𝒐𝒓 𝑷𝒖𝒓𝒄𝒉𝒂𝒔𝒆 𝑪𝒐𝒔𝒕 =  $𝟐𝟔𝟖 𝟏𝟎𝟎 
𝒀𝒆𝒂𝒓 𝒐𝒇 𝒑𝒖𝒓𝒄𝒉𝒂𝒔𝒆 = 𝟐𝟎𝟏𝟎 
𝑬𝒔𝒄𝒂𝒍𝒂𝒕𝒊𝒐𝒏 𝒓𝒂𝒕𝒆 =  𝟔% 𝒑𝒆𝒓 𝒂𝒏𝒏𝒖𝒎 
𝐶𝑢𝑟𝑟𝑒𝑛𝑡 𝑝𝑢𝑟𝑐ℎ𝑎𝑠𝑒 𝑐𝑜𝑠𝑡 = 𝐶𝑜𝑠𝑡 × (1 + 𝑒𝑠𝑐𝑎𝑙𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒)     
 
Equation A-10 
𝐹𝑒𝑟𝑚𝑒𝑛𝑡𝑜𝑟 𝑐𝑜𝑠𝑡2017 = $268 100 × (1 + 0.06)
(2017−2010) 
𝐹𝑒𝑟𝑚𝑒𝑛𝑡𝑜𝑟 𝑐𝑜𝑠𝑡2017 = $403 123.27 
All equipment costs rounded to the nearest $1000 
𝑭𝒆𝒓𝒎𝒆𝒏𝒕𝒐𝒓 𝒄𝒐𝒔𝒕𝟐𝟎𝟏𝟕 = $𝟒𝟎𝟑 𝟎𝟎𝟎 
Cost specifications for each piece of major equipment calculated as per the above example, are detailed 
in Tables A-5… A-7 on the proceeding pages. Costs marked with an asterisk (*) were valued using 
Intelligen SuperPro 9.5 Academic software built in cost models.  
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Table A-5    Base case model equipment specifications 
Process step Process step Description Equipment tag SuperPro Equipment Real equipment Purchase cost 
[2017 US $] 
SS-01 Inoculum preparation I-101 Shaker incubator Infors HT multitron 35 000 
SS-01f 0.22µm Filtration P-101 Peristaltic pump Watson Marlow 620 DuN pump 8 000 
SS-02f 
SS-02 Medium preparation T-101 60L s/steel mixing tank Biozeen s/steel jacketed vessel 164 000* 
SS-03 Fermentation R-101 32L s/steel fermentor Pierre Guerin 32L s/steel fermentor 403 000 
SS-04 Neut./Cationic precipitation T-102 60L s/steel mixing tank Biozeen s/steel jacketed vessel 164 000* 
SS-05 Centrifugation C-201 Disk stack bowl centrifuge Hettich Rotosilenta 630RS 65 000 
S-06 TFF into TRIS/NaCl TF-201 Tangential flow filtration skid EMD Millipore Cogent M1 76 000 
S-07 TFF in Na2CO3 
SS-08 TFF hold ST-201 Magnetic stirrer IKA MAG MR1 magnetic stirrer 5 000 
SS-10 Re-N-Acetylation 
SS-20 Resuspension 
SS-09 Protein removal F-201 Filter housing EMD Millipore Millistak filter housing 1000* 
SS-11 0.22µm Filtration P-201 Peristaltic pump Watson Marlow 520 DuN pump 5 000 
SS-22 Final 0.22µm Filtration 
SS-12 2 - 8 °C hold Cold Room Tote with temperature control Cold room 5000* 
SS-13 PS activation R-301 Jacketed glass reactor 0 – 5 L Radley's Reactor Ready system 14 000 
SS-15 TT activation R-302 
SS-17 Conjugation R-303 
SS-18 Precipitation R-304 Jacketed glass reactor 6 – 20 L De Deitrich Pharma Reactor system 300 000 
SS-16 TFF TT TF-301 Tangential flow filtration skid EMD Millipore Cogent M1 76 000 
SS-19 Centrifugation C-301 Tubular centrifuge Riera Nadeu RINA tubular centrifuge 123 000* 
SS-21  TFF final TF-302 Tangential flow filtration skid EMD Millipore Cogent M1 76 000 
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Table A-6    Additional Equipment specifications for 20L scale Single Use 
Process step Process step Description Equipment tag SuperPro Equipment Real equipment Purchase cost 
[2017 US $] 
SU-02 Medium preparation SUT-101 50L SU mixing tank Pall Allegro 50L magnetic mixer 73 500 
HY-02 
SU-04, Neut./Cationic precipitation SUT-102 100L SU mixing tank Pall Allegro 100L magnetic mixer 100 000* 
HY-04 
SU-03 20L Fermentation SUR-101 50L SU fermentor Sartorius CultiBag STR 50L 118 000* 
 
Table A-7    Additional Equipment specifications for 200 L processing scale 
Process step Process step Description Equipment tag SuperPro Equipment Real equipment Purchase cost 
[2017 US $] 
SS200-04 
200L Fermentation 
R-102 340L Stainless steel fermentor Pierre Guerin 300L s/steel fermentor 620 000* 
HY200-04 
SS200-02 T200-1 200L s/steel mixing tank Biozeen 200L s/steel mixing tank 171 000* 
SS200-0 T200-2 600L s/steel mixing tank Biozeen 600L s/steel mixing tank 199 000* 
SU200-02 
Medium preparation SUT-200-1 200L SU mixing tank Sartorius Flexel 200L magnetic mixer 150 000* 
HY200-02 
SU200-05 
Neut./Cationic precipitation SUT-200-2 650L SU mixing tank Sartorius Flexel 650L magnetic mixer 300 000* 
HY200-05 
SU200-04 200L Fermentation SUR-102 500L SU fermentor Xcellerex XDR MO 500L fermentor 800 000* 
HY200-05 Centrifugation C-200-1 Disk stack centrifuge Alfa Laval BTPX 305s centrifuge 300 000* 
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A.5 Consumables specifications 
Tables A-8… A-10 below show all consumable costs used in the simulation models. Costs marked with an asterisk (*) are valued using Intelligen SuperPro 9.5 
Academic software built in cost parameters.  
Table A-8    Base case model consumable type specifications 
Process 
step 
Process step Description Equipment tag SuperPro consumable Real consumable Cycle 
lifetime 
Cost per unit 
[2017 US $] 
SS-01 Inoculum preparation I-101 4000 mL glass shake flask 4L glass Erlenmeyer flask  100 60 
SS-01f 
0.22 µm filtration 
P-101 
0.22 µm filter cartridge Merck Opticap XL150 filter 1 630 
SS-02f 
SS-11 P-201 
SS-22 Final 0.22 µm filtration P-301 
SS-03 Fermentation R-101 100 mL SU sampling bag 100 mL Sartorius Flexboy bag 1 20 
SS-05 Centrifugation C-201 2L centrifuge bottle 2L Nalgene centrifuge bottle 100 45 
SS-06 TFF into TRIS/NaCl 
TF-201 
30 kDa TFF membrane 
Merck Pellicon 30 kDa TFF 
membrane 
15 10 000/m2 
SS-07 TFF into Na2CO3 
SS-14 TFF Mod-PS 
SS-16 TT diafilter TF-301 
SS-21 TFF polish TF-302 
SS-08 TFF hold 
ST-201 5L Glass bottle Schott Duran 5L Glass bottle 100 10 SS-10 Re-N-Acetylation 
SS-20 Resuspension 
SS-09 Protein removal F-201 Carbon filter EMD Millipore U-pod filter 1 210 
SS-12 2-8 °C hold Cold Room 3L SU storage bag 3L Sartorius Flexboy bag 1 20 
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Table A-9    Additional consumables specifications for 20L scale Single Use 
Process 
step 
Process step Description Equipment tag SuperPro consumable Real consumable Cycle 
lifetime 
Cost per unit 
[2017 US $] 
SU-01, 
HY-01, 
Inoculum preparation I-101 3000 mL SU shake flask 
3L Corning Erlenmeyer single use 




Medium preparation SUT-101 50L SU mixing bag Pall Allegro 50L mixing bag 1 900 
SU-04,  
HY-04 
Neut./Cationic precipitation SUT-102 100L SU mixing bag Pall Allegro 100L mixing bag 1 1200 
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Table A-10    Additional consumables specifications for 200 L processing scale 
Process step Process step Description Equipment tag SuperPro consumable Real consumable Cycle 
lifetime 
Cost per unit 
[2017 US $] 
SS200-02f20 






SS-200-20 Resuspension ST-201a 5L Glass bottle Schott Duran 5L Glass bottle 100 10 
SS-08 TFF hold 




200L Fermentation SUR-102 500L SU fermentation bag Xcellerex XDR MO 500L bag 1 5530 
SU200-02 
HY200-02 
Medium preparation SUT-200-1 200L SU mixing bag Sartorius Flexel 200L bag 1 2000  
SU200-05, 
HY200-05 
Neut./Cationic precipitation SUT-200-2 650L SU mixing bag Sartorius Flexel 650L bag 1 3000 
SU200-13, 
HY200-13 
2-8 °C hold Cold Room 10L SU storage bag 10L Sartorius Flexboy bag 1 100 
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A.6 Raw material specifications 
Tables A-11… A-14 below show the properties used for all raw material inputs and product outputs. These properties are located in the SuperPro materials 
database. For materials that were not in the SuperPro database, this data was entered from literature sources: (Dean, 1999; Perry & Green, 2008; Haynes, 
2014; Aspen Technology Inc., 2017; Intelligen Inc., 2017). Properties marked with an asterisk (*) were estimated due to no data being available. 
Table A-11    Fermentation Raw Materials 




Density at 25°C 
[g/L] 
Unit cost  
[US $/kg] 
Cost reference 
Biomass N/A CH1.8O0.5N0.2 24.630 1050 0.00 N/A 
D-(+)-Glucose 50-99-7 C6H12O6 180.157 1173.7  48.49 (Sigma Aldrich, 2017a) 
BD Bacto Soytone  N/A N/A 100* 1000* 287.98 (Fisher Scientific, 2017a) 
BD Bacto Yeast Extract N/A N/A 180* 1560* 249.28 (Fisher Scientific, 2017b) 
L-Cysteine hydrochloride 52-89-1 C3H8ClNO2S 157.612 1721 703.76 (Sigma Aldrich, 2017b) 
Tris base 77-86-1 C4H11NO3 121.14 1328 7.75 (Sigma Aldrich, 2017c) 
Tris hydrochloride 1185-53-1 C4H11NO3.HCl 157.597 2164 1588.40 (Sigma Aldrich, 2017d) 
Sodium carbonate 497-19-8 Na2CO3 105.989 2479.8 115.98 (Sigma Aldrich, 2017e) 
Sodium chloride 7647-14-5 NaCl 58.443 1935.1 133.61 (Sigma Aldrich, 2017f) 
Magnesium sulfate (anhydrous) 10034-96-5 MgSO4 120.366 2660 201.40 (Sigma Aldrich, 2017g) 
Ferrous sulfate heptahydrate 7782-63-0 FeSO4.7H2O 278.006 2003 95.31 (Sigma Aldrich, 2017h) 
Ethanol (96% vv) 64-17-5 CH3OH 46.069 785.9 159.12 (Sigma Aldrich, 2017i) 
Hydrogen Chloride 7647-01-0 HCl 36.461 797.5 223.44 (Sigma Aldrich, 2017j) 
Sodium Hydroxide 1310-73-2 NaOH 39.997 1913.4 47.08 (Sigma Aldrich, 2017k) 
Calcium Chloride 10043-52-4 CaCl2 110.983 2400 145.16 (Sigma Aldrich, 2019a) 
Air N/A N/A 28.97 1.2 0.0 N/A 
WFI 7732-18-5 H2O 18.015 994.7 0.40 (Intelligen Inc., 2017) 
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Table A-12    Additional Purification Raw Materials 




Density at 25°C 
[g/L] 
Unit cost  
[US $/kg] 
Cost reference 
Tris base 77-86-1 C4H11NO3 121.14 1328 7.75 (Sigma Aldrich, 2017c) 
Sodium chloride 7647-14-5 NaCl 58.443 1935.1 133.61 (Sigma Aldrich, 2017f) 
Sodium carbonate 497-19-8 Na2CO3 105.989 2479.8 115.98 (Sigma Aldrich, 2017e) 
Acetic anhydride 108-24-7 (CH3CO)2O 102.090 1082 89.38 (Sigma Aldrich, 2019b) 
WFI 7732-18-5 H2O 18.015 994.7 0.40 (Intelligen Inc., 2017) 
 
Table A-13    Additional Conjugation Raw Materials 




Density at 25°C 
[g/L] 
Unit cost  
[US $/kg] 
Cost reference 
CDAP 59016-56-7 C8H10BF4N3   234.990 1500* 464 360.00 (Sigma Aldrich, 2017l) 
Acetonitrile 75-05-08 CH3CN 41.052 776.7 176.37 (Sigma Aldrich, 2017m) 
Triethylamine (TEA) 121-44-8 (C2H5)3N 101.191 724.5 150.74 (Sigma Aldrich, 2017n) 
MES 1266615-59-1 C6H13NO4S 195.240 1400 667.89 (Sigma Aldrich, 2019c) 
Carrier protein N/A N/A 150000* 1050* 55 000.00* N/A 
Adipic acid Dihydrazide (ADH) 1071-93-8 C6H14N4O2 174.200 1230 2120.40 (Sigma Aldrich, 2017o) 
EDC 25952-53-8 C8H17N3.HCl 191.703 877 24 715.20 (Sigma Aldrich, 2017p) 
Glycine 56-40-6 C2H5NO2 75.067 1470.9 245.33 (Sigma Aldrich, 2017q) 
Ammonium Sulfate 7783-20-2 (NH4)2SO4 132.134 1769 102.30 (Sigma Aldrich, 2017r) 
Phosphate Buffered Saline (PBS) N/A N/A N/A 1003.1 0.12 (Intelligen Inc., 2017) 
Potassium dihydrogen phosphate 7778-77-0 KH2PO4 136.077 1636 N/A N/A 
Sodium hydro phosphate 7558-79-4 Na2HPO4 141.950 1679 N/A N/A 
WFI 7732-18-5 H2O 18.015 994.7 0.40 (Intelligen Inc., 2017) 
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Table A-14    Reaction Products and intermediates 









Biomass N/A CH1.8O0.5N0.2 24.630 1050 
N/A 
Carbon dioxide 124-38-9 CO2 44.010 2.0 
Lactic Acid 598-82-3 C2H5OCOOH 90.079 1220.9 
Acetic Acid 64-19-7 CH3COOH 60.053 1042 
Acetoin 107-89-1 C4H8O2 88.106 1100.5 
Formic Acid 64-18-6 HCOOH 46.026 1213.7 
GBS 3 polysaccharide (PS-III) N/A (C35H52O31N2)n 996* 1050* 
Activated PS (Mod-PS-III) N/A N/A 996* 1050* 
Activated protein (TT-ADH) N/A N/A 150000* 1050* 
Conjugate API (TT-PS-III) N/A N/A 246000* 1050* 6 000 000 (est.) # (Kim et al., 2014) 
# Single dose estimated as 5 µg  
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Tables A-15… A-18 below show the compositions of media and buffers used in the models: 
Table A-15    Inoculum medium composition 
Component Conc.[g/L] 
BD Bacto Soytone 20.0 
D-(+)-Glucose 2.5 
L-Cysteine hydrochloride 0.1 
Sodium Chloride 5.0 
Magnesium Sulfate (anhydrous) 0.1 
Ferrous Sulfate heptahydrate 0.02 
Sodium Carbonate 0.6 
Tris base 0.8 
Tris hydrochloride 3.0 
WFI 956.1 
 
Table A-16    Fermentation medium composition 
Component Conc.[g/L] 
BD Bacto Soytone 30.0 
D-(+)-Glucose 20.0 
L-Cysteine hydrochloride 0.1 
Sodium Chloride 5.0 
Magnesium Sulfate (anhydrous) 0.1 
Ferrous Sulfate heptahydrate 0.02 
Sodium Carbonate 0.6 
WFI 944.7 
 
Table A-17    Fermentation feed composition 
Component Conc.[g/L] 




Table A-18    Phosphate Buffered Saline (PBS) 
Component Conc.[g/L] 
Potassium chloride 0.002 
Potassium dihydrogen phosphate 0.002 
Sodium chloride 8.0 
Sodium hydro phosphate 1.1 
WFI 993.9 
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A.7 Utilities specifications 
 Simplified CIP cycle for stainless steel vessels: 0.1N NaOH wash for 15 min at 5 L/min.m, 
WFI rinse for 15 min at 5 L/min.m. 
 Fermentor assumed to have integrated CIP skid. 
 CIP for centrifuge: 0.1N NaOH wash for 30 min at 150 L/h, WFI rinse for 30 min at 150 L/h. 
 CIP for TFF skids 0.1N NaOH wash at 10 L/m2 for 15 min, flush with WFI for 30 min at 
20L/m2 
 CIP for reactors: 0.1N NaOH wash for 15 min at 5 L/min.m, WFI rinse for 15 min at 5 
L/min.m. 
 Upstream (fermentation) and downstream each have their own CIP skids 
 Simplified SIP cycle: Sterilize for 30min at 150°C (3 barg sat. steam) at 100 kg/h/m3 steam 
usage for vessels and 300 kg/h usage for centrifuge. 
 Where not specified, charge / transfer rates for material are set to 100 kg/h 
 Estimated utilities costs are shown in Table A-19: 
 
Table A-19    Utilities used in Simulation Models 
Utility Used for Cost  
Steam (3barg saturated) Heating vessels 12.00 $/MT 
Electricity (single phase) Heating small equipment, centrifugation 0.10 $/kWh 
Hot water (40 °C, return 30°C) Heating product after cold storage 0.05 $/MT 
Chilled water (5°C, return 10 °C) Cooling vessels, centrifuges 0.40 $/MT 
Ethylene glycol (-10°C, return 0°C) Cooling glass reactors 0.35 $/MT 
 
A.8 Cost Assumptions and Sample calculations 
 All equipment and consumables purchased new as of 2017 prices 
 7% Asset cost inflation rate 
 13.16 ZAR USD exchange rate (SARB, 2019) 
 28% Corporate Income Tax rate (SARS, 2015, 2019) 
 Equipment depreciation by straight line method, 10 years, 20% scrap value 
 Construction period 24 months; Start-up period 3 months; First year output 50%, Project 
lifetime 12 years 
 API product value $ 6 million /kg based on $ 30 per 5 µg dose 
 Hurdle rate 25% (High risk investment assumed) 
 Direct Fixed Capital (DFC) financing 35% loan (10-year loan at 12% compound interest) 
 Working capital 15% loan (6-year loan at 12% compound interest) 
 Weighted Average Cost of Capital (WACC) 20% 
𝑊𝐴𝐶𝐶 =  𝐸𝑞𝑢𝑖𝑡𝑦 𝑣𝑎𝑙𝑢𝑒 × 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐸𝑞𝑢𝑖𝑡𝑦 + 𝐿𝑜𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 × 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑙𝑜𝑎𝑛  
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Installation costs factors of Equipment purchase cost (EC) are shown in Table A-20 below: 
Table A-20    Installation cost factors 
Unit operation/ equipment 
types 
Equation 
Filtration 0.50 × 𝐸𝐶 
Shaker Incubator 1.50 × 𝐸𝐶 
Stainless steel fermentor 0.30 × 𝐸𝐶 
Single Use fermentor 1.50 × 𝐸𝐶 
Stainless steel mixing tank 0.30 × 𝐸𝐶 
Single use mixing tank 0.10 × 𝐸𝐶 
Centrifuge 0.50 × 𝐸𝐶 
TFF skid 0.50 × 𝑃𝐶 
Generic mixing 1.50 × 𝑃𝐶 
Cold room 0.10 × 𝑃𝐶 
Chemical reactor 0.50 × 𝑃𝐶 
 
𝑈𝑛𝑙𝑖𝑠𝑡𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 𝑐𝑜𝑠𝑡 (𝑈𝐶)  =  0.2 × 𝐿𝑖𝑠𝑡𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 𝑐𝑜𝑠𝑡 (𝐸𝐶) Equation A-11 
𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑢𝑛𝑙𝑖𝑠𝑡𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 =  0.5 × 𝑈𝐶  Equation A-12 
𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑟𝑐ℎ𝑎𝑠𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 𝐶𝑜𝑠𝑡 (𝑃𝐶) = 𝐸𝐶 + 𝑈𝐶 Equation A-13 
𝑷𝑪 = 𝟏. 𝟐𝟓 × 𝑬𝑪 Equation A-14 
𝐷𝑖𝑟𝑒𝑐𝑡 𝑐𝑜𝑠𝑡𝑠 (𝐷𝐶)
= 𝑃𝐶 + 𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 + 𝑃𝑖𝑝𝑖𝑛𝑔 + 𝐼𝑛𝑠𝑡𝑟𝑢𝑚𝑒𝑛𝑡𝑎𝑡𝑖𝑜𝑛 + 𝐸𝑙𝑒𝑐𝑡𝑟𝑖𝑐𝑎𝑙
+ 𝐵𝑢𝑖𝑙𝑑𝑖𝑛𝑔𝑠 + 𝑌𝑎𝑟𝑑 + 𝐴𝑢𝑥𝑖𝑙𝑖𝑎𝑟𝑦 𝑓𝑎𝑐𝑖𝑙𝑖𝑡𝑖𝑒𝑠 
Equation A-15 
 
Table A-21    Factorial estimation for Direct Costs (DC) 
Parameter Equation 
Piping 0.45 × 𝑃𝐶 
Auxiliary facilities 0.20 × 𝑃𝐶 
Instrumentation 0.15 × 𝑃𝐶 
Electrical 0.10 × 𝑃𝐶 
Buildings 0.10 × 𝑃𝐶 
Yard Improvement 0.05 × 𝑃𝐶 
 
𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐶𝑜𝑠𝑡𝑠 (𝐼𝐶) = 𝐸𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑖𝑛𝑔 + 𝐶𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑖𝑜𝑛 Equation A-16 
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Table A-22    Factorial estimation for Indirect Costs (IC) 
Parameter Equation 
Engineering 0.25 × 𝐷𝐶 
Construction 0.45 × 𝐷𝐶 
 
𝑂𝑡ℎ𝑒𝑟 𝑐𝑜𝑠𝑡𝑠 (𝑂𝐶) =  𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑜𝑟𝑠 𝑓𝑒𝑒 +  𝐶𝑜𝑛𝑡𝑖𝑛𝑔𝑒𝑛𝑐𝑦 Equation A-17 
 
Table A-23    Factorial estimation for Other Costs (OC) 
Parameter Equation 
Contractors fee 0.05 × (𝐷𝐶 + 𝐼𝐶) 
Contingency 0.10 × (𝐷𝐶 + 𝐼𝐶) 
 
Direct Fixed Capital (DFC) = Direct Costs (DC) + Indirect Costs (IC) + Other Costs (OC) 
𝐷𝐹𝐶 = 𝐷𝐶 + 𝐼𝐶 + 𝑂𝐶 Equation A-18 
 
Total Capital Cost (CAPEX) = Direct Fixed Capital (DFC) + Working Capital (WC) + Start-up cost 
𝐶𝐴𝑃𝐸𝑋 = 𝐷𝐹𝐶 + 𝑊𝐶 Equation A-19 
𝑊𝐶 estimated as 30 days of operating cost (Labour, materials, utilities & waste treatment) 
 
A.8.1 Sample Calculation – CAPEX for 20L Stainless Steel technology 
Equipment costs as per Table A-5    Base case model equipment specifications A-5: 
𝐸𝐶 (𝑡𝑜𝑡𝑎𝑙) = $ 1 547 000  
𝑈𝑛𝑙𝑖𝑠𝑡𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 𝑐𝑜𝑠𝑡 (𝑈𝐶) =  0.2 𝑥 𝑇𝑜𝑡𝑎𝑙 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 𝑝𝑢𝑟𝑐ℎ𝑎𝑠𝑒 𝑐𝑜𝑠𝑡 (𝑃𝐶) Equation A-20 
𝑇𝑜𝑡𝑎𝑙 𝑃𝑢𝑟𝑐ℎ𝑎𝑠𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 𝐶𝑜𝑠𝑡 (𝑃𝐶) = 𝐸𝐶 + 𝑈𝐶 Equation A-21 
 





𝑷𝑪 = $ 𝟏  𝟗𝟑𝟑 𝟕𝟓𝟎 
𝑷𝑪 →  $ 𝟏 𝟗𝟑𝟒 𝟎𝟎𝟎 
𝑈𝐶 = 0.2 × 𝑃𝐶 = 0.2 × $ 1 934 000 = $ 386 750 
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Installation (As per Table A-20 with 𝐸𝐶 from Table A-5) 
𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 𝑓𝑜𝑟 𝑙𝑖𝑠𝑡𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 (𝐼𝐸𝐶) =  $ 664 625 
𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑠𝑡 𝑓𝑜𝑟 𝑢𝑛𝑙𝑖𝑠𝑡𝑒𝑑 𝑒𝑞𝑢𝑖𝑝𝑚𝑒𝑛𝑡 (𝐼𝑈𝐶) =  0.5 × 𝑈𝐶  Equation A-22 
𝐼𝑈𝐶 = 0.5 × $ 386 750 = $ 193 375 
𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 =  𝐼𝐸𝐶 + 𝐼𝑈𝐶 = $ 664 625 + $ 193 375 
𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 = $ 858 000 
𝐷𝑖𝑟𝑒𝑐𝑡 𝑐𝑜𝑠𝑡𝑠 (𝐷𝐶)
= 𝑃𝐶 + 𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 + 𝑃𝑖𝑝𝑖𝑛𝑔 + 𝐼𝑛𝑠𝑡𝑟𝑢𝑚𝑒𝑛𝑡𝑎𝑡𝑖𝑜𝑛 + 𝐸𝑙𝑒𝑐𝑡𝑟𝑖𝑐𝑎𝑙
+ 𝐵𝑢𝑖𝑙𝑑𝑖𝑛𝑔𝑠 + 𝑌𝑎𝑟𝑑 + 𝐴𝑢𝑥𝑖𝑙𝑖𝑎𝑟𝑦 𝑓𝑎𝑐𝑖𝑙𝑖𝑡𝑖𝑒𝑠 
Equation A-15 
𝐷𝐶 = 𝑃𝐶 + 𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 + 0.45𝑃𝐶 + 0.15𝑃𝐶 + 0.1𝑃𝐶 + 0.1𝑃𝐶 + 0.05𝑃𝐶 + 0.2𝑃𝐶 
𝐷𝐶 = 2.05𝑃𝐶 + 𝐼𝑛𝑠𝑡𝑎𝑙𝑙𝑎𝑡𝑖𝑜𝑛 = (2.05 × $ 1  933 750) + $ 858 000 
𝑫𝑪 = $ 𝟒 𝟖𝟐𝟐 𝟏𝟖𝟖 
𝑫𝑪 →  $ 𝟒 𝟖𝟐𝟐 𝟎𝟎𝟎 
𝐼𝑛𝑑𝑖𝑟𝑒𝑐𝑡 𝐶𝑜𝑠𝑡𝑠 (𝐼𝐶) = 𝐸𝑛𝑔𝑖𝑛𝑒𝑒𝑟𝑖𝑛𝑔 + 𝐶𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑖𝑜𝑛 Equation A-16 
𝐼𝐶 = 0.25𝐷𝐶 + 0.45𝐷𝐶 = 0.70𝐷𝐶 = 0.70 × $ 4 822 188 
𝑰𝑪 = $ 𝟑 𝟑𝟕𝟓 𝟓𝟑𝟏  
𝑰𝑪 →  $ 𝟑 𝟑𝟕𝟔 𝟎𝟎𝟎 
𝑂𝑡ℎ𝑒𝑟 𝑐𝑜𝑠𝑡𝑠 (𝑂𝐶) =  𝐶𝑜𝑛𝑡𝑟𝑎𝑐𝑡𝑜𝑟𝑠 𝑓𝑒𝑒 +  𝐶𝑜𝑛𝑡𝑖𝑛𝑔𝑒𝑛𝑐𝑦 Equation A-17 
𝑂𝐶 = 0.05 × (𝐷𝐶 + 𝐼𝐶) + 0.10 × (𝐷𝐶 + 𝐼𝐶) = 0.15(𝐷𝐶 + 𝐼𝐶) 
𝑂𝐶 = 0.15 × ($ 4 822 188 + $ 3 375 531) 
𝑶𝑪 =  $ 𝟏 𝟐𝟐𝟗 𝟔𝟓𝟕 
𝑶𝑪 → $ 𝟏 𝟐𝟑𝟎 𝟎𝟎𝟎 
𝐷𝐹𝐶 = 𝐷𝐶 + 𝐼𝐶 + 𝑂𝐶 Equation A-18 
𝐷𝐹𝐶 = 𝐷𝐶 + 𝐼𝐶 + 𝑂𝐶 = $ 4 822 000 + $ 3 376 000 + $ 1 230 000 
𝑫𝑭𝑪 = $ 𝟗 𝟒𝟐𝟖 𝟎𝟎𝟎 
𝑊𝐶 = $ 48 000, 𝑆𝑡𝑎𝑟𝑡𝑢𝑝 𝑐𝑜𝑠𝑡 = $ 471 000 
𝐶𝐴𝑃𝐸𝑋 = 𝐷𝐹𝐶 + 𝑊𝐶 Equation A-19 
𝐶𝐴𝑃𝐸𝑋 = $ 9 428 000 + $ 48 000 + $ 471 000 
𝟐𝟎𝑳 𝑺𝒕𝒂𝒊𝒏𝒍𝒆𝒔𝒔 𝑺𝒕𝒆𝒆𝒍 𝑪𝑨𝑷𝑬𝑿 = $ 𝟗 𝟗𝟒𝟕 𝟎𝟎𝟎 
A.9 Labour Cost Assumptions 
Labour costs were estimated using the website Payscale.co.za for the year 2017. Table A-24 below 
shows the estimated hourly rates for operational personnel requirements used in the models: 
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Table A-24    PayScale Salary data 









Production Operator R 122 679 R 50.11 $9 323.60 $3.81 (PayScale, 2017a) 
Production Specialist R 256 376 R 104.73 $19 484.58 $7.96 (PayScale, 2017b) 
Production Supervisor R 203 245 R 83.02 $15 446.62 $6.31 (PayScale, 2017c) 
Pharmacist R 417 287 R 170.46 $31 713.81 $12.95 (PayScale, 2017d) 
The labour requirements for various process operations were estimated based on typical operations 
requirements for a pilot scale operation, shown in Table A-25: 
Table A-25    Man-hours estimations for pilot-scale operations 










All other (basic 
operations) 
Production Operator 2.0 2.0 2.0 2.0 
Production Specialist 0.0 1.0 1.0 0.0 
Production Supervisor 0.1 0.1 0.1 0.1 
Pharmacist 1.0 0.0 0.0 0.0 
 For overnight reactions and storage an assumption of 50% the above hours were applied.  
 It was assumed that the operating labour requirements for the 200 L scale process were 
the same as the 20 L process (3-6 personnel per shift). 
 Management, Quality and regulatory labour costs are not included. 
A.10 Batch Recipe and Scheduling 
 Plant total uptime 46 weeks / year uptime  
 6 weeks / year downtime (maintenance and validation) 
 20 L scale process scheduling: 
 Batch time 110 h, 58h turnaround – Total cycle time 1 week 
 46 batches / year 
 200 L scale process scheduling: 
 Batch time 142 h, 26h turnaround – Total cycle time 1 week 
 46 batches / year 
 10 % batch failure rate 
A.11 Additional Operating Cost Adjustments 
 Annual maintenance 10% of equipment purchase cost 
𝐿𝑎𝑏𝑜𝑢𝑟 𝐶𝑜𝑠𝑡  𝑝𝑒𝑟 𝑙𝑎𝑏𝑜𝑢𝑟 𝑡𝑦𝑝𝑒 =  𝐶𝑜𝑠𝑡 𝑝𝑒𝑟 𝑙𝑎𝑏𝑜𝑢𝑟 𝑡𝑦𝑝𝑒 × 𝐷𝑒𝑚𝑎𝑛𝑑 𝑝𝑒𝑟 𝑙𝑎𝑏𝑜𝑢𝑟 𝑡𝑦𝑝𝑒  
 Start-up validation cost estimated as 5% of DFC 
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A.12 Model screenshots 
A.12.1 20L Stainless steel technology process model screenshots 
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A.12.2 20L Single Use technology process model screenshots 
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A.12.3 20L Hybrid technology process model screenshots 
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A.12.4 200L Stainless steel technology process model screenshots 
 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Appendix A: Methods 
 
  150 
 
 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Appendix A: Methods 
 
  151 
 
 
Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Appendix A: Methods 
 




Process simulation as a decision support tool for biopharmaceutical process development 
Wesley Collair   Appendix A: Methods 
 
  153 
 
A.12.5 200L Single Use technology process model screenshots 
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A.12.6 200L Hybrid technology process model screenshots 
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A.13 Sensitivity Analysis Electricity price Sample Calculations  
Table A-26    Monthly diesel price in cents per litre, 0.005% sulfur SA coastal 2017 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
1105.83 1126.83 1124.83 1114.03 1146.03 1123.03 1063.03 1093.03 1137.03 1179.03 1206.03 1263.33 
(SAPIA - South African Petroleum Industry Association, 2019) 









= (1105.83 + 1126.83 + 1124.83 + 1114.03 + 1123.03 + 1063.03 + 1093.03
+ 1137.03 + 1179.03 + 1206.03 + 1263.33) = 13682.06 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖𝑒𝑠𝑒𝑙 𝑐𝑜𝑠𝑡 2017 (𝑅𝑎𝑛𝑑𝑠) =
13 682.06
12000
= 𝑅 11.4017 /𝐿 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖𝑒𝑠𝑒𝑙 𝑐𝑜𝑠𝑡 2017 ($) =










𝑨𝒗𝒆𝒓𝒂𝒈𝒆 𝒅𝒊𝒆𝒔𝒆𝒍 𝒄𝒐𝒔𝒕 𝟐𝟎𝟏𝟕 ($) = $ 𝟎. 𝟖𝟕 /𝑳 
𝐴𝑠𝑠𝑢𝑚𝑒 50 𝑘𝑉𝐴 𝐷𝑖𝑒𝑠𝑒𝑙 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑜𝑟 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  0.5 𝐿/𝑘𝑊ℎ  
𝐸𝑙𝑒𝑐𝑟𝑡𝑖𝑐𝑖𝑡𝑦 𝐶𝑜𝑠𝑡 𝑓𝑟𝑜𝑚 𝑑𝑖𝑒𝑠𝑒𝑙 =  𝑑𝑖𝑒𝑠𝑒𝑙 𝑐𝑜𝑠𝑡 2017 ($) × 𝐷𝑖𝑒𝑠𝑒𝑙 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑜𝑟 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦  Equation A-24 







𝑬𝒍𝒆𝒄𝒓𝒕𝒊𝒄𝒊𝒕𝒚 𝑪𝒐𝒔𝒕 𝒇𝒓𝒐𝒎 𝒅𝒊𝒆𝒔𝒆𝒍 = $ 𝟎. 𝟒𝟑 /𝒌𝑾𝒉 
Example: 10% electricity derived from diesel generator: 
𝐶𝑜𝑚𝑝𝑜𝑠𝑖𝑡𝑒 𝑒𝑙𝑒𝑐𝑡𝑟𝑖𝑐𝑖𝑡𝑦 𝑐𝑜𝑠𝑡 = 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒  × 𝑐𝑜𝑠𝑡    Equation A-25 
𝐶𝑜𝑚𝑝𝑜𝑠𝑖𝑡𝑒 𝑒𝑙𝑒𝑐𝑡𝑟𝑖𝑐𝑖𝑡𝑦 𝑐𝑜𝑠𝑡 = 10% × 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑑𝑖𝑒𝑠𝑒𝑙 𝑝𝑜𝑤𝑒𝑟 + 90% × 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑐𝑜𝑎𝑙 𝑝𝑜𝑤𝑒𝑟 
𝐶𝑜𝑚𝑝𝑜𝑠𝑖𝑡𝑒 𝑒𝑙𝑒𝑐𝑡𝑟𝑖𝑐𝑖𝑡𝑦 𝑐𝑜𝑠𝑡 = 0.1 × $ 0.43 /𝑘𝑊ℎ + 0.9 × $ 0.1 /𝑘𝑊ℎ 
𝐶𝑜𝑚𝑝𝑜𝑠𝑖𝑡𝑒 𝑒𝑙𝑒𝑐𝑡𝑟𝑖𝑐𝑖𝑡𝑦 𝑐𝑜𝑠𝑡 = $ 0.13/𝑘𝑊ℎ, 𝑟𝑜𝑢𝑛𝑑𝑒𝑑 𝑢𝑝 𝑡𝑜 $0.15 /𝑘𝑊ℎ  
𝑪𝒐𝒎𝒑𝒐𝒔𝒊𝒕𝒆 𝒆𝒍𝒆𝒄𝒕𝒓𝒊𝒄𝒊𝒕𝒚 𝒄𝒐𝒔𝒕, 𝟏𝟎% 𝒇𝒓𝒐𝒎 𝒅𝒊𝒆𝒔𝒆𝒍 = $𝟎. 𝟏𝟓 /𝒌𝑾𝒉  
 
